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SUMMARY
Sensorineural hearing loss is often the first symptom reported in a number of 
mitochondrial myopathies. Neuronal tissue is very sensitive to alterations in 
oxidative phosphorylation which often occur in these diseases. During an 
investigation of thirty three patients with non-syndromic sensorineural hearing 
loss by RFLP (Restriction Fragment Length Polymorphism) analysis, for known 
mutations associated with specific mitochondrial mutations, one patient was 
found to have lost the Xbal site at np 7440.
This patient is part of a large maternal pedigree in which 14 members suffer from 
some degree of sensorineural hearing loss. The entire mitochondrial DNA 
sequence of this patient was sequenced revealing that the Xbal site loss was due to 
a homoplasmic A->G change at np 7445. The nucleotide at this position has a 
role on both strands: part o f the stop codon of the COI (Cytochrome Oxidase 
subunit I) gene on the major coding strand and the extreme 3' nucleotide of 
tRNAser(UCN) on the other.
The biochemical effects o f this mutation were investigated in permanent cell-lines 
created by EBV (Epstein Barr Virus) transformation o f lymphocytes from the 
index case, and from a normal control. In studies of lactate/pyruvate ratios, 
Complex II + III activity, Complex IV activity, growth with galactose as the 
carbon source and in the presence of chloramphenicol there was no difference 
between the two cell-lines. Measurement o f growth in the presence o f various 
concentrations of streptomycin was carried out twice with inconclusive results.
In addition Northern blotting experiments indicated no difference in the level or 
length o f the COI transcript in the cell-line with the np 7445 mutation. 
M itochondrial translation products were measured by 35S-labelling in the 
presence of emetine and no differences seen in the amount or sizes o f any of the 
labelled proteins.
The entire mitochondrial DNA of a patient with LHON (Lebers Hereditary Optic 
Neuropathy) and sensorineural hearing loss was sequenced and found to have the 
so-called "classical" LHON mutation a tnp  11778.
In addition two patients with aminoglycoside antibiotic induced deafness were 
found to have a previously reported, homoplasmic A->G at np 1555 in 12SrRNA.
The work in this project has established that two mitochondrial DNA mutations 
are found in association with sensorineural hearing loss. That at np 1555 had 
previously been reported; that at np 7445 was novel. Both mutations are at 
positions o f the human m itochondrial genome which have some direct 
involvement in mitochondrial translation.
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CHAPTER 1 INTRODUCTION
1:1 MITOCHONDRIA - A BRIEF REVIEW
Mitochondria are cytoplasmic organelles present in almost all eukaryotic cells in 
varying numbers; up to hundreds per cell. Each is enclosed by a double 
membrane, an outer membrane separating the mitochondrion from the cytosol and 
an inner membrane enfolded to form cristae, which partially divide the inner 
compartment. The two membranes are separated by an inter-membrane space and 
the area internal to the inner membrane is known as the matrix.
The mitochondrion is often referred to as "the powerhouse of the cell" and this 
description is apt as it is the site of oxidative phosphorylation in which most of 
the ATP used within the cell is produced. Approximately 100 polypeptides 
involved in this oxidative phosphorylation process are located in the inner 
mitochondrial membrane in an extremely ordered fashion: See Figure 1:1. There 
are multi subunit complexes which span the inner mitochondrial membrane, 
through which electrons are passed. The electrical potential drives protons out 
across the membrane at complexes I NADH-ubiquinone reductase, III 
cytochrome-c reductase and IV cytochrone-c oxidase until at complex V, i.e. ATP 
synthase, protons are brought back across the membrane into the matrix where 
they take part in the formation of ATP.
1:1:1 Mitochondrial DNA
Mitochondria have their own DNA, quite separate from the cell's nuclear DNA. 
Approximately 1% of mammalian cellular DNA is mitochondrial. The size, 
organisation and control of expression of mitochondrial DNA is diverse 
throughout eukaryotes: size ranging from 16 kb in mammals to 2400 kb in plants. 
In some eukaryotes there are large non-coding regions and introns within genes; a 
small number of essential functions have been preserved in a wide range of 
species. Animal mitochondrial DNA is much more compact than in most plants 
and lower eukaryotes, ranging in size from about 13 kb to about 20 kb, with the 
organisation of genes within the genome being relatively highly conserved.
Figure 1:2 show's the gene organisation of human mitochondrial DNA and is 
typical of animal mitochondrial DNA. The human mitochondrial genome is a 
circular, double-stranded DNA molecule of 16,569 base pairs which codes for the 
two mitochondrial ribosomal RNAs, 12S & 16S, the small ribosomal subunit 
(SSU) and the large ribosomal subunit (LSU) respectively; 22 tRNAs and the 
mRNAs coding for 13 of the subunits of the oxidative phosphorylation pathway.
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F igu re  1:1 M itochondrial Respiratory Com plexes within the inner 
mitochondrial membrane.
CoQ - Coenzyme Q
CYTC - Cytochrome c.
ANT - Adenine Nucleotide Transpoi ter
Adapted from: Wallace cl al, 1988.
Seven of these 13, ND1, ND2, ND3, ND4, ND4L, ND5 and ND6 are subunits of 
Complex I; cytochrome b is part of Complex III; COI, COII and COIII are three 
of the 13 subunits of Complex IV and ATPase 6 and 8 are subunits of Complex 
V. 22 tRNAs are sufficient for translation of the protein coding sequences of the 
human mitochondrial genome, due to a more simplified codon-anticodon pairing 
than is required to read the nuclear genetic code. The number of tRNAs varies 
slightly between species, but in humans eight mitochondrial tRNAs recognise 8 
codon families with 4-fold degeneracy and, 14 recognise the remaining codon 
pairs (Shoffner and Wallace 1990).
The two strands of mitochondrial DNA can be separated according to density 
difference due to a strand bias in GT content. The so-called heavy strand (H) has 
the greatest density and encodes more genes than the less dense light (L) strand.
There are only two short non-coding regions in mammalian mitochondrial DNA: 
at the origin of light strand replication (O jJ and the D-loop. The D-loop is the 
least conserved region of the mitochondrial DNA, containing the predominant 
control regions for both replication and transcription: the origin of H strand 
replication (O h ) and both H and L strand promoters.
The H-strand of animal mitochondrial DNA begins replicating before the L- 
strand. The origin of L-strand replication is approximately 2/3 of way round the 
genome (clockwise on Figure 1:2) from the origin of H-strand replication. H- 
strand replication starts at Oh using the L-strand as template. The D-loop is 
formed by displacement of the parental H-strand from the L-strand by short H- 
strand sequences which function in priming DNA synthesis. Initiation of L-strand 
synthesis occurs when the growing H-strand exposes the single stranded parental 
H-strand which can be used as template for synthesis of the L-strand. L-strand 
synthesis then continues, counter clockwise as shown in Figure 1:2 (Nelson, 
1987).
The H and L strand promoters lie within 150 nucleotide of each other within the 
D-loop (see Figure 1:2). Although consensus elements have been found in lower 
eukaryote and plant mitochondrial promotors (Jaehning, 1992) mammalian 
mitochondrial transcrioptional start sites show little sequence conservation. It 
seems that elements upstream of the initiation sites are important for positioning 
of the RNA polymerase by binding the transcription stimulatory factor, mtTFI 
(Parisi & Clayton, 1991).
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Figure 1:2 Schematic representation of the 16.6 kb human mitochondrial
DNA. Coding regions for the 13 polypeptides: ND1, ND2, 
ND3, ND4, ND4L, ND5, ND6 of Complex 1; cytochrome b of 
Complex III; COI, COII & COIII of Complex IV and ATPasc 
6 and 8 of Complex V. The 22 tRNAs are represented by their 
single letter code; the 12S rRNA by SSU and 16S rRNA by 
LSU. Op and Op are the origins of heavy and light strand 
replication respectively. A rrows indicate  d irec tion  of 
transcription or replication.
The H strand and L strand are transcribed as probably genome-length 
polycistronic transcripts: the H strand encodes the two ribosomal RNAs, 12S and 
16S, 14 tRNAs and 12 of the 13 polypeptides; the L strand codes for 8 tRNAs 
and only 1 polypeptide. Punctuation of the genome with tRNAs is thought to 
allow processing of the polycistronic transcript at the 5' and 3' ends of the tRNAs 
(Attardi, 1985). An RNaseP-like enzyme which cuts at the 5! end of tRNAs has 
been identified in HeLa cells (Doersen et al, 1985); the processing enzyme for the 
3' end of tRNAs has not been identified.
Mitochondrial biogenesis requires co-ordination of nuclear and mitochondrial 
gene expression. The remaining mitochondrial proteins are encoded by the 
nuclear DNA. The genes for these are transcribed in the nucleus, their mRNAs 
translated in the cytosol and the polypeptides transported into the mitochondrion 
(for review see Hard et al 1989). Then, in concert with the mitochondrially 
encoded subunits, they are assembled to form the complexes of the oxidative 
phosphorylation pathway. Control of mitochondrial gene expression is thought to 
be via nuclear encoded factors: mtTFA, the product of a nuclear gene, stimulates 
transcription from the two mitochondrial promoters. This gene is itself under the 
control of so-called nuclear respiratory factors (NRF), transcription factors which 
thus provide nuclear regulation at mitochondrial transcription and (indirectly) 
translation (Virbasius & Scarpulla, 1994).
Until recently human mitochondrial DNA was thought to be inherited exclusively 
from the mother (Giles et al 1980). However, a report by Gyllenstein et al (1990) 
provides evidence, from studies in mice, that mitochondrial DNA from the father 
is inherited at a low level.
1:2 MITOCHONDRIAL DNA POLYMORPHISMS
Variations in mitochondrial DNA occur naturally in all human populations 
(Vilkki et al 1988), but most individuals appear to be homoplasmic, i.e. have only 
one type of m itochondrial DNA. A mixture of more than one type of 
mitochondrial DNAs, i.e. wild-type and mutant, is known as heteroplasmy.
The speed of evolutionary divergence of human mitochondrial DNA is rapid in 
comparison to that of nuclear genes. This property, in addition to the virtually 
exclusive maternal inheritance of mitochondrial DNA, allows sequence 
differences, i.e. polymorphisms to be. extensively used to measure rates of 
divergence of the various populations within the human species. Cann et al 
(1987) calculated that the average number of base pair differences between two
3
human mitochondrial genomes is 9.5. In contrast Merriweather et al (1991) stated 
that two individuals would differ on average by 0.4% which gives a figure of 66 
base changes.
Using such comparisons Cann et al (1987) traced the human mitochondrial 
genomic ancestor to Africa approximately 200,000 years ago; Merriweather et al
(1991) are in agreement with this. This time scale is contested by 
paleoanthropologists who estimate the time of human origin, by means of 
archeological data, dental and bone remains and nuclear genetic factors, as much 
earlier. Many populations have now been studied using mitochondrial DNA 
polymorphisms: Asian (Bonne-Tamir et al 1986); American (Torroni et al 1992); 
Russian (Lemza et al 1992).
The human mitochondrial DNA sequence- the so-called "Cambridge" sequence - 
was published in 1981 (Anderson et al) and is the sequence to which all other 
sequence is compared. However, in the last few years a number of differences 
from the Cambridge sequence have been repeatedly reported. See Table 1:1. 
Explanations given for these discrepancies are that there are mistakes in the 
reading of the original sequences, or that the Cambridge sequence was obtained 
using a source of DNA containing an unusual array of polymorphisms. The 
sequence published in 1981 was a mosaic of sequence from a number of human 
placentas and HeLa cells (Wolstenholme, 1992) and this could perhaps account 
for some of the differences.
When a large sequencing project is undertaken these differences have to be borne 
in mind and where an apparently novel polymorphism is associated with disease 
the possibility that it is a naturally occurring, though rare, polymorphism must be 
considered.
1:3 MITOCHONDRIAL DISEASE
In recent years an increasing number of diseases have been found, characterised 
by identifiable defects in the oxidative phosphorylation pathway. These diseases 
are known collectively as the mitochondrial encephalomyopathies and the range 
of symptoms is very wide: deafness, optic atrophy, muscle weakness, dementia, 
cardiac defects and so on. Advances in molecular genetics have revealed that 
many of these diseases are associated with mutations in the mitochondrial 
genome or in nuclear genes involved in mitochondrial gene expression. 
Differential tissue expression of these mutations is thought, in part, to result from 
the variable reliance of tissues on mitochondrial energy production: not all tissues 
have the same oxidative phosphorylation requirement. The central nervous
4
Gene Position Change on 
sense-strand
Amino Acid
12S rRNA 1438 A->G -
ND1 3423 G->T val-conserved
ND2 4769 A->G met-conserved
4985 G->A gly-conserved
ATPase 6 8860 A->G thr->ala
ND4 11335 T->C asn-conserved
11719 G->A gly-conserved
ND5 13702 G->C gly->arg
ND6 14199 G->T pro->thr
14272 G->C phe->leu
14365 G->C val-conserved
14368 G->C phe->leu
Cyt b 15326 A->G thr->ala
Table 1:1 Discrepancies from the "Cambridge" sequence of human
mitochondrial DNA reported in normal individuals. Compiled 
from Howell et al (1992) and Marzuki et al (1992).
system (CNS) is most dependent on oxidative phosphorylation and this could 
explain why there are so many neurological symptoms in these diseases. 
However, as symptoms vary widely and are to some extent correlated with the 
particular mutation, this is clearly not the whole explanation.
In an attempt to make a more systematic study of mitochondrial diseases Shoffner 
& Wallace (1990) produced a classification system:
Class I nuclear DNA mutations
Class II mitochondrial DNA point mutations
Class III mitochondrial DNA deletions and duplications
Class IV of unknown inheritance
With a similar aim Zeviani et al (1990) proposed that mitochondrial diseases be 
classed into three categories depending on aetiology:
1) defective transcription or translation of mitochondrial proteins coded by 
nuclear genes.
2) mutations of mitochondrial DNA.
3) mutations of nuclear genes which control mitochondrial gene expression.
The latter categorisation is more meaningful but it is probable that many of the 
mitochondrial diseases involve a nuclear gene defect acting in conjunction with or 
sometimes causing a mitochondrial DNA mutation. Consequently most diseases 
do not fit neatly into one category and I shall discuss a number of the best 
documented diseases with regard to the mitochondrial mutations identified and 
their putative role in the pathology.
1:4 LEBER'S HEREDITARY OPTIC NEUROPATHY (LHON)
Leber's Hereditary Optic Neuropathy is a form of optic atrophy which was first 
described in 1871 by a German ophthalmologist - Theodore von Leber - (Leber 
1871) as a disease of the central nervous system. It is characterised by acute 
bilateral blindness, the age of onset of which is around 20 years; there is found to 
be a sex bias in that only 15% of those affected are female (Went et al 1975). As 
early as 1935 (Imai et al) studies were being undertaken into the genetic basis of 
the disease and it was suggested to be a case of "cytoplasmic inheritance". 
However, in 1970 Douglas Wallace studied a large pedigree of 101 individuals, a 
number of whom suffered from LHON, and suggested that the maternal pattern 
of inheritance was consistent with vertical transmission of a virus. Erickson 
(1972) also observed that the disease exhibited a non-Mendelian pattern of
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inheritance and that it was exclusively maternally inherited. In 1984 
Nikoskelainen et al suggested that since it was known that mitochondrial DNA 
was exclusively maternally inherited, it may play a role in the disease.
1:4:1 The "Classical mutation" in LHON
It was not until 1988 that Wallace et al found a mutation in the mitochondrial 
DNA of patients suffering from LHON, which correlated strictly with the disease. 
In order to minimise the chances of associating LHON with a rare ethnic 
polymorphism (most LHON pedigrees are caucasoid) a large pedigree of black 
LHON patients were examined for candidate mutations. Restriction enzyme 
analysis of PCR products of mitochondrial DNA from lymphoid and muscle 
tissue excluded large deletions as the cause of LHON. By cloning and 
sequencing, 25 base substitutions were found, 8 of which altered amino-acids, and 
Wallace set out criteria for implication of a mitochondrial replacement mutation 
in LHON:
If it: 1. changed a highly conserved amino acid
2. was frequently found in LHON
3. could not be found in normal controls
Six of the 8 base substitution mutations were excluded as candidate mutations 
using these criteria. A change at np 9163 was found to convert a highly 
conserved Valine to an Isoleucine in ATPase 6. However, in hybridisation 
studies this mutation was not found in all LHON patients but only in one 
pedigree, leading Wallace to conclude that this mutation did not correlate with 
LHON.
Finally the G->A transition at np 11778, which causes the replacement of an 
Arginine residue by a Histidine residue at a highly conserved site in the 
respiratory chain subunit ND4 (Figure 1:3) was found to be the only change 
which fulfilled his criteria. This base change in the mitochondrial genome 
destroys an SfaNl restriction enzyme site and therefore provides a relatively 
simple screening method. This point mutation was found in 9/11 LHON families 
and was not present in 45 controls.
Wallace found that individuals carrying this mutation were homoplasmic; Vilkki 
et al (1989) confirmed this finding in an initial study of 19 Finnish LHON 
families where they found that 10/19 families had the mutation. Holt et al (1989) 
reported both wild-type and mutated mitochondrial DNA (heteroplasmy) in the 
peripheral blood of 4/8 LHON families and correlated the proportions of the
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Figure 1:3 Partial amino acid sequence of subunit ND4 in human, mouse, 
rat, bovine, Xenopus, Drosophila and sea urchin showing 
conserved Arginine residue at amino acid 340 in different 
phyla.
mitochondrial DNA types with the severity of the disease. They found that in the 
families without the 11778 mutation, recovery of vision to a functionally 
significant extent approximately 4 years after onset of symptoms, was often the 
case. In addition those patients with the 11778 mutation at high percentage, i.e. 
> 98% mutant, were worst affected. The symptomless carrier females in the 
families with the 11778 mutation had levels of heteroplasmy of < 80% mutant.
1:4:2 Mutation at np 3460 in LHON
Huoponen et al (1990) reported that they could not find the previously described 
ND4 mutation in 9/20 families with members diagnosed as having LHON. This 
group (Huoponen et al 1991) have subsequently found another mitochondrial 
mutation in 3 Finnish LHON families. A G->A transition at nucleotide 3460 was 
observed, in blood mitochondrial DNA, this transition causes substitution of an 
Alanine by a Threonine in the ND1 subunit of complex I. The homoplasmic 
mutation abolishes an Aha II restriction site and consequently can also be easily 
detected. The ND4 mutation np 11778 was not observed in any of these families.
1:4:3 Mutations at np 4160 and np 4136
A number of LHON families do not have any detectable mutation, though the 
mitochondrial genomes of some of these have not been fully sequenced, 
obviously there may be mutations present in the parts of the genome not already 
sequenced: Howell and McCullough (1990) looked at a large Australian family 
and could find no candidate mutations in ND5, ND4L, ND4 or the contiguous 
tRNA genes. They suggested that LHON might be genetically heterogeneous, i.e. 
that a set of related diseases might be being identified and classified as LHON. 
However, this group (Howell et al 1991) subsequently reported two mutations in 
the above family, in the mitochondrial gene for the ND1 subunit.
The first mutation found was a T->C transition at np 4160; all members of the 
family studied appeared to be homoplasmic for the mutation, but only 5 shared 
symptoms of the disease in a similar way that not all individuals with the 11778 
and 3460 mutations show symptoms of disease. This change in the DNA causes a 
leucine to be replaced by a proline in a small helix of hydrophilic loop of the ND1 
protein subunit. Another m utation was identified at position 4136, a 
homoplasmic A->G transition which results in substitution of cysteine for 
tyrosine at amino-acid 277 of the ND1 protein subunit. This second mutation was 
not identified in all family members carrying the first mutation. Of those people 
carrying both mutations only two were clinically abnormal, but these two 
exhibited less severe symptoms than other family members with only the np 4160
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mutation. Howell et al (1991) suggested that these data support the idea that the 
second (np 4136) mutation acts as a partial suppressor of the first.
The Queensland family in which this mutation has been identified is one of only a 
few LHON families in which a biochemical defect has been reported. Parker et al 
(1989) showed a decrease in Complex I activity in platelet mitochondria in four 
members of this family.
Approximately fifty percent of LHON pedigrees have been shown to have the np 
11778, ND4 mutation, while 15-25% of the remainder carry the ND1, np 3460 
mutation.
1:4:4 Additional mutations associated with LHON
Since 1991 a number of other mutations of mitochondrial DNA have been linked 
with LHON. Table 1:2 shows all the mutations thus far associated with LHON. 
The changes reported by Johns and Berman in 1991 were also found in controls, 
albeit at lower frequencies. In addition, the change at np 4216 in ND1 was never 
found alone, but always in conjunction with either the change at np 13708 or that 
at np 4917. The G->A change at np 13708 was later reported by Brown et al
(1992), who found it in 11778 positive and negative LHON patients; it was also 
reported at lower frequency in controls. Two additional mutations were reported 
by Brown et al (1992): one at np 15257 and one at np 15812, both in Cytochrome 
b. They found that all patients with the np 15257 change also had the change at 
np 13708 and all those with the np 15812 mutation had those np 15257 and np 
13708. This led Brown et al to propose that a number of mutations of 
mitochondrial DNA may work in concert to produce the disease phenotype: the 
"disease haplotype" theory.
In 1992 Johns et al reported yet another mitochondrial DNA mutation, associated 
with LHON, which has not been identified in controls. This is a T->C change at 
np 14484 which changes a methionine to a valine in ND6 ; it was found in 14 
LHON families. It occurred in association with the 13708 change in 10/14 
patients and with another mis-sense change at np 3394 in 5/14 patients. This 
group also proposed the interaction of various independent mutations working 
together to give rise to disease. Another recently reported mutation associated 
with LHON is a G->A transition at np 7444 (Brown et al 1992). The mutation 
was found in 2/22 (9%) of LHON patients who lacked the 11778 mutation and 
6/545 (1%) of controls. The change causes the loss of an Xbal restriction site and 
therefore the presence of the mutation is easy to screen.
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This change alters the termination codon-AGA of cytochrome c oxidase subunit I 
(COI) to become AAA and it is proposed that the COI peptide is extended by 3 
amino acids. A decrease in cytochrome-c oxidase activity was also reported in 
EBV-transformed lymphocytes from one of the patients with the np 7444 
mutation and on this basis it was proposed that the mutation leads to a partial 
respiratory deficiency which could lead to the pathogenesis of LHON.
There are a number of patients diagnosed as suffering from LHON who have 
none of the above mutations; this, and the association with such a large number of 
different mitochondrial mutations, make the molecular mechanisms leading to 
the disease difficult to determine. The biochemical basis of the disorder has not 
been satisfactorily defined: biochemical defects evident in blood may not have 
relevance to their effects in the optic nerve. An additional factor has frequently 
been hypothesised in the development of LHON in order to explain why some 
members of LHON pedigrees develop symptoms, while others remain healthy. 
Sex linkage, an autosomal nuclear gene, or environmental factors have all been 
cited and will be discussed below.
1:4:5 Possible X-Linkage in LHON
Although LHON is exclusively maternally inherited, the imbalance of male to 
female patients (70-80% male, 20-30% female) seems to indicate that some X- 
linked gene could also be involved in expression of the disease phenotype. It has 
been proposed that the disease is the result of the combination of a mitochondrial 
DNA mutation and an X-linked gene. Chen et al (1989), in a multipoint linkage 
analysis, found no linkage between LHON and 15 X-chromosome markers in 3 
LHON families. In a 2 point linkage analysis Vilkki et al (1991) found tentative 
evidence of linkage to locus DXS7 on the proximal arm of the X-chromosome to 
which other hereditary eye diseases have been mapped: retinitis pigmentosa and 
congenital stationary night blindness (Gal et al 1989).
Bu and Rotter in 1991 proposed, based on segregation analysis, that LHON is a 
two locus disorder; one mitochondrial, one X-chromosome linked. They 
proposed that females affected by LHON are so due to X-inactivation and that 
these females would be heterozygous for the defective nuclear gene.
However, in 1993 the Finnish group re-evaluated their linkage data (Juvonen et al 
1993), re-examining the families previously studied and including a number of 
additional pedigrees. The result of this exhaustive study was that they could not 
confirm the previously reported linkage and they concluded that the reasons for 
the male bias in LHON remain unknown.
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1:4:6 Environmental Factors and LHON
Other factors which could influence the sexual bias in presentation of the disease 
should also be taken into account. Hormonal involvement is the obvious one, as 
the age of onset is usually in late adolescence when great hormonal changes are 
taking place. It is not known if there is some hormonal influence on the 
manifestation of the disease phenotype which is greater than males than in 
females.
In the past the suggestion was made that a defect in cyanide metabolism could be 
involved in the aetiology of LHON (Wilson, 1965). The enzyme Thiosulphate- 
sulphur transferase (also called Rhodanese) is a mitochondrial matrix enzyme 
which detoxifies cyanide. Since smoking increases the level of cyanide in the 
blood stream some studies were made on the effect of smoking on the onset and 
progression of the disease. However, no convincing correlation was ever found 
and the idea has largely been abandoned (Nikoskelainen 1984). What the 
pathogenic mechanisms are in the development of LHON, what role the 
mutations described here play in the damage to the optic nerve remains unknown.
1:5 MITOCHONDRIAL ENCEPHALOMYOPATHY WITH LACTIC 
ACIDOSIS AND STROKE LIKE EPISODES (MELAS)
Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes 
(MELAS) is a second, well-documented mitochondrial disease. The principal 
symptoms are stroke-like episodes, muscle weakness and retinal degeneration 
(Kobayashi et al 1987); elevated levels of lactate and reduced NADH-CoQ 
reductase (Complex I) activity were found in the CSF of two patients (Kobayashi 
et al, 1987). These two biochemical defects were thought to play a role in the 
disease. Using the polymerase chain reaction (PCR) and sequencing strategies, 
an A->G transition at np 3243 of the mitochondrial DNA, in the gene for 
tRNA Leu(UUR)was f°und in MELAS patients (Goto et al 1990; Kobayashi 1990). 
This mutation causes the gain of an Apal restriction enzyme site and is therefore 
simple to detect by restriction fragment length polymorphism (RFLP) analysis.
In the case of the np 3243 mutation heteroplasmy is always the case, with 
populations of mutant mitochondrial DNA in muscle, from 50% to 92%. Figure 
1:4 illustrates the proposed secondary structure of the m itochondrial 
tRNALe^uuR) an£* shows the position of the 3243 mutation: this site is 
conserved in mitochondrial tRNAs from human to sea urchin (Goto et al, 1990).
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Hess ct al (1991) observed that the mutation lies in the middle of sequences 
involved in transcription termination of the mitochondrial 16S rRNA. Although 
the human mitochondrial genome is transcribed as a polycistronic molecule there 
are relatively more rRNA in comparison to other RNA molecules. The boundary 
of the genes for 16S rRNA and tR N A L^uuR ) *s the major determinant in the 
control of the relative synthesis. A partially purified protein of 34 kD was found 
to bind to a tridecamer sequence at the 16S rRNA/tRNALg^uuR) boundary. 
When the mutation at np 3243 was present in the DNA substrate the binding of 
the protein was decreased by approximately 50%. In addition an increase in the 
amount of full length run off transcript, with little or no prematurely terminated 
transcript, was observed when the iRNAl^ uur) mutation was present. The 
conclusion was that the mutation prevents binding of the termination factor and 
therefore termination at the 16S rRNA/tRNAL^uuR) boundary. Hess et al
(1991) have suggested that the molecular defect leading to the symptoms 
associated with MELAS may be the lack of production of the correct type and/or 
quantity of ribosomal RNA, in relation to the levels of other mitochondrial 
transcription products, in the affected tissues. In contrast to this, Moraes et al
(1992) measured the steady state ratios of mRNA:rRNA in vitro, by in situ 
hybridisation of muscle biopsy sections. They found that some MELAS patients 
had increased mRNAirRNA but others did not. In addition similar increases in 
mRNA:rRNA were also found in patients suffering from MERRF, who do not 
have the np 3243 mutation but do have a mutation at np 8344 (see below). 
Moraes et al concluded that the np 3243 mutation in MELAS causes no specific 
changes in steady-state ratios of mRNA:rRNA.
Only 75% of MELAS patients have the np 3243 mutation, and other 
mitochondrial DNA mutations have been associated with some cases of MELAS. 
Goto et al (1991) reported a T->C transition at np 3271 which is also in the 
tRNA Leu(UUR) gene- This polymorphism was not found in any of the 46 patients 
with other mitochondrial diseases nor in 50 controls. The mutation lies outside 
the area involved in transcription termination, giving support to the idea that 
tRNA abnormalities, which may cause altered binding to the ribosome, or its 
cognate aminoacyl-tRNA synthetase, or non-charging or mischarging of the 
tRNALeu(UUR)m°lecules, are involved in the mechanisms leading to the disease 
state. This mutation has not been reported by others.
The mutation at np 3243 has also been found in a number of families in which 
diabetes mellitus (DM) and/or sensorineural deafness is maternally inherited 
(Reardon et al, 1992; van den Ouweland et al, 1992). The differences in disease 
phenotype in patients with this mutation in tR N A j^u u R ) probably reflects
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differential tissue expression of the mutation under the control of mitochondrial 
or nuclear factors.
1:6 MYOCLONIC EPILEPSY WITH RAGGED RED FIBRES (MERRF)
Myoclonic Epilepsy with Ragged Red Fibres (MERRF) is also known as 
Fukuhara disease. The symptoms are heterogeneous but the main clinical features 
are ataxia, myopathy with ragged-red fibres and myoclonic epilepsy. Other 
symptoms reported are deafness, dementia and mild cardiomyopathy. Wallace et 
al (1988) noted that the syndrome was maternally inherited implying that there 
could be a defect in the mitochondrial DNA. When sections of muscle biopsies 
are stained with modified Gomori trichome, structures referred to as Ragged Red 
Fibres are observed (Moraes et al 1989). Electron microscope studies show these 
to be aggregates of abnormal mitochondria with paracrystalline arrays and 
degeneration of the cristae (Wallace et al 1986). These structures are, in fact, a 
common symptom of many of the mitochondrial encephalomyopathies.
Examination of mitochondrial DNA from the muscle of MERRF patients using 
PCR (Saiki et al 1988) and direct sequencing revealed a point mutation at np 8344 
(Shoffner et al 1990). This mutation was found to be an A->G transition 
which alters an evolutionarily conserved base in the Ti|>C loop of the tRNAsLys 
gene, and creates a CWJI restriction enzyme site. The creation of this site allows 
the mutation to be easily detected and both wild-type and mutated mitochondrial 
DNA (heteroplasmy) in varying proportions has been found in MERRF patients.
Silvestri et al (1993) reported levels of heteroplasmy between 56% and 100% in 
eleven MERRF patients; in this study the mutation was identified in both blood 
and muscle. No correlation was found between the severity of disease and the 
percentage of mutated mitochondrial DNA molecules. Wallace et al in 1988 had 
reported defects in Complexes I and IV in MERRF patients, but the more recent 
report by Silvestri identified a significant decrease only in Complex IV. 
However, no correlation was found between the biochemical defect and the level 
of heteroplasmy.
1:7 NEUROGENIC M USCLE W EAKNESS, A TAXIA AND 
RETINITIS PIGMENTOSA (NARP)
Neurogenic muscle weakness, ataxia and retinitis pigmentosa (NARP) has been 
identified as a variable combination of developmental delay, retinitis pigmentosa, 
dementia, ataxia, muscle weakness and sensorineuropathy. In 1990 Holt et al 
identified a maternal pedigree in which 4 members were seen to have two
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populations of mitochondrial DNA in blood and muscle. One population had a 
previously unreported T->G point mutation at np 8993, changing a highly 
conserved leucine to an arginine in the ATPase 6  gene. Some correlation between 
the degree of heteroplasmy and clinical severity was observed.
Tatuch et al (1992) identified this heteroplasmic np 8993 change in skin, brain, 
kidney and liver of an infant whose symptoms were consistent with Leigh's 
disease (a fatal neurodegenerative disease similar to NARP, but identified in 
infants). This mutation has now been found in a number of families and its 
identification has been used in prenatal diagnosis of the syndrome (Harding et al 
1992).
Differential tissue expression and threshold levels of mutant mitochondrial DNA 
may play some role in the development of the disease. Tatuch et al (1992) 
identified unaffected members of a family with NARP, who had up to 71% 
mutant mitochondrial DNA in fibroblasts but only 39% in lymphoblasts. It has 
been proposed that the insertion of an arginine residue in a hydrophobic sequence 
of the ATPase 6  subunit of ATP synthetase interferes with the H+ channel formed 
by ATPase subunits 6  and 9, leading to diminished ATP synthesis.
1:8 DISEASES ASSOCIATED WITH REARRANGEM ENTS O F
MITOCHONDRIAL DNA
Rearrangements of the mitochondrial genome in the form of partial duplications 
and deletions have been reported in a wide range o f m itochondrial 
encephalomyopathies. Holt et al (1988) used multiple restriction enzyme 
analysis of mitochondrial DNA extracted from muscle to identify the presence of 
deletions. They reported 9/25 patients with mitochondrial myopathy had 
detectable levels of mitochondrial DNA molecules deleted by up to 7 kb; they 
later reported (Holt et al 1989) that 40% of patients with mitochondrial 
myopathies have these large deletions. Poulton et al (1989), using similar 
restriction enzyme analysis, observed large scale duplications (around 8  kb) in 2  
patients with mitochondrial myopathy. It has since been realised that it can be 
difficult to differentiate between partial duplications and partial deletions. It is 
only possible to identify a duplication when a restriction enzyme which cuts 
uniquely at a site within the deleted region is used (Poulton et al, 1994).
1:8:1 Kearns Sayre Syndrome/Chronic External Ophthalmoplegia
The disease on which most work on the study of rearrangements of the 
mitochondrial DNA has been done is Kearns/Sayre Syndrome (KSS). This is a
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disease chracterised by progressive external ophthalmoplegia (paralysis of the 
external eye muscles), cardiac defect, sensorineural deafness and pigmentary 
retinopathy with the mean age of onset around 20 years. Chronic progressive 
external ophthalmoplegia (CPEO) is a milder form of KSS which presents later in 
life. Microscopically, ragged red fibres are seen in muscle tissue (Shoffner et al 
1989) these contain large amounts of deleted mitochondrial DNA (Shoubridge et 
al, 1990); biochemically there is a reduction in respiratory chain enzyme activity, 
in particular of cytochrome c oxidase. Various large scale deletions of the 
mitochondrial DNA have been reported in different patients:- around 5 kb - 
Lestienne et al 1988; 1.3->7.6 kb (but an identical 4.9 kb deletion in 11 patients) - 
Moraes et al 1989; 4.9 kb - Shoffner et al 1989; a number of different deletions in 
different patients but a common 5 kb in > 33% patients - Schon et al 1989.
Heteroplasmy is always the case as may be easily predicted since if all the 
mitochondrial genomes in a patient were deleted to this extent the oxidative 
phosphorylation pathway would be non functioning and death would result. The 
deletions are most commonly from the region spanning np 8500 to around np 
13000 which removes all or part of the genes for ATPase 6 /8 , COIII, ND3, 
ND4L/4, ND5, ND6  and a number of tRNA genes.
These reported deletions had been thought to be sporadic but Poulton et al in 1991 
reported a patient with KSS and two asymptomatic relatives with the same 
mitochondrial DNA deletion. Using PCR they observed the so called common 
deletion of 5 kb in the blood and muscle of both the patient and relatives. Zeviani 
et al (1990) also reported a large pedigree in which the inheritance of multiple 
deletions in the mitochondrial genome appears to be autosomal dominant. 
Cormier et al (1991) noted that carriers of such multiple deletions were not 
always clinically affected and, in agreement with Zeviani et al (1990), suggested 
that a mutation in a nuclear gene triggers multiple deletions of the mitochondrial 
genome.
The realisation by Poulton et al (1994) that there can be a failure to discriminate 
simple deletions from multiple rearrangements in mitochondrial DNA prompted a 
reinvestigation of a number of KSS and CPEO patients. Figure 1:5 shows a 
schematic representation of a partial duplication and partial deletion of human 
mitochondrial DNA molecules. The 6.4 kb partial deletion could result from 
recombination between the duplicated portion of the 23 kb partial duplication 
molecule. Using appropriate restriction enzymes Poulton et al (1994) found that 
10/10 KSS patients had both deletions and duplications while 8 /8  CPEO patients 
had only duplications. The role of the different rearrangements in the 
development of different phenotypes is unknown.
14
I 2 3  r P MA
0
H
6.4kb
P v uNO I /  NO 5
A l t e r e d  f r o m  D u n b a r  el al .  199.1.
Figure 1:5 Schematic diagram showing A. a partially duplicated mt DNA
molecule. B. normal mitochondrial genome and the molecule 
produced by a partial deletion of the molecule shown in A.
The mechanisms by which rearranged molecules arise are also unknown: one 
theory is of intramolecular recombination (Mita et al, 1990), although this would 
be difficult to reconcile with the presumed lack of a DNA repair system in human 
mitochondrial DNA. Another theory is one of replication slippage (Shoffner et al, 
1989) due to direct repeats at the breakpoint of the rearrangement. A nuclear 
gene defect could be implicated in either theory to explain the deletions which 
are apparently inherited. The sporadic deletions may result from a mistake in 
mitochondrial DNA replication during some crucial developmental stage, in a 
particular cell-type.
1:8 :2 Diabetes and deafness
Ballinger et al (1992) studied a pedigree in which diabetes mellitus (DM) was 
inherited, along with deafness, via the maternal line. This combination of 
symptoms was inherited over 3 generations. The mitochondrial DNA of muscle 
from the index case was found to be heteroplasmic: 31% normal, 69% deleted by
10.4 kb, i.e. only 6 .1 kb in length. By direct sequencing the deletion was found to 
be between np 4308 and np 14874. The muscle of the index case also showed 
severe reduction of all the complexes of oxidative phosphorylation. Surprisingly 
there were no reported muscle symptoms in this family. The effect of this 
deletion on m itochondrial protein synthesis was measured using EBV- 
transformed lymphoblast cell-lines and primary myoblast cell-lines. The 
lymphoblast cell-line, with 53% of the mitochondrial DNA molecules deleted, 
showed a decrease of 52% in 3 5S-Methionine incorporation into mitochondrial 
translation products. The myoblast cell-line from the same patient had only 17% 
deleted mitochondrial DNA molecules and mitochondrial protein synthesis at a 
normal level. Ballinger et al (1992) concluded that the deletion was associated 
with decreased mitochondrial protein synthesis. The mechanism by which this 
results in the symptoms observed is unknown.
This three generation family was subsequently re-examined (Ballinger et al, 1994) 
and found to have at least two species of rearranged mitochondrial DNA 
molecules: a duplication and deletion dimer. The duplicated molecule has a 6.1 
kb insertion duplicating the origin of heavy strand replication but not the origin of 
light strand replication. The deleted molecule comprises tandem copies of the 6.1 
kb segment giving a deletion dimer. The proportions of duplicated and deleted 
mitochondrial DNA vary greatly within the family, but it seems that transmission 
is of a mitochondrial DNA duplication. The deleted molecules accumulate in 
somatic tissues, and may cause a decline in oxidative phosphorylation. When 
ATP production falls below a critical level in pancreatic p cells diabetes mellitus 
is presumed to result.
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Dunbar el al (1993) identified a partially duplicated mitochondrial DNA in the 
blood and muscle of a patient and his mother, both of whom had late onset DM. 
The duplicated molecule was found (by various restriction enzyme digestions) to 
extend from np 13445 (ND5) to np 3318 (ND1), flanked by an imperfect direct 
repeat.
The development of diabetes in families in which there are partial duplications in 
mitochondrial DNA, in addition to those families with the np 3243 mutation in 
tRNALeu(UUR) (Reardon et al, 1992; van den Ouweland et al, 1992) implies a 
possible common pathogenic mechanism.
1:9 DISEASES ASSOCIATED W ITH M ITOCHONDRIAL DNA 
DEPLETION
Recently a small number of patients have been identified who have a quantitative 
change in mitochondrial DNA, in contrast to the qualitative changes, i.e. point 
mutations, rearrangements, so far described. Moraes et al (1991) described four 
infants who were found to have a severe depletion of mitochondrial DNA in 
tissues in which symptoms of mitochondrial disease were observed. The levels of 
mitochondrial DNA depletions in these patients correlated well with decreased 
Cytochrome c oxidase (COX) activity: one patient had COX activity which was 
only 2% of control in muscle, and 7% in liver, which correlates with 2% and 12% 
of control mitochondrial DNA levels.
All 4 patients in this study died in early infancy presumably due to an inability of 
tissue to survive with virtually no oxidative phosphorylation. Mazziotta et al
(1992) also described a child with a fatal, in this case liver, disease in which there 
was severe depletion of mitochondrial DNA. Biochemical studies indicated 
marked deficiencies of respiratory chain complexes I, III and IV activity in the 
liver.
It has been proposed that mitochondrial DNA depletion is caused by a nuclear 
gene defect impairing mitochondrial DNA replication. In order to investigate this 
hypothesis Bodnar et al (1993) studied fibroblasts from a patient who had a 
similar fatal mitochondrial disease, in which mitochondrial DNA was greatly 
depleted. These cells in culture had a requirement for uridine and pyruvate, 
which is a characteristic of rho° cells.
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Tissue culture cells will become rho°, i.e. devoid of mitochondrial DNA, after 
long term exposure to low concentrations of ethidium bromide (King and Attardi 
1989). Bodner et al (1993) fused enuncleated fibroblasts (cytoplasts) from a 
patient with normal fibroblasts and found that normal levels of patient 
mitochondrial DNA were restored: the implication being that a normal nuclear 
gene product can restore replication of the patient's mitochondrial DNA.
Nuclear DNA involvement would be consistent with the proposed mechanisms of 
inheritance of mitochondrial DNA depletion, which is either autosomal recessive 
(Moraes et al 1991) or autosomal dominant with incom plete penetrance 
(Mazziotta et al 1992). Mitochondrial DNA depletion is a recent and rarely 
reported phenomenon. It is probable in future, that levels of mitochondrial DNA 
will be measured in patients who present with clinical symptoms of combined 
respiratory chain complex deficiencies. This, in addition to examination for the 
presence of mitochondrial DNA mutations will further elucidate the disease 
mechanisms in this heterogeneous group of patients.
1:10 M ETHODS OF INVESTIGATION OF M ITO CH O N D RIA L 
MUTATIONS IN RELATION TO DISEASE
Mutations, of the mitochondrial genome, associated with specific diseases have 
been investigated in a number of ways. In many studies mitochondrial DNA has 
been prepared from muscle biopsies (Moraes et al, 1992) or blood (Hammans et 
al, 1991) and sequence changes investigated by RFLP analysis.
Many studies have been carried out using cell-lines created from tissue, of various 
types, obtained from patients. Fibroblasts (Robinson et al, 1987), myoblasts 
(Kobayashi et al, 1992) have all been used. The advantages are that in vitro 
studies of oxidative phosphorylation capacity, mitochondrial DNA, RNA and 
proteins can be easily carried out. The disadvantage of studies using cell-lines is 
in the tissue-specificity of many mitochondrial diseases. For example, the 
decrease in cytochrome-c oxidase activity found in lymphoblastoid cell-line 
prepared from a LHON patient (Brown et al, 1992) is difficult to relate to the 
clinical phenotype of LHON.
Another method has been the use of cybrid cell-lines which are produced by 
fusion of two different kinds of cell, one of which has been enucleated. This 
method was particularly useful in early studies of chloramphenicol resistance 
(Bunn et al, 1974). More recently cybrids have been made between normal cells 
which are rho° and enucleated cells with mutant mitochondrial DNA. These 
have been used in the study of MELAS (Chomyn et al, 1992; King et al, 1992)
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and have provided a means to study the genetic and biochemical effects of the np 
3243 mutation. Obviously combinations of the above methods will provide most 
information regarding the relationship of specific mitochondrial DNA mutations 
to particular diseases.
1:11 INHERITED DEAFNESS
There are many known or suspected environmental causes of deafness: noise, 
infection, antibiotics, vaccination. Congenital deafness accounts for 
approximately 50% of childhood hearing loss and this can be divided into two 
categories: syndromic and non-syndromic. There are a large num ber of 
syndromes in which deafness is a major symptom, e.g. Usher Syndrome and 
Waardenburg Syndrome. Most congenital deafness is non-syndromic, and it can 
be tentatively categorised into autosomal recessive, which accounts for 60-70% of 
cases, autosomal dominant, 20-30% of cases and X-linked, 2% of cases (Jaber et 
al 1992). A recent addition to this category is maternally inherited deafness. As 
will be described later in this thesis, it is probable that some inherited deafness 
previously categorised as above will in fact turn out to be maternally inherited.
In general, all pedigree analyses involving deafness are fraught with problems as 
deaf individuals tend to associate with and partner other deaf people. 
Determining the mode of inheritance is also impeded by the fact that most 
pedigrees are too small to determine unambiguously the mode of inheritance.
The identification of genes causing deafness in the mouse is likely to be fruitful in 
identifying human homologues. Large families of mice can be generated in a 
relatively short time providing a powerful resource for identifying candidate 
genes by positional cloning (K. Steel, 1993). In addition, the structure and 
function of the mouse and human inner ear are very similar. The inner ear 
pathology observed in genetic deafness is very similar as is involvement of other 
features such as deafness with pigmentation defects or with digit malformations. 
Waardenburg syndrome is one disease in which studies in mice have led to 
identification of the human homologue.
Mutations in the Pax-3 gene in mouse result in a mouse phenotype called Splotch 
which has coat pigmentation alterations and is deaf. The homologue in humans, 
PAX-3, and mutations in exons 2 and 4 of this gene have been identified in 
Waardenburg syndrome (A. Read, 1993). The use of mice in the study of the 
genes associated with deafness will obviously result in the identification of genes 
responsible. A major problem could be in the study of less severe forms of 
deafness, as is the case in the family described in Chapter 4 of this thesis. It is
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unlikely that mild to moderate hearing loss, which can be debilitating in humans, 
could be easily identified in mice.
1:11:1 Sensorineural hearing loss in Mitochondrial Disease
The symptom of deafness is one often described in mitochondrial disease and a 
number of families have now been identified in which deafness inherited via the 
maternal line is the sole or predominant feature (Bu et al 1993; Elverland and 
Torbergsen 1991). In addition, maternally inherited deafness has been found in 
combination with other symptoms - most commonly diabetes (see Section 1:7); 
but also myoclonus (Vaamonde et al 1992) and epilepsy (Kobayashi et al 1987). 
Various types of mitochondrial mutation have been identified in these patients: 
large deletions or duplications, point mutations of tRNA genes or of the 12S 
rRNA genes. The pathological mechanisms by which this wide range of 
molecular defects in mitochondrial DNA cause the development of sensorineural 
hearing loss have not been elucidated.
1:11:2 Antibiotic-induced deafness
Streptomycin is known to cause deafness when administered in high doses and 
over long periods of time, as is the case in the treatment of pulmonary 
tuberculosis. In fact all of the aminoglycoside antibiotics are known to be 
ototoxic; the mode of action is thought to involve damage to the Organ of Corti 
(part of the cochlea) hair cells (Ballantyne 1970), in addition to toxicity to the 8 th 
cranial nerve. Characteristic initial effects of such antibiotic treatment is loss of 
hearing at high frequencies. Since 1964 when the first family study was reported 
(Prazic et al 1964) there have been a number of reports of families in which 
susceptibility to streptomycin is inherited. Johnsonbaugh et al (1974) and Viljoen 
et al (1983) both studied families in which streptomycin had been administered 
and both concluded that the inheritance was autosomal dominant.
There have now been a number of studies in which the predisposition to become 
deaf after treatment with aminoglycosides has been found to be maternally 
inherited. Higashi in 1989 identified 28 families where this was the case; in 1991 
Hu et al analysed 36 Chinese pedigrees and found similar results. Prezant et al
(1993) have discovered a point mutation at np 1555 in the 12S rRNA in this latter 
group of families. This A->G change at np 1555, which has not been identified in 
normal controls, is in a highly conserved region of the 12S rRNA which is very 
similar to a region of E. coli 16S rRNA at which aminoglycosides are known to 
bind. They postulate that the mutation lengthens the binding site for the
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am inoglycoside causing increased binding and a consequent increase in 
susceptibility to such antibiotics.
1:12 AIMS OF PROJECT
The aim of this study was to identify any mutations of human mitochondrial DNA 
which are to be found only in association with sensorineural hearing loss. The 
project was initiated after a patient previously diagnosed as having LHON 
developed sensorineural hearing loss. This was a previously unreported 
combination of symptoms.
At the beginning of the project it had not been established whether this patient 
had any of the previously reported mitochondrial mutations associated with 
LHON. Sequencing of the entire mitochondrial genome was undertaken to 
establish which, if any, LHON mutation was present in addition to other 
mutations which could play a role in the development of deafness.
Patients suffering from sensorineural hearing loss of no known aetiology were 
selected to be screened, by RFLP analysis, for the presence of known mutations. 
This in combination with the complete sequence of the LHON patient would 
indicate whether any of these mutations should be further investigated to establish 
their role in the aetiology of deafness.
Patients suffering from AAID were included in a limited study of firstly, a 
mutation already identified in maternally inherited sensorineural hearing loss at 
np 1555 and secondly, a mutation in the Xbal site at np 7440 already identified in 
LHON.
One of the sensorineural hearing loss patients was studied in much more detail as 
a result of her apparently maternally inherited deafness, in addition to the 
discovery of a previously unreported mutation in her mitochondrial DNA. 
Sequencing of the entire mitochondrial genome of this patient was undertaken in 
a similar way to that of the LHON patient in order to establish whether the two 
had any mutations in common and as such could be implicated in the 
development of deafness.
The role of any mutations found would be investigated by in vitro studies using 
lymphoblastoid cell-lines created using patient lymphocytes. This strategy was 
designed to identify any mitochondrial mutation which may be responsible, in 
combination with nuclear genetic or environmental factors, for the development
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of hearing loss. It would also yield preliminary data regarding the molecular 
mechanisms involved.
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CHAPTER 2 MATERIALS AND METHODS
2:1 SOURCES OF CHEMICALS AND ENZYMES
Chemical/enzyme
General chemicals and solvents 
Culture media 
Biochemicals
Agarose
Film
Radiochemicals 
Restriction enzymes
Modifying enzymes 
PCR product purification systems 
Magnetic beads 
Biotin Phosphoramidite 
Digoxigenin-labelling and detection 
Sequenase Version 2 sequencing kit 
Silver staining kit 
Long Ranger & MDE gel 
Sequencing gel solution 
NA45 paper
Source
BDH, ICN 
GIBCO BRL, ICN 
Sigma, BRL
BRL
Dupont
NEN (Dupont)
BRL, New England Biolabs, 
Boehringer Mannheim, Promega
Boehringer, BRL, Promega
Promega, Qiagen
Dynal
Cruachem
Boehringer Mannheim 
United States Biochemical 
BioRad
Hoefer Scientific 
NBL
Schleicher & Schull
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2:2 SOLUTIONS
B&W Buffer (2X)
COX Assay Buffers
Coomassie Blue stain
Destain for Coomassie blue 
D enaturing solution (Southern 
blots)
DIG prehybridisation solution
DIG Buffer 1 
DIG Buffer 2 
DIG Buffer 3
DIG Washing buffer 
Solution D
Emetine
K-Buffer
Lactate Buffer
Lysing solution for blood 
Methylene blue stain 
MOPS
10 mM Tris/HCl pH 7.5, 1 mM EDTA, 2 
MNaCl
40 mM KPi Buffer (see below)\vith 0.2% 
Saponin, 16 mg Cytochrome c in 20 ml of 
40 mM KPi Buffer, 6.5 mg/ml KCN. 10% 
Digitonin w/v in Dimethyl sylphoxide
1.5 g Coomassie blue, 550 ml ethanol, 
110 ml acetic acid, 550 ml of dH 2 0
1 0 % acetic acid, 1 0 % ethanol 
0.5 M NaOH, 1.5 M NaCl
5X SSC (see below), 1 % Blocking
reag en t (B o e h r in g e r) , 0 .1 %  N-
lauroylsarcosine, 0.02% SDS
0.1 M Maleic acid, 0.15 M NaCl, pH 7.5
Buffer 1 + 1% Blocking reagent
0.1 M Tris/HCl, 0.1 M NaCl, 50 mM
MgCl2, pH 9.5
DIG Buffer 1 + 0.3% Tween 20 
4 M guanidinium thiocyanate, 25 mM Na 
citrate (pH 7.0), 0.5% sarcosyl, 0.1 M 2 - 
mercaptoethanol
stored at 4°C as 100 mM stock solution in 
dH20
50 mM KC1, 10 mM Tris/HCl (pH 8 ), 2.5 
mM MgCl2, 0.5% Tween 20, 100 pg/ml 
freshly dissolved Proteinase K
46.5 ml of 0.1 M Tris HC1 (pH 9.3), 3.5 
ml of 30 mM NAD, 500 pi Hydrazine 
hydrate, 280 pi Lactate dehydrogenase 
(5mg/ml)
1% v/v Triton-X-100, 0.33 M sucrose, 5 
mM MgCl2, 10 mM Tris/HCl (pH 7.5) 
0.04% methylene blue, 0.5 M sodium 
acetate pH 5.2
0.4 M MOPS, 3 -[N-Morpholino]propane- 
sulphonic acid, 0.1 M Na acetate pH 7.0, 
0.02 EDTA
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MOPS gel
Neutralisation Buffer (Southern 
blots)
NET-High salt 
NET-Low salt 
PBS (IOX)
Phosphate Buffer (KPi) 0.2 M
Phosphate Buffer (KPi) 0.4 M
Protein gel running buffer
Protein gel separating buffer 
Protein gel stacking buffer 
Pyruvate buffer
RNA loading buffer 
SDS sample buffer (2X)
Sucrose/Tris Buffer
Solution for Proteinase K (2X) 
SSC (20X)
TBE(IOX)
TE(100X)
0.75 g agarose, 55.5 ml dH O, 7.5 ml 
10X MOPS, 12 ml Formaldehyde when 
cooled to 60° C
1.5 M NaCl, 0.5 M Tris/HCl (pH 7), 1 
mM EDTA
1 M NaCl, 0.1 mM EDTA, 20 mM 
Tris/HCl (pH 8.0)
150 mM NaCl, 0.1 mM EDTA, 20 mM 
Tris/HCl (pH 8.0)
0.026 M KC1, 0.15 M K H 2 P 0 4  (anhyd), 
0.08 M N2H P04 , 1.37 M MaCl 
A-0.2 M KH 2PO4 ; B - 0.2 K2HPO4 . For 
200 ml 56.5 ml of A and 43.5 ml of B 
were mixed and the volume adjusted 
with dH20  (final pH 6.65)
For pH 7.5: 16ml of A and 84ml of B 
diluted to 2 0 0 ml.
A-0.4 M ; B-o.4M. for 200ml 51 ml of 
A and 49ml of B (Final pH 7.0).
15.2 g Tris, 72 g Glycine (pH 8.5), 0.1% 
SDS
1.5 M Tris/HCl (pH 8 .8 )
0.5 M Tris/HCl (pH 6 .8 )
47.5 ml of 0.4 mM KPi (pH 7.0), 2.5 ml 
of 2 mM NADH, 28.7 pi Lactate 
dehydrogenase
25% Ficoll, 0.25% bromophenol blue 
2.3% SDS, 3.5 mM Tris/H C l (pH 
6 . 8 ) ,1 0 %  g ly c e r o l ,  5%  2-
mercaptoethanol, 0.25% bromophenol 
blue
0.25 M Sucrose, 0.01 M Tris/HCl (pH 
7), 1 mM EDTA
150 mM NaCl, 50 mM EDTA, 1% SDS 
3 M NaCl, 300 mM Na citrate (pH 7.0)
89 mM Tris/HCl, 89 mM Boric acid, 2 
mM EDTA
1 M Tris /HC1 (pH 8.0), 0.1 M EDTA
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2:3 PREPARATION OF OLIGONUCLEOTIDES
Oligonucleotide primers were synthesised on an Applied Biosystems DNA 
synthesiser. To facilitate direct sequencing those 5' primers used to amplify 
products for subsequent sequencing had 2 Biotin moieties added at the 5' end 
during synthesis. The biotin phosphoramidite reagent was always used within 24 
hours of opening.
Tables 2:1:1, 2:1:2 and 2:1:3 list the primers prepared for use in DNA 
amplification for sequencing.
Table 2:2 lists the primers used only for sequencing.
Table 2:3 lists sequencing primers which were gifts from Dr Ian Holt of the 
Department of Biochemical Medicine, University of Dundee.
2:4 PREPARATION OF DNA
2:4:1 Blood
Blood was collected into EDTA tubes and either processed immediately or stored 
at -20°C until DNA preparation. 50 pi of blood was mixed with 500 pi of TE 
buffer, vortexed briefly and centrifuged at 14000 gmax for 5 minutes. The pellet 
was resuspended in a further 500 pi of TE and the process repeated twice. The 
final pellet was resuspended in 100 pi of K-buffer, vortexed and incubated at 
56° C for 45 minutes. The protease was then inactivated by heating to 75° C for 
10 minutes. The DNA prepared in this way was stored at -20°C until required.
2:4:2 Tissue culture cells
Cells from one 75 cm^ flask (30 ml of 1 x 10^/ml were washed once in PBS and 
the pellet resuspended in 10 times the cell pellet volume of PBS. Cells were lysed 
by adding 10% SDS to a final concentration of 0.05% and sterile NaCl was added 
to give a final concentration of 1M. This was mixed gently, then incubated 
overnight at 4°C to precipitate the chromatin. After centrifugation at 16000 gmax 
for 30 minutes at 4°C, the supernatant was decanted and further SDS added to a 
final concentration of 0.05%.
Contaminating protein was removed by addition of 100 pg/ml Proteinase K. 
Digestion was effected at 65°C for 15 minutes. When the samples had cooled to 
room temperature they were extracted twice with phenol and once with 
chloroform/isoamylalcohol (24:1) once. The DNA was precipitated overnight at 
-20°C following addition of 1/10 volume of 3M NaAc (pH 5.0) and 2 volumes of
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REFERENCE
CODE
REGION OF 
MITOCHONDRIAL 
GENOME
SIZE OF 
FRAGMENT (np)
FR61/23B D-LOOP 645
FR60/668L D-LOOP
FR14/618B tRNA phe 940
FR15/1570L 12S rRNA
FR12/1444B 12S rRNA 680
FR13/2125L 16S rRNA
FR10/2470B 16S rRNA 610
FR11/3080L 16S rRNA
FR6/3013B 16S rRNA 690
FR7/3698L ND1
FR8/3628B ND1 870
FR9/4505L ND1
FR16/4417B tRNA met 900
FR17/5258L ND2
FR25/5163B ND2 627
FR26/5790L tRNA cys
FR54/5703B tRNA as$f 819
FR28/6522L COI
Table 2:1:1 Primers used to amplify PCR products for sequencing; region 
from np 23 in D-LOOP to np 6522 in COI gene. Reference 
code key: primers with -B suffix have two Biotin moieties at 5' 
end, number after dash is 5' np coordinate; primers with -L 
suffix are 3 1 primers on L-strand, number after dash is 3' np 
coordinate.
REFERENCE
CODE
REGION OF
MITOCHONDRIAL
GENOME
SIZE OF
FRAGMENT (np)
FR29/6456B COI 796
FR30/7252L COI
FR31/7178B COI 662
FR32/7840L c o n
FR33/7773B COI1 789
FR34/8562L ATPase 6
FR35/8469B ATPase 8 742
FR36/9211L COIII
FR37/9131B ATPase 6 798
FR38/9937L COIII
FR39/9848B COIII 825
FR40/10673L ND4L
FR41/10617B ND4L 658
FR42/11275L ND4
FR43/11164B ND4 750
L2/11914L ND4
FR51/11836B ND4 717
FR44/12553L ND5
Table 2:1:2 Primers used to amplify PCR products for sequencing; region 
from np 6456 in COI gene to np 12553 in ND5 gene.
REFERENCE
CODE
REGION OF
MITOCHONDRIAL
GENOME
SIZE OF
FRAGMENT (np)
FR45/12472B ND5 669
FR46/13141L ND5
FR1/12907B ND5 827
FR2/13734L ND5
FR47/13627B ND5 780
FR48/14447L ND6
FR55/14401B ND6 8 6 6
FR23/15267L Cyt b
FR52/15194B Cytb 863
FR53/16057L D-Loop
FR63/15980B tRNA pro 643
FR62/54L D-Loop
Table 2:1:3 Primers used to amplify PCR products for sequencing; region 
from np 12472 in ND5 gene to np 54 in D-loop. Reference 
code key as in Table 2:1:1.
REFERENCE CODE REGION
FR18/3519L ND1
FR19/4171L ND1
FR20/3321L ND1
FR21/1268L 12S rRNA
FR22/5003L ND2
FR24/14683H tRNA Glu
FR56/8200L c o n
FR57/9656L COIII
FR58/11548L ND4
FR59/14070L ND5
FR64/8630L ATPase 6
FR65/10295L ND3
FR66/12822L ND5
FR67/10996L ND4
FR68/1073L 12S rRNA
FR70/15217L Cyt b
FR71/707L 12S rRNA
FR72/12080L ND4
FR73/14576L ND6
FR74/14827L Cyt b
FR75/15715L Cyt b
FR76/16208 D-loop
FR49/7324H COI
FR50/7567L tRNASer
FR78/14973H Cyt 6
Table 2:2 Primers used as sequencing primers. Reference code key:
primers with -H suffix encode the H-strand sequence, the 
number after the dash is the 5' np coordinate; primers with -L 
suffix encode the L-strand sequence, the number after the dash 
is the 3' np coordinate.
REFERENCE CODE
REGION OF
MITOCHONDRIAL GENOME
IH3/4739H ND2
IH5/I6054H D-loop
IH8/3122L 16S rRNA
IH14/3621L ND1
IH27/15800L Cyt b
IH28/483H D-loop
IH30/2429H 16S rRNA
IH31/2363L 16S rRNA
IH33/5914L COI
IH42/15460H Cyt b
IH44/13523H ND5
IH60/6880L COI
IH63/7935L c o n
IH91/3100H 16S rRNA
2:3 Primers used as sequencing primers; a gift from Dr Ian Holt, 
Department of Biochemical Medicine, University of Dundee.
absolute ethanol. The DNA was pelleted by centrifugation at 14000 g max for 10 
minutes; washed in 10% ethanol and dried at room temperature. RNA 
contaminating the pellet was removed by adding boiled RNase to a concentration 
of 100 pg/ml and incubating at 37°C for 1 hour. SDS and Proteinase K treatment 
was repeated as above followed by extraction with phenol, extraction with 
chloroform and precipitation with ethanol. The final, dried DNA sample was 
resuspended in 100 pi TE and stored at -20°C.
2:4:3 Buccal cells
10  ml of sterile distilled water was swilled round the mouth for approximately 
one minute before being put into a 15 ml falcon tube. After centrifugation at 
3000 g max for 5 minutes the buccal cell pellet was resuspended in 500 pi TE and 
treated as for blood (section 2:4:1).
2:5 ESTIMATION OF DNA CONCENTRATION USING ETHIDIUM
BROMIDE PLATES
In order to estimate the amount of DNA extracted from either blood or cells 20 ml 
of 1% agarose was prepared: to this 1 pi of 1 0  mg/ml of ethidium bromide was 
added, giving a final concentration of 500 ng/ml. This was poured into a standard 
(90 mm) petri dish and allowed to set. A dilution series from undiluted to 
1:10,000 of a known concentration of DNA was spotted onto the agarose 
alongside a dilution series of prepared DNA samples. Once dry the plate was 
viewed under a UV light and the amount of DNA estimated by comparing the 
intensity of fluorescence.
2:6 POLYMERASE CHAIN REACTION (PCR)
2:6:1 PCR reaction conditions
Twenty microlitre reactions were set up; in each approximately 100 ng of 
template DNA was mixed with 200 pM each of dATP, dCTP, dTTP and dGTP 
and 20 pmol each of forward and reverse primers in IX  Taq polymerase buffer 
supplied by the manufacturer of the Taq polymerase. One unit of Taq polymerase 
was added and the reaction overlaid with mineral oil before thermal cycling.
2:6:2 Conditions for thermal cycling
A Cambio thermal cycler was employed. Unless otherwise stated, the conditions
for amplification were:
2 6
94°C x 6  minutes 
55°C x 1 minute 
72°C x 3 minutes 
94°C x 1 minute 
72° C x 15 minutes
}
} 30 cycles
}
In order the minimise the risk of amplification artifacts being mistaken for 
sequence mutations, when amplification was carried out for sequencing four 
reaction were set up and the amplified products pooled before purification. 
Amplified products were always checked by agarose gel electrophoresis and 
subsequent ethidium bromide staining.
Where the agarose gel indicated that there was only one major amplified product, 
this was purified using the PROMEGA "Magic" PCR purification system or the 
Qiagen PCR purification system. Where there were minor products in addition to 
the obvious major product, the major product was purified using NA45 paper.
The paper was washed at room temperature for 10 minutes in 10 mM EDTA, then 
5 minutes in 0.5 M NaOH. After several rapid washes in sterile distilled water 
the activated paper can be stored in distilled water at 4°C for several months.
The amplified product was loaded, alongside size markers, onto 1% agarose gel 
and run overnight at 20 volts to ensure good separation of bands. After ethidium 
bromide staining the gel was viewed under UV light and a cut, the width of the 
well, made just beyond the band to be isolated. A piece of activated paper was 
inserted into the cut and the gel electrophoresed for a further 10  minutes at 1 0 0  
volts. The NA45 paper was removed and viewed under UV to check that the 
DNA had run into the paper.
2:7:3 Elution of amplified product
The DNA-containing paper was washed three times in 500 pi Low salt NET, 
followed by incubation in High salt NET at 6 8 °C for 15 minutes. The eluate was 
removed and stored, while a further 100 pi of High salt NET was added and the 
paper further incubated at 6 8 °C for 30 minutes. The 2 eluates were pooled and
2:7 PURI FI C ATI ON OF AMPLIFIED PRODUCTS
2:7:1 Activation of NA45 paper
2:7:2 Separation of amplified product
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precipitated by addition of 1/10 volume of 3M Na acetate and 2 volumes of 
ethanol. The purified product was stored at -20°C in this form.
2:8 RESTRICTION ENZYME DIGESTION
2:8:1 Total cell DNA
DNA was prepared as described in Section 2:4:1. 10 pg was digested with 10
units of restruction enzyme, according to the manufacturers instructions, in a total 
volume of 200 pi. Digestion products were precipated in ethanol and after drying 
and resuspension in TE electrophoresed through 0.8% agarose gels at 100 volts 
for 2 hours. DNA was visualised by Ethidium bromide staining.
2:8:2 Amplified PCR products
PCR was carried out with appropriate forward and reverse primers to amplify 
specific mitochondrial DNA regions. After purification, 1 pg of amplified 
product was digested with 1 unit of restriction enzyme according to the 
manufacturers instructions. Digestion products were electrophoresed through 
1.5% agarose or 3% Nusieve agarose gels at 100 volts for 2 hours. DNA was 
visualised by Ethidium bromide staining.
2:9 DNA STRAND SEPARATION PRIOR TO SEQUENCING
The 2 strands of purified amplified products were separated using Streptavadin- 
coated Dynabeads (see Figure 2:1). For each 50 pi of purified product 25 pi of 
Dynabeads were washed once with IX B&W Buffer, resuspended in 50 pi of 2X 
B&W Buffer and mixed with 50 pi of purified PCR product. The DNAwas 
bound to the Streptavidin-coated beads (via the biotin) during incubation at room 
temperature for 15 minutes after which the beads were washed once with IX 
B&W Buffer. In order to elute the non-biotinylated strand the beads were 
resuspended in 8  pi of freshly prepared 0.1 M NaOH and kept at room 
temperature for 1 0  minutes.
After this period the non-biotinylated strand was removed in the 8  pi to a fresh 
tube and 4 pi of 0.2 M HC1 plus 1 pi of 1 M TrisHCl (pH 7.5) added to neutralise. 
The volume was made up to 20 pi with distilled water and the DNA precipitated 
at -20°C using 3 M Na acetate and ethanol. The Dynabeads bearing the 
biotinylated strand were washed successively with 50 pi 0.1 M NaOH, 50 pi IX 
B&W Buffer, and 50 pi TE Buffer. The beads were finally resuspended in 7 pi of 
sterile distilled water, ready for sequencing.
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FCR sequencing using a biotinylated primer and Streptavidin- 
coated Dynabeads. Taken from Hultman et al, 1989.
2:10 SEQUENCING OF AMPLIFIED PRODUCT
2:10:1 Biotinylated strand 
Annealing reaction:
7 pi Dynabeads with +Bio strand attached 
2 pi Sequenase dilution buffer 
1 pi Primer (1 pmol)
Incubated at 65°C for 2 minutes, allowed to cool slowly to 37°C then put at 4°C 
for up to 4 hours before sequencing.
Sequencing was then carried out using 35S dATP according to the Sequenase 
Version 2 protocol (US Biochemicals). Before addition of stop solution the 
supernatant containing excess nucleotides and primers was taken from the beads 
using a magnet. The sequenced products were then eluted off the beads by 
addition of stop solution. It was not necessary to remove the beads before loading 
samples onto the sequencing gel.
2:10:2 Sequencing the non-biotinylated strand
The non-biotinylated strand was precipitated at -20° C for at least 24 hours. After 
washing in 70% ethanol and drying at room temperature the precipitated -Bio 
strand was taken up in 7 pi of distilled water and sequenced exactly according to 
the Sequenase Version 2 protocol (US Biochemicals).
2:10:3 Electrophoresis of sequenced products
Sequencing gels were made using Long Ranger gel solution and 0.6 x TBE used 
as running buffer. A BRL sequencing gel apparatus was used. After denaturation 
at > 80°C for 3 minutes 2 pi of -i-Bio samples, or 3 pi of -Bio samples were loaded 
and electrophoresed at constant power (60 Watts) for the required length of time. 
The polyacrylamide gel was transferred to 3 MM paper (Whatman), protected by 
Saran wrap and dried using a Genevac pump on a BioRad gel drier (model 583). 
The dried gel was exposed to X-ray film at room temperature and the film 
subsequently developed using an X-ray processer (X-o-graph, Compact x 2).
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2:11 SINGLE-STRANDED CONFORMATIONAL POLYMORPHISM 
(SSCP) ANALYSIS
2:11:1 Denaturation of samples
To 5 pi of purified amplified product 1 pi of 0.5 MNaOH/10 mM EDTA was
added and samples were incubated at 42°C for 5 minutes after which 2.5 pi of
loading buffer were added to each.
2:11:2 Electrophoresis of samples
Samples were loaded onto a 16 cm x 11 cm MDE gel, prepared according to the 
manufacturer's instructions, after each well had been washed out with IX TBE. 
Electrophoresis was carried out at constant power (20 Watts) with circulating 
water to maintain the gel temperature around 20°C. Each gel was run until the 
xylene cyanol dye had reached the bottom of the gel, normally approximately 4  
hours.
2:11:3 Staining of gels
Electrophoresed samples in MDE gels were stained using silver stain according to 
the manufacturer's instructions. The silver stain kit and protocol was supplied by 
BioRad. Briefly, the gel was agitated sequentially with:
40% Methanol - 30 minutes
10% Ethanol - 2 x 5  minutes
Oxidiser - 5 minutes
dH2 0  - 4 x 5  minutes or until yellow colour faint
Silver solution - 20 minutes
(JH2O 1 minute
Developer - 30 seconds; 2 x 5  minutes
5% Acetic acid - overnight
The stained gel was transferred to 3 MM paper and dried using a BioRad gel 
drier.
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2:12 SOUTHERN BLOTTING
2:12:1 Transfer of DNA to membrane
DNA digested with an appropriate restriction enzyme was electrophoresed 
through agarose gels, denatured by soaking for 30 minutes in denaturing solution 
and neutralised by soaking for 30 minutes in neutralising solution, before being 
transferred to positively charged nylon membrane (Boehringer Mannheim) by 
capillary blotting overnight in 6  x SSC. DNA was subsequently fixed to the 
membrane by baking at 80°C for 120 minutes.
2:12:2 DIG-random labelling
1 pi of denatured, purified PCR product was labelled by incubation with 2 pi of 
dNTP labelling mixture (lO x) containing DIG-11-dUTP, 2ul of hexanucleotide 
mixture and 1 pi (2u/pl) of Klenow enzyme in a total volume of 20 pi. Afteri 
ovemightincubation at 37 C the reaction was terminated by addition of 2 pi of 
200 mM EDTA. The labelled DNA was precipitated by incubation with 0.1 
volume of 4 M LiCl and 3 volumes of ethanol at -20°C.
2:12:3 Hybridisation
Membranes were prehybridised in DIG-prehybridisation solution at 42°C for at 
least 2 hours. 200 ng of denatured DIG-random-labelled PCR product was added 
into the prehybridisation solution and hybridisation carried out at 42°C 
overnight. The blot was washed twice in 2 x SSC/0.1% SDS at room temperature 
and twice in 0.1 x SSC/0.1% SDS at 65 °C .
2:12:4 Detection of hybridised molecules
Hybridisation was detected according to Boehringer Mannheim's DIG protocol. 
After washing, the membrane was equilibrated in DIG Buffer 1 for 5 minutes. 
The membrane was then blocked by gentle agitation in DIG Buffer 2 for 30 
minutes. The membrane was then incubated in anti-DIG-alkaline phosphatase at 
1:10,000 (75 mu/ml) for 30 minutes with gentle agitation. The membrane was 
then washed in DIG-Washing buffer for at least 30 minutes after which it was 
equilibrated in DIG Buffer 3 for 5 minutes before addition of substrate AMPPD 
(4-methoxy-4-(3-phosphate-phenyl)-spiro( 1,2-dioxetene-3,2-adamantane) 
disodium salt) solution (10 mg/ml). After incubation for 5 minutes the 
membrane was removed (the substrate solution can be reused) and blotted for a 
few seconds on Whatman 3 MM paper. The membrane was then sealed in a
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plastic bag and incubated at 37°C for 10-15 minutes before exposure to X-ray 
film for 15-25 minutes at room temperature.
2:13 Culture of Epstein-Barr Virus (EBV)-transformed cell-lincs
Transformation of lymphocytes by Epstein-Barr Virus was carried out at the 
European Collection of Animal Cell Cu;tures (ECACC), or at the Department of 
Medical Genetics, Yorkhill Hospital, Glasgow. Cells were received as frozen 
vials or as growing, suspension cultures. Cells were maintained in RPMI + 10% 
heat inactivated foetal calf serum + 2 mM Glutamine + 100 u/ml Penicillin + 100 
pg/ml Streptomycin. Growth conditions were 37°C in humidified 5% CO2 .
2:14 RNA MANIPULATIONS
2:14:1 Preparation of RNA from tissue-culture cells
5 x 109  cells were resuspended in 2 ml of solution D. Sequentially added were 
200 pi of 2 M Na acetate (pH 5), 2 ml of water equilibrated Phenol, 400 pi of 
chloroform/isoamyl alcohol (24:1), mixing after each addition.
After shaking for 10 seconds this mixture was kept on ice for 15 minutes, then 
centrifuged at 10,000 gmax for 20 minutes at 4°C. The aqueous phase was 
removed to a fresh tube and 2 ml of isopropanol added to precipitate the RNA at 
-20°C. After 24 hours the precipitate was spun down at 10,000 gmax for 20 
minutes at 4°C. After centrifugation RNA was present in the aqueous phase
which was transferred to a fresh tube, mixed with 1 ml of isopropanol and put at
-20°C for at least one hour. After centrifugation at 10,000 gmax for 20 minutes 
the RNA pellet was dissolved in 300 pi of solution D and 300 pi of isopropanol 
was added to reprecipitate the RNA at -20°C overnight. After washing the 
pelleted RNA in 70% ethanol and drying, the RNA was taken up in 50 pi TE and 
stored at -70° C until required.
2:14:2 Electrophoresis of RNA
To 10 pg of RNA were added 10 pi of deionised formamide, 2 pi of 10 x MOPS 
and 3.2 pi of formaldehyde. The solution was incubated at 65°C for 15 minutes 
then stored on ice until ready to load into the gel. 5 pi of loading buffer was 
added. Samples were electrophoresed through 1% agarose gel containing 
formaldehyde (see MOPS-gel) gel at 80 Volts for one hour.
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2:15 NORTHERN BLOTTING
2:15:1 RNA transfer
RNA was transferred to Boehringer positively charged nylon membrane by 
overnight capillary blotting of the gel in 10 x SSC.
After fixation of RNA to the membrane, by baking at 80° C for 2 hours or 120°C 
for 30 minutes, successful transfer was confirmed by methylene blue staining of 
membrane, as follows: Briefly: the membrane was soaked in methylene blue 
stain for 1 0  minutes, then destained with a few changes of H2O until very little 
blue background remained.
2:15:2 Northern Hybridisation
Hybridisation was carried out in hybridisation bottles with a mock filter of the 
same dimensions as the test filter separated from the test filter by nylon mesh. 
Prehybridisation was carried out at 50°C for > 4 hours using DIG 
prehybridisation solution. 200 ng of denatured, DIG-labelled PCR product was 
added and hybridised overnight at 50°C. Washing and detection was as for 
Southern blots.
2:16 ANALYSIS OF MITOCHONDRIAL TRANSLATION PRODUCTS
2:16:1 35S Methionine labelling
1 x 106 cells were incubated in 100 pi of RPMI medium minus Methionine for 
one hour at 37°C. Emetine was added at concentrations of 100 nM or 10 nM, in 
the presence and absence of 1 mM chloramphenicol. 25 pci of 35S labelled 
methionine (1175 Ci/mmol) was then added and the cells incubated at 37°C for a 
further 1 hour. Cells were then washed in 1 x PBS and resuspended in 20 pi of 1 
x SDS-loading buffer.
2:16:2 Electrophoresis of proteins
After denaturation at 100° C for 10 minutes samples were electrophoresed through 
an SDS/12% polyacrylamide gel at constant current (20 mA) for 4 hours. Gels 
were stained with Coomassie blue, and destained overnight before being washed 
in "Amplify” (Amersham) for 30 minutes. After drying onto 3 MM paper 
proteins were visualised fluorographically by exposing to film at -70°C for at 
least 24 hours before developing.
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2:17 CYTOCHROME-c OXIDASE (COX) ASSAY
5 x 106 cells were washed with 1 x PBS and resuspcnded in 1 ml of Sucrose-Tris 
(pH 6.7). These were kept on ice until reagents prepared. Immediately prior to 
assay the cells were disrupted by being frozen in dry ice/ethanol and thawed at 
37°C three times. 30 pi of disrupted cells were mixed with 1.8 pi of 10% 
Digitonin for 10 minutes on ice. 25 pi of this was mixed (in a 1 ml cuvette) with 
470 pi of KPi buffer and 500 pi of cytochrome c which had been fully reduced by 
adding Na dithionite. Absorbance at 550 nm was read over a period of 5 minutes 
at room temperature. In order to measure the level of autoxidation (it should be 
minimal) a reference sample was set up with no cells but with 10 pi of 6.5 mg/ml 
KCN. After 30 seconds at room temperature the absorbance at 550 nm was 
measured. If any rate was observed the cytochrome c had not been fully reduced 
and further Na dithionite was added until no rate was observed.
2:18 SUCCINATE/CYTOCHROME c REDUCTASE (SCCR) ASSAY
Cells disrupted for COX assay were also used in the SCCR assay but without 
Digitonin treatment. Mixed in a cuvette were: 800 pi of 30mM KPi Buffer (pH 
7.5) 50 pi of 60 mM Succinate, 50 pi of 2 mM Cytochrome c which was fully 
oxidised i.e. no Na dithionite added, 50 pi of 50 mg/ml BSA, 50 pi of 20 mM 
KCN and 25 pi disrupted cells.
Absorbance at 550 nm was measured at room temperature over a period of 5 
minutes against a blank with every component except cells.
2:19 LACTATE/PYRUVATE MEASUREMENTS
2:19:1 Preparation of cells
5 x 105 cells were resuspended in 2 ml of RPMI 1640 (from ICN) + 4% foetal 
calf serum + 2 mM glutamine + 50 pg/ml uridine and incubated in 25 cm 2 flasks 
for 48 hours at 37° C in humidified 5% CO2 .
After 48 hours the medium was removed and 1/5 volume of 10% TCA added 
before centrifugation at 3000 g max for 10 minutes. This was frozen at -20°C 
overnight until ready to assay. Immediately prior to assay samples were 
centrifuged at 3000 gmax for 5 minutes and the supernatant assayed for both 
lactate and pyruvate.
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2:19:2 Lactate assay
Standards within the range 100 pM-20 mM lactic acid were prepared. 25 pi of 
substrate was added to 975 pi lactate buffer and incubated at 37°C for 
approximately 1 hour. Absorbance of NADH at 340 nm was measured for each 
against a reference with lactate buffer and water.
2:19:3 Pyruvate assay
Standards within the range 1-200 pM sodium pyruvate were prepared. 200 pi of 
substrate was added to 800 pi pyruvate buffer and incubated at 37°C for 
approximately 30 minutes before measuring optical density at 340 nm.
2:20 MTT ASSAYS
2.0 x 106  cells were incubated in 25 ml of RPMI medium in 25 cm 2 flasks. 500 
pi samples were taken in triplicate and 50 pi of MTT (3-(4,5-dimethyj-thiazol-2- 
yl)-2.5-di-phenyl tetrazolium bromide) at 5 mg/ml added to each. After 
incubation at 37° C in humidified 5% CO2 for 1 hour 500 pi of 10% SDS was 
added to each sample which was re-incubated at 37°C for up to 24 hours. Optical 
density at 570 nm was measured on all samples at the end of the sampling period.
2:21 AUDIOMETRY
Pure tone audiometry was performed (by staff of the ENT Dept., Victoria
Infirmary, Glasgow ) in an acoustically treated booth to standard ISO/DIS 8253,
using a Kamplex AC3 clinical audiometer.
CHAPTER 3 INVESTIGATION OF PATIENTS SUFFERING  
FROM NON-SYNDROMIC SENSORINEURAL  
HEARING LOSS
3:1 STUDIES OF PATIENTS WITH SENSORINEURAL HEARING
LOSS OF UNKNOWN AETIOLOGY
Sensorineural hearing loss is one of the most common symptoms reported in 
diseases associated with mutations of mitochondrial DNA. The identification of a 
patient with sensorineural hearing loss in addition to LHON (further discussed in 
Chapter 5) prompted this investigation of patients with no known aetiology for 
their deafness. The intention was to examine mitochondrial DNA from patients 
with non-syndromic deafness for readily identified mutations. This was to be 
done initially by means of PCR and restriction digestion of amplified products.
3:1:1 Selection of patients
This study was undertaken in collaboration with Mr Guy Vemham at the Victoria 
Infirmary, Glasgow. He selected patients suffering from sensorineural hearing 
loss, with no known aetiology, who fulfilled specific criteria. The age range was 
from 10 years to 55 years, in order to exclude a) early childhood deafness which 
can have many causes and b) presbycusis (deafness due to advanced age). 
Patients must not have been exposed to an environment of extreme or prolonged 
noise; in addition patients should at no time in their lives have had a course of 
aminoglycoside antibiotics.
Mr Vemham measured the degree of bilateral hearing loss by means of pure-tone 
audiometry, as described in Section 2:21 and defined the deafness as mild, 
moderate or severe. The definitions of 20-35 dB as mild, 35-85 dB as moderate 
and > 85 dB as severe were made by Mr Vemham, with the additional factor of 
the age of the subject taken into account. Detailed audiometric data was not 
made available to us, consequently the precise degree of deafness of each patient 
is not given. 33 patients were examined; 27 age, sex and ethnically matched 
normal individuals were selected by Mr Vemham and examined audiometrically 
before inclusion in the study as controls. Blood samples were taken from all 
patients and controls and processed immediately or stored at -20° C until DNA 
extraction as in Section 2:4.
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3:1:2 Medical history of patients obtained by questionnaire
In order to identify patients who had other symptoms commonly reported in 
mitochondrial disease e.g. muscle weakness, in addition to their hearing loss, a 
questionnaire was produced. This was completed by all patients and provided 
information regarding the family history of deafness or other reported symptoms.
Each patient was asked to complete the questionnaire as shown in Figure 3:1. 
Age of onset of deafness was not known in the majority of cases; no patient 
reported muscle weakness or epilepsy. The only eye disorder identified was short 
or long-sightedness with a requirement for spectacles. One patient, number 112, 
had a history of diabetes which was said to be "borderline" (her words), no other 
clinical information regarding her diabetes was available. Of the 33 deaf patients, 
6  identified migraine as a problem (5 females, 1 male); this is very similar to the 
incidence of migraine reported by the 27 normal controls (18.5% c.f.19%).
These figures are both much higher than the normally quoted incidence of 2% of 
the general population (C Reid, personal communication). The difference is 
probably due to misunderstanding by the patients and controls questioned in our 
study, of what constitutes a migraine headache. Figures gathered by medical 
audit are calculated from numbers of patients treated for migraine. Many people 
use the term "migraine" when w hat they mean is a bad headache. The data from 
the questionnaires indicates that the patients in this study suffered from nothing 
other than sensorineural hearing loss, indicative of their diagnosis as having non- 
syndromic deafness.
3:1:3 Restriction fragment length polymorphism (RFLP) analysis
A number of restriction enzyme sites, mutations at which had previously been 
associated with various mitochondrial diseases, were screened in both patients 
and controls. As shown in Table 3:1 sites investigated were np 3243, mutations 
at which are associated with MELAS and identified in a number of patients with 
diabetes associated with deafness; np 3460; np 4917, np 7440, np 11777, and np 
13708, all of which have been found in association with LHON. All of the sites 
investigated have previously been associated with phenotypes involving 
sensorineural loss of function; hearing loss in np 3243 and visual loss in LHON. 
Table 3:1 shows the primers used to amplify, by PCR, segments of mitochondrial 
DNA containing the restriction enzyme sites. Table 3:2 shows the results of the 
RFLP analysis for the 33 patients in the study. The only difference from wild 
type found was in patient number 31 who had lost the Xbal site at 7440. This 
patient was further investigated and the results are given in Chapter 4. No
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Would you please complete the following questionnaire and return it to:
Mrs Fiona Reid
Robertson Institute of Biotechnology 
Dumbarton Road 
Glasgow G 12 8 QQ
NAME: ..........................................................................................................................
A DDRESS:.......................................................................................................................
DATE OF BIRTH:..........................................................................................................
NATIONALITY: .............................................................................................................
DO YOU OR HAVE YOU EVER SMOKED?............................................................
AGE AT ONSEr OF DEAFNESS:..............................................................................
HAVE YOU ANY HISTORY OF: 1. Diabetes ............................................
2. Migraine ............................................
3. Muscle W eakness................................
4. Visual Disorders..................................
5. Epilepsy................................................
Please gives names and dates of birth of any brothers or sisters (living or dead). 
Include half brothers or sisters and state which parent you have in common.
How many brothers and sisters (living or dead) does your Mother have?
How many brothers and sisters (living or dead) does your Father have?
Have any of these relatives suffered from any of the above disorders, including 
deafness?
If any relatives are affected in any way could you supply their name and address?
F igure  3:1 Questionnaire completed by patients with non-syndromic 
hearing loss of no known aetiology, and control individuals.
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RFLP Analysis
No Age Sex Age of Enzyme: Apal Ahall Mael Xbal SfaNI BstNI
Onset Site: 3243 3460 4917 7440 11778 13708
1 30 F Nk + + + + + +
2 31 F Nk + + + nd + nd
3 38 M Nk + + + nd + +
4 24 F Nk + + nd + + nd
13 39 M Nk + + nd + + nd
14 28 F 27 + + nd + + +
15 35 M Nk + + nd + + nd
16 27 F Nk + + nd + + +
17 36 F <12 + + nd + + nd
18 25 M Nk + + nd nd + nd
21 28 F 25 + + nd nd + nd
25 40 F 20 + + nd nd + nd
*31 11 F 3 + + + - + +
34 56 F 49 + + + + + +
35 35 F Nk + + + + + +
36 27 F Nk + + + + + +
37 44 M Nk nd nd nd + + +
38 48 F Nk nd nd nd + + nd
39 32 F Nk + + nd + + nd
41 46 F Nk + + nd + + nd
42 55 M Nk + + + + + nd
44 48 M Nk + + + + + nd
45 24 M Nk + + + + + nd
46 51 M Nk + nd nd + nd nd
=47 12 M Nk + nd + + nd nd
=48 11 M Nk + + + nd nd nd
49 42 F 40 + nd nd + nd nd
50 38 M Nk + nd nd + nd nd
51 42 F 35 + nd nd + nd nd
52 42 F 40 + nd nd + nd nd
80 28 M 22 + nd nd + + +
95 50 F 49 + nd nd + + +
112 40 F 30 + + + + + +
T a b l e  3:2 Compilation of RFLP analysis of patients with non syndromic
sensorineural hearing loss
* Index case in pedigree study - see Chapter 4
= Brothers
Nk Not known
nd Not determined
+ Wild type
- Mutant
deviation from normal was found at any site tested in any of the 27 normal 
controls screened.
3:1:4 Analysis of the Apal restriction site encompassing np 3243
Creation of an Apal restriction site by a nucleotide change at np 3243 is found in 
patients suffering from MELAS or in some cases of diabetes with deafness (see 
Section 1:5), due to an A->G transition in the tRNALeU(uuR) gene.
The mechanism by which this mutation results in a pathological phenotype 
remains unknown. The possibility of involvement of this mutation in the 
development of non-syndromic deafness prompted us to screen our patients for 
this mitochondrial DNA mutation.
None of the deaf patients screened had gained an Apal site in the segment of 
DNA spanning np 3243. Figure 3:2A shows a typical RFLP analysis using Apal 
on two of the patients: numbers 3 and 17. As positive controls DNA was also 
analysed from cybrid cell lines produced from fusion of rho° cells and cells 
derived from MELAS patients with varying proportions of mutant mitochondrial 
DNA. These cybrids maintained a stable percentage of mutant DNA (Ian Holt, 
personal communication). Cell-line 206.3243 (143B - derived) had previously 
been shown to have > 90% mutant mitochondrial DNA, whilst B2.3243 (A549 - 
derived) had approximately 45% mutant. Without densitometry these figures 
cannot be accurately confirmed, but examination of Figure 3:2B indicates that our 
restriction digestion experiments gave approximately similar results. This 
suggests that the lack of digestion product in the patient samples is not simply due 
to the enzyme being inactive.
3:1:5 Evaluation of the presence of deletions in the mitochondrial DNA of 
deaf patients using PCR
As outlined in detail in Chapter 1:8, rearrangements of mitochondrial DNA have 
been identified in a number of mitochondrial diseases in which sensorineural 
deafness is a feature. For this reason it was decided to screen as many deaf 
patients as possible for the presence of deletions or duplications of mitochondrial 
DNA. Constraints of time allowed only a limited study, the results of which are 
presented below.
Patients 1, 36, 50 and 80 were screened for the presence of partially deleted 
mitochondrial DNA molecules using forward and reverse primers which, in 
theory, would normally amplify large sections of mt DNA, but which will
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Subject 17 3 Sizemarkers Sample B2 206 Sizemarkers
Apal - + - + /  Apal - + - + /
F igu re  3:2 A RFLP analysis o f the genotype at np 3243 by restriction
digestion o f a 690 np PCR product created using FR6/3103B 
as forward primer and FR7/3698L as reverse primer. In both 
patients, 17 and 3, there has been no gain of an Apa\ site; the 
690 np product remains uncut.
B Positive controls to show that the Apa\ enzyme is effective. 
PCR product created using template DNA from cybrid 
cell-lines with varying proportions of the mutation at np 3243 
were cut w'ith A pa\. The digestion results are in agreement 
with previous estimates that B2.3243 cells have 45% mutant 
and 206.3243 cells 90% mutant mitochondrial DNA.
These experiments were carried out on different days.
produce much smaller sized PCR products in the presence of partially deleted 
template DNA. Contained in Table 3:3 are details of the primers used and sizes of 
products expected if one of the previously identified deletions given is present. 
Figure 3:3 is an illustration of the human mitochondrial genome showing the 
position of the three deletions described in Table 3:3 in relation to the pairs of 
oligonucleotide primers used in PCR reactions. I had previously shown that 
under the conditions for PCR used products greater than 3.5 kb cannot be 
amplified.
Figure 3:4 shows the products obtained using DNA from patient 1 as template, 
showing no evidence of a large scale deletion. Similar results were obtained with 
patients 36, 50 and 80.
Figure 3:5 is a diagramatic representation of the expected PCR product with each 
pair of primers in the presence of each deletion. It should be noted that under the 
PCR conditions used here deletions B & C would give the same result. Only if 
PCR conditions which allow amplification of greater than 5 kb were developed 
could the two be distinguished.
3:1:6 Evaluation of the presence of duplications/deletions by Southern 
analysis of digested mitochondrial DNA
DNA from a small number of patients was digested using Pvull. Normal human 
m itochondrial DNA has only one restriction site for the enzyme Pvull, 
consequently restriction digestion of mitochondrial DNA with this enzyme 
linearises the DNA molecule. After Southern transfer the DNA was probed 
using a random DIG-labelled PCR product created using FR31/7178B as forward 
primer and FR32/7840L as reverse primer.
This probe should hybridise to the COI gene which lies outwith the most common 
deletion found in mitochondrial disease, the breakpoints of which map to np 8470 
and np 13459. In normal linearised mitochondrial DNA this probe should 
hybridise and be visualised as a 16.5 kb band. If the common deletion is present 
then the probe will still be able to hybridise and reveal a much shorter DNA 
molecule. Obviously if a deletion is present which encompasses the region to 
which the probe will hybridise, no mitochondrial DNA molecule can be 
visualised.
Figure 3:6 is a Southern blot showing DNA treated in this way from patients, all 
of whom have a single band of approximately 16 kb, indicating that no large scale
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Figure 3:3 Illustration of human mitochondrial genome showing
the PCR primers described in Table 3:3 in relation to the 
position of previously descibed deletions A,B and C.
Primers are abbreviated :
FR1 = FR1/12907B; FR2 = FR2/1373L
FR8 = FR8/3628B; FR9 = FR9/4505L
FR24 = FR24/14683H; FR23 = FR23/15267L
Figure 3:4
? ‘ze, 5 4 3 2 1 Primer Pair
Marker —
5kb
4kb
3kb
2kb
lkb
877np 
827np
500np 584np
PCR amplificationof template DNA from patient number 1. 
Primer pairs 1-5 correspond to those shown in Table 3:3. 
The control PCR reaction (without DNA) is not shown - no 
amplification product was present.
SIZE WILDTYPE A B . C
MARKERS 5 4 3 2 1 5 4 3 2 1 5 4 3 2 1 5 4 3 2 1
- — — —
1 0 k b - - —
— — —
5 k b - -
2 k b -
1 k b - —
—
— mm
500bp  -
Figure 3 :5  D iagram atic represen tation  o f the PCR products expected  using 
prim ers given in T able 3:3, in the p resence o f three prev iosly  
described  deletions, A, B and C, the b reakpoin ts o f w hich are given 
in T able 3:3.
B ands show n in bold w ould be those expected , o thers in sam ples A, 
B and C, reflect w ild-type bands w hich w ould  still be present.
duplication or deletion is present. Patients 2,16,33,36,49 and 1 12 (see Table 3:1) 
were investigated in this way and similar results obtained.
3:1:7 Discussion of results obtained in study of patients suffering from 
sensorineural hearing loss with no known aetiology
Clinical manifestations of mitochondrial disorders are extremely variable as 
described in Chapter 1. The auditory system has a high energy demand and 
requires efficient oxidative phosphorylation; it is among the first tissues to be 
affected by a decrease in oxidative phosphorylation (Elverland & Torbergsen, 
1991). In accessibility of the sensory structures in the ear (mainly the cochlea) 
results in a poor understanding of the biochemical deficiencies which lead to 
deafness, either solely or in association with other symptoms. Sensorineural 
hearing loss is often said to be the initial symptom in mitochondrial disease, but 
often no details regarding the audiometric status of the patient is given. Deafness 
is a symptom described in a number of mitochondrial diseases: MELAS 
(Macmillan et al, 1993), Kearns/Sayre (Shoffner et al, 1989), MERRF (Shoffner 
et al, 1990), and in association with diabetes (Ballinger et al, 1992; van den 
Ouweland et al, 1992).
This study of patients suffering from sensorineural hearing loss with no known 
aetiology was initiated by Mr Andreas Nicolaides at the Victoria Infirmary, 
Glasgow and continued after his departure by Mr Guy Vemham. A number of 
m itochondrial RFLPs previously identified in association with various 
mitochondrial diseases were investigated.
The results of this analysis, given in Table 3:2, showed that one patient, number 
31, had lost the Xba\ site at 7440, an RFLP which had previously been found in 
association with LHON (Brown et al, 1992). The results of the detailed 
investigation of this patient are described in Chapter 4 of this thesis.
The remaining 32 patients had normal (wild type) sized restriction digestion 
products with all other enzymes used. There are obviously additional disease 
associated enzyme sites which could have been screened by RFLP analysis but 
time did not permit this.
It should be borne in mind that, in general, for a restriction site gain caused by a 
disease associated mutation only these particular point mutations would be 
detected in our study. A different point mutation within the same restriction site 
would go undetected. In view of the two different point mutations, at np 8993,
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Figure 3:6 Southern blot o f mitochondrial DNA from patients 32, 33, 49 
and 112 cut withFVwII and hybridised with a DIG-random 
labelled PCR product created using primers FR31/7178B and 
FR32/7840L.
which have now been found in NARP (Santorelli et al, 1994) this is an important 
point.
A number of patients were investigated for the presence of large scale 
rearrangements of their mitochondrial DNA. Figure 3:4 is typical of the results 
obtained, by Southern analysis, for all patients screened in this way. The single 
band of 16 kb is linearised mitochondrial DNA. Small rearrangements would not 
be detected using this technique. The limits of detection of this method are 
difficult to assess,. It obviously depends on the resolution of different sized DNA 
molecules during electrophoresis through agarose. Rearrangements altering the 
size of the mitochondrial genome by less than 1 kb would, by my estimation, be 
difficult to detect using this method. As discussed in Chapter 1 the presence of 
duplications has been underestimated in a number of previous investigations 
(Poulton et al, 1994). Restriction digestion using a number of different enzymes 
followed by Southern blotting and probing with labelled total mitochondrial DNA 
would reveal duplications and deletion monomers where present.
The entire mitochondrial genome can be am plified using optimised PCR 
conditions (Cheng et al, 1994). This will facilitate the use of PCR in the 
investigation of rearrangements of mitochondrial DNA. In the limited study 
carried out on 4 of the patients in Table 3:2, large scale deletions could be 
excluded; bearing in mind that the limit of the length of PCR product possible, 
using PCR conditions outlined in Chapter 2:6 is approximately 3 kb, small 
deletions would not be detected using the PCR primers given in Table 3:3. PCR 
conditions which enable amplification of the entire mitochondrial genome can 
easily be used to screen patients for rearrangements of their mitochondrial DNA, 
using a relatively small number of PCR primers.
Three of the 33 patients investigated (numbers 1, 2 and 31) had a maternal 
relative who was also deaf, consistent with a mitochondrial defect being 
associated with their development of deafness. Other explanations are possible, 
e.g. inheritance of an autosomal dominant deafness trait, exposure to similar 
environmental agents. With the advances in automated sequencing technology 
the entire mitochondrial genome of patients 1 and 2  could be sequenced relatively 
rapidly, to reveal any novel polymorphisms which may be further investigated for 
their association with sensorineural hearing loss.
In conclusion, no patient in this survey (apart from number 31) had any of the 
mitochondrial DNA mutations screened. Their non-syndromic deafness cannot, 
therefore, be associated with either the common MELAS or LHON associated 
mutations, based on the results presented here. It is possible, however, that
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previously identified mutations in mitochondrial DNA are present in some of 
these patients. Further investigations should be undertaken to screen for many 
more mutations e.g. 8993 in NARP, identified using restriction enzymes Aval and 
Mspl (Santorelli et al, 1994). Another possibility is to use SSCP (see Chapter 4) 
to screen all of the patients.
In view of the large number of neurological symptoms found in mitochondrial 
disease, and the fact that deafness is a common first symptom, it would be 
surprising if some of the patients in this study did not have other disease- 
associated mutations.
3:2 IN V E ST IG A T IO N  OF PA TIEN TS SU FFER IN G  FROM  
AMINOGLYCOSIDE ANTIBIOTIC-INDUCED SENSORINEURAL 
HEARING LOSS
In 1991 Hu et al reported an epidemiological study of 36 pedigrees in which there 
were patients with AAID and found that in 22 the trait was maternally 
transmitted. They concluded that in these 22 pedigrees there may be a mutation of 
mitochondrial DNA which is associated with the development of deafness. This 
study prompted us to look at DNA from AAID patients for the presence of some 
previously identified mitochondrial DNA mutations.
3:2:1 Medical history of Chinese patients
Eighteen patients suffering from sensorineural hearing loss, which developed 
after treatment with aminoglycoside antibiotics, were selected by Dr Wei-Qin Qiu 
of Shanghai. DNA was prepared from blood samples in Shanghai using a 
protocol provided by our laboratory (Section 2:4) and the DNA transported to 
Glasgow as a dry precipitate. Table 3:4 gives details of the patients as supplied 
by Dr Qiu: no information regarding which aminoglycoside, the dose or the 
duration of the treatment, was provided. Although the intention was to study 
patients belonging to pedigrees in which the AAID was maternally inherited, the 
DNA which Dr Qiu brought was from sporadic cases. In addition we are unaware 
of the degree of deafness suffered by these patients or whether the hearing loss 
was bilateral.
3:2:2 Medical history of Scottish patients
Three patients with sensorineural hearing loss who had been treated with 
aminoglycosides whilst in babycare at the Royal Infirmary, Glasgow were 
selected by Professor George Browning. Gentamycin was the antibiotic used in
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Age at Age at Xbal site Genotype
Patient Examination Treatment at np 7440 at np 1555
CHI 8 y 10m Wt wt
CH 2 8 y lm Wt wt
CH3 7 y 6.5m Wt wt
CH4 9 y 3y wt wt
CH 5 9 y lm wt wt
CH 6 8 y ? wt wt
CH7 9 y 2y wt wt
CH 10 10  y iy wt wt
CH 11 12 y iy wt wt
CH 12 i i  y ly 8 m wt wt
*CH 13 16 y 3y wt A->G
*CH 14 16 y 3y wt A->G
CH 15 1  y iy wt wt
CH 16 6  y 8 m wt wt
CH 17 6  y ly 2 m wt wt
CH 18 6  y ly wt wt
CH 19 7 y 2 m wt wt
CH 20 7 y 4y wt wt
Table 3:4 Data from aminoglycoside-treated Chinese patients. The Xbal
site was screened by restriction digestion of the 662 np 
fragment created by PCR using FR31/7178B as forward primer 
and FR32/78404 as reverse primer. The genotype at np 1555 
was determined by direct sequencing of PCR products.
y-years; m-months; wt-wild type; *CH13 and CH14 are 
identical twins.
each case, doses ranging from 7 mg/day to 15 mg/day for a duration of 1 day to 4 
days: Table 3:5 shows the age of examination. Each patient completed the 
questionnaire; there was no history of diabetes, epilepsy, muscle weakness or 
serious eye problems. Patient 115 reported that she suffers from episodes of 
migraine, as does her two brothers and her mother.
DNA was prepared from blood of patients number 113 and 114 and from buccal 
cells in a mouthwash sample from patient 115 (Section 2:4).
3:2:3 RFLP analysis of mitochondrial DNA from patients suffering from 
aminoglycoside antibiotic-induced deafness (AAID)
The Xbal site loss at np 7440 of mitochondrial DNA previously reported in 
LHON patients (Brown et al, 1992) and found in one patient (number 31) in our 
study of non-syndromic deaf patients, was investigated in both Chinese and 
Scottish patients in a similar manner to that given in Section 3:1:3. As Tables 3:4 
and 3:5 show, in no AAID patient had this Xbal site been lost.
During his time working in Glasgow Dr Wei-Qin Qiu screened a small number of 
the Chinese AAID patients for the mutation site at np 3243, detected by Apal site 
gain and that at 3460 detected by Ahall site loss. No change from wild type was 
found in any patient tested, but Dr Qiu left no written data in Glasgow when he 
returned to China.
3:2:4 Sequence analysis of Chinese patients in the region around np 7440
In view of the sequence change causing loss of the Xbal site, found in patient 31 
(see Chapter 4), the region of the mitochondrial genome around the Xbal site at 
np 7440 was sequenced in the Chinese AAID patients. A PCR product of 662 np 
was amplified using primers FR31/7178B and FR32/7840L and the sense strand 
sequenced using primer FR49/7324L. No nucleotide change in this Xbal site was 
found in any of the patients, but as Figure 3:7 shows a T->C change at np 7389 
was seen in patient CH18. This change was confirmed by sequencing the other 
strand. This mutation changes a Tyrosine to a Histidine and the nucleotide 
sequence change creates an M alll restriction site. The remaining Chinese 
patients were all wild-type at this site.
3:2:5 Evaluation of the genotype at np 1555 in AAID patients
As a result of a report by Prezant et al (1993) of an A->G homoplasmic change at 
np 1555 in the mitochondrial DNA of patients with maternally transmitted AAID,
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Age at Age at Xbal site Genotype
Patient Examination Treatment at np 7440 at np 1555
113
114
115
14 y
13 y
14 y
Id
Id
l-4d
wt
wt
wt
wt
wt
wt
Table 3:5 Aminoglycoside treated Scottish patients,
y-years; d-days.
Treatment was with Gentamycin at a dosage of 7-15 mg/day/1 - 
4 days after birth.
Subject CH3 CH18
G A T C  G A T C
A
T
A
T
C
A
G
T
G
A
G
G
T
C
C
T
A
©
A
T
C
A
G
T
G
A
G
G
T
C
C
Figure 3:7 Direct DNA sequencing o f the region around np 7440 in 
patient CHS and C h i8. A PCR product of 662 np was 
amplified using forward primer FR31/7178B and reverse 
primer FR32/7840L. The sense strand is shown with the 
T->C at np 7389 in patient C H I8 indicated by a circle.
we decided to screen the AAID patients available to us for this mutation. A 682 
np am plification product from the 12S rRNA gene was prepared using 
FR12/1444B as forward primer and FR13/2125L as reverse primer. After 
purification the biotinylated strand of the amplified product was sequenced using 
the primer FR69/1705L (Section 2:10). Patients CH13 and CH14, who were 
identical twins, were found to have the same homoplasmic A->G change at np 
1555 reported by Prezant et al (1993). No other AAID patient tested had this 
mutation, and no other mutation was found in this region of the 12S rRNA gene 
in any AAID patient.
Figure 3:8 shows the homoplasmic mutation on the antisense strand of patient 
CH14 alongside the normal sequence of patient CH5.
3:2:6 Discussion of results obtained in the survey of AAID patients of 
Chinese and Scottish origin
3:2:6:1 Association of aminoglycoside antibiotics and developm ent of 
deafness
Aminoglycoside antibiotics, in particular Streptomycin, but also Kanamycin, 
Gentamycin, Tobramycin and Neomycin, are known to be ototoxic and 
nephrotoxic, streptomycin being less nephrotoxic than the other aminoglycosides 
(Appel and Neu, 1977). The loss of hearing which can result from such treatment 
is related to dosage, age of subject, renal function and inherited predisposition. 
Streptomycin sulphate was widely used to treat pulmonary tuberculosis in the 
1950s and 60s. In some instances it was used to treat much less serious 
infections; in Japan bacterial infections following the common cold were treated 
with streptomycin (Higashi, 1989). When the toxic effects of aminoglycosides 
became evident its use was restricted in many countries.
Some patients seem to have an inherited predisposition to develop deafness after a 
single short course of treatment. The pattern of inheritance in many cases 
appeared to be compatible with autosomal dominance. Viljoen et al (1983) 
studied a large kindred in which there were eight persons, over four generations, 
with bilateral sensorineural hearing loss attributed to aminoglycoside treatment. 
The pattern of inheritance was claimed to be autosomal dominant but re­
exam ination of the pedigree shows it to be com patible with maternal 
transmission. Higashi (1989) compiled 28 pedigrees in which deafness following 
aminoglycoside treatment was inherited only from females or through the female 
line. In many of these families the pattern of inheritance had previously been 
categorised as autosomal dominant.
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Subject CHS CH14
G A T C  G A T C
Figure 3:8 Direct DNA sequencing o f a PCR product derived from the 
12S rRNA gene from patient C H I4 (mutant) and CH5 
(wild-type). Sequence shown is o f the antisense strand.
The T-> C mutation at np 1555 is indicated by a circle.
Aminoglycosides are still widely used in China to treat a variety of infections: 
Hu et al (1991) made a study of 36 pedigrees with AAID. In 22 of these 
pedigrees, transmission of the predisposition to become deaf after antibiotic 
treatment was exclusively through females. In the remaining 14 pedigrees 
transmission could not be ascertained. This report prompted us to contact the 
Chinese group in Shanghai and arrange a collaborative study of some of their 
families. Blood was obtained and DNA prepared in Shanghai (under the direction 
of Dr Wei-Qin Qiu who subsequently brought the samples to Glasgow) from a 
collection of 18 patients with sporadic AAID.
3:2:6:2 Sequence changes identified in AAID patients
The presence of the Xbal site at np 7440 was screened in the 18 Chinese patients 
and 3 Scottish patients. As Tables 3:4 and 3:5 show no change from normal was 
found in any of the patients.
Sequencing of all 18 Chinese AAID patients in the region encompassing the 3'- 
end of the COI gene and the 3' end of the tRNAser gene, revealed that patient 
CH18 has a T->C mutation at np 7389. This is in the COI gene and causes an 
amino acid substitution, but as Figure 3:9 shows there is poor conservation of the 
amino acid at this position. The nucleotide change creates an M all restriction 
enzyme site and this could be used to screen normal controls, non-syndromic deaf 
patients, sporadic and maternally inherited AAID patients to establish whether 
this mutation is simply an uncommon polymorphism. None of the members of 
pedigree or normal controls, described in Chapter 4, who had this region of their 
mitochondrial DNA sequenced had the T->C change at np 7389.
In July 1993 Prezant et al published a report of a significant nucleotide change in 
the mitochondrial DNA of three unrelated patients with familial AAID. This 
mutation is an A->G change at np 1555 in the 12S rRNA gene; it had not been 
identified in more than 270 controls. The mutation was also identified in a large 
Arab-Israeli kindred with maternal transmission of deafness but no association 
with the use of antibiotics.
As a result of this report the three Scottish and eighteen Chinese samples were 
screened by means of PCR and direct sequencing, for the mutation at np 1555. 
As Table 3:4 shows, the A->G mutation at np 1555 was present in 2/18 Chinese 
patients; these two patients are identical twins. Figure 3:8 shows the 
homoplasmic A->G change at np 1555 in patient CH I4 compared to the normal 
sequence in patient CH5. All the Chinese patients, with the exception of CH13 
and CH14, had no family history of aminoglycoside induced deafness, i.e. they
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Human (IfcLa) 
Patient CHI8 
Rat
Mouse 
Sea Urchin 
Xenopus 
Bovine 
Drosophila
L B w L
Y
G C P P P
r S P
N - T
Figure 3:9 Amino acid sequence of the region of COI from amino acid 
492 to 502. Human sequence of HeLa cells is aligned with the 
counterpart in Patient CH18, rat, mouse, sea urchin, Xenopus, 
cow and Drosophila. The dots represent identity, the dashes 
that no amino acid is assigned to that position. The boxed area 
shows the lack of conservation of amino acid 496.
were sporadic cases. The three Scottish AAID patients were also sporadic and 
were found by direct sequencing to have normal sequence at np 1555.
The A->G at np 1555 has now been found in 5 pedigrees with AAID (Hutchin et 
al, 1993); it has never ocurred in 414 hearing people studied. This mutation 
results in the loss of a BsmAl restriction site providing a potentially rapid means 
of screening a large number of individuals.
3:2:6:3 Mechanism of action of streptomycin
The precise mechanism and site of action of aminoglycosides, which lead to the 
development of deafness, is unclear. Damage is thought to be to the hair cells in 
the Organ of Corti (Ballantyne, 1970) which lies within the cochlea (see Figure 
3:10). Streptomycin is also known to damage the nerve fibre and ganglion cells.
The molecular mode of action of aminoglycosides (as antimicrobial agents) has 
been elucidated by studies using E. coli and streptomycin, clinically the most 
commonly used aminoglycoside. Streptomycin has been shown to interfere with 
bacterial protein synthesis by binding to the small (30S) subunit of the 
prokaryotic ribosome (Cox et al, 1964).
The 30S subunit of E coli ribosomes is a ribonucleoprotein complex consisting of 
21 proteins and 16S rRNA. The protein subunits designated S4, S5 and S12 have 
been mapped by immuno-electron microscopy to a site within the ribosome where 
codon-anticodon interaction takes place. This maps to the region of 16S rRNA 
from nucleotide 1400-1500 (Stem et al, 1988). If 30S ribosomal subunits are 
reconstituted, in vitro , without S12 protein they no longer bind streptomycin 
(Ozaki et al, 1969). When no drugs are present such S 12-deficient ribosomes are 
less prone to mis-reading than normal ribosomes; therefore it appears that protein 
S12 is in part responsible for inherent infidelity of translation and that this is 
enhanced by aminoglycosides.
Mutations in the ribosomal protein S12 have been shown to confer Streptomycin 
resistance or dependance in E. coli (Allen & Noller, 1989). Specific residues in 
the 530 stem and loop of 16S rRNA are protected by S12 in chemical protection 
assays (see Figure 3:10) indicating that S12 is bound in this region (Finken et al, 
1993) and probably exerts its influence by perturbing the 3D structure of 16S 
rRNA.
Assays in which 16S rRNA has been shown to be protected from RNA-specific 
chemical reagents, such as dimethyl sulphate, by streptomycin indicate that
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Figure 3:10 H u m a n  c o c h l e a  ( A ) ,  s h o w i n g  th e  c o c h l e a r  n e r v e ,  a n d  c r o s s -  
s e c t i o n  ( B )  s h o w i n g  the  p o s i t i o n  o f  t h e  O r g a n  o f  C o r t i  w i t h i n  
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Figure 3:11 S c h e m a t i c  s e c o n d a r y  s l i m l i n e  o l  l(nS i R N A  ol IC. coli t a k e n  
l i o i n  P u r n h i l  a n d  S l e m  ( 1 9 9 4 ) .
streptomycin protects a group of residues in the 915 region of E. coli 16S rRNA 
(O'Connor et al, 1991). Mutations at nucleotide 1491 in the 16S rRNA of E. coli 
abolish Watson & Crick base pairing to the C-nucleotide at 1409 (De Stasio et al, 
1989) and confer resistance to streptomycin. Since mitochondria are thought to 
be derived from a eubacterial endosymbiont, the mitochondrial ribosomes are 
more akin to prokaryotic ribosomes than to cytosolic ribosomes. It is likely, 
therefore, that mitochondrial ribosomes will be susceptible to the action of 
antibiotics which act on prokaryotic ribosomes. Figure 3:12 shows the 16S rRNA 
of E. coli in the region 1392-1534 in comparison with the 3' end of human 
mitochondrial small subunit 12S rRNA. The position np 1555 in 12S rRNA gene 
at which the mutation in some AAID patients has been mapped is structurally 
equivalent to position 1491 in E. coli 16S rRNA. The A->G change at nucleotide 
1555 will permit Watson - Crick base pairing to the C at nucleotide 1494 of 12S 
rRNA creating a structure in the mitochondrial 12S rRNA very similar to the 
region in E. coli 16S rRNA outlined by O'Connor et al (1991) as a region with 
which streptomycin interacts. Thus the change at this position facilitates the 
binding of streptomycin to the small subunit of the mitochondrial ribosome where 
it could play a role in impairing fidelity of translation analogous to its role in 
bacteria.
It has been confirmed in this study that some sporaidc AAID patients have an 
A->G change at np 1555, while others who apparently suffer the same symptoms, 
do not. It is possible that there are other mutation sites within the 12S rRNA of 
the remaining Chinese and Scottish patients which confer aminoglycoside 
sensitivity by a different, but related mechanism. Identification of other 
mutations could only be achieved by direct sequencing of the entire gene of each 
patient. An attractive possibility is that other mutations exist which play a role in 
aminoglycoside binding, or in the binding of one of the ribosomal proteins as with 
protein S12 in E. coli.
3:2:6:4 Final conclusions
As indicated by Ballantyne (1970) deafness is thought to result from the death of 
hair cells within the Organ of Corti. Exactly how mistranslation of mitochondrial 
proteins brings this about is still unknown. Hutchin et al (1993) suggest that hair 
cell death is due to excitotoxicity.
Albin and Greenamyre (1992) suggested that neuronal death could be intiated by 
impairment of cellular metabolism which, in turn, leads to failure of the Na/K 
ATPase which maintains normal membrane potential. When the membrane 
becomes depolarised the Mg 2+ion blockade of receptors for excitotoxic amino
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Figure 3:12 The 3’ end of human mitochondrial 12S rRNA in comparison 
with the 3' end of E. coli 16S rRNA. The position of the A->G 
at np 1555 in human mitochondrial 12S rRNA is indicated. 
Taken from Hutchin et al (1993).
acid (EAA), such as Glutamate, is reduced, allowing receptor activation and 
subsequent excitotoxic effects.
It remains unclear why it is only the neurons involved in the auditory system that 
are affected by aminoglycosides. As with most mitochondrial diseases, the tissue 
specific pathology accompanying the np 1555 mutation cannot be explained 
without invoking a role for some external factor. The presence of the np 1555 
m utation in the large A rab-Israeli kindred, with no involvem ent of 
aminoglycosides, leads to the conclusion that this mutation in association with 
either an external factor, e.g. streptomycin, a set of other mt DNA sequence 
polym orphism s, or a nuclear gene product results in the phenotype of 
sensorineural deafness.
There is obviously much scope for further investigation of the mechanisms 
involved in the development of disease in AAID.
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CHAPTER 4 STUDY OF SENSORINEURAL HEARING LOSS 
WITHIN A LARGE MATERNAL PEDIGREE
4:1 IDENTIFICATION OF THE FAMILY
During the survey carried out at the Victoria Infirmary, Glasgow, of patients 
suffering from sensorineural hearing loss (outlined in Chapter 3) a female aged 11 
(patient number 31 in Table 3:1) with moderate bilateral deafness since age 3 was 
identified, whose mother was also known to have a hearing problem. The mother 
had been diagnosed at age 18 and was found when re-examined audiometrically, 
as part of this study, to have a mild bilateral hearing loss. Neither the mother nor 
child had ever had any episode of migraine, epilepsy, muscle weakness; neither is 
diabetic.
Via the questionnaire the mother revealed that one of her three sisters, a number 
of nieces and a nephew had hearing problems. These members of the immediate 
family were contacted and attended the Victoria Infirmary for audiometric testing 
and donation of blood samples. Completed questionnaires indicated that there are 
branches of the family elsewhere, in Australia and in Southern Africa including 
Zimbabwe, some of whom were thought to suffer from deafness.
The maternal pedigree of this family, as far as it is now known, is shown in 
Figure 4:1. Additional information was supplied by II-8 regarding the deceased 
parents of generation I: the mother was bom in Poole, Dorset circa 1888 and the 
father in Lochgoilhead, Argyll circa 1870. There is no knowledge of their hearing 
status. Of generation I only 1-6 remains alive, presently residing in Australia. 
This woman is known to have mild hearing loss, but this is probably presbycusis 
as she is now over 70 years old. Individual II-2 is in Zimbabwe where he was 
contacted by telephone and confirmed that none of his two children (III-4 and III - 
5), his brother (II-1), nor his brother's children (III-1, III-2 and III-3) has any 
hearing problem. To his knowledge his now deceased father (1-1) also had no 
history of deafness. Subject II-3 has no hearing loss but is reported to have an 
olfactory problem: she has no sense of smell. Of her three sons only one (III-6) 
has a history of deafness: he was diagnosed as suffering from bilateral 
sensorineural hearing loss at age 9 and has had progressive loss since that age - he 
is now 34. His mother recalls him having suffered from German measles at 
approximately the same age as his deafness was diagnosed, but no connection 
was ever suggested by clinicians.
4:2 MEDICAL HISTORY OF THE PEDIGREE
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Neither of the sisters of subject II-3, i.e. II-4 and II-5 are reported to have hearing 
problems. II-4 is now resident in Canada where she has been contacted. Neither 
she nor her daughter (III-9) would agree to be audiometrically tested. The 
remaining sister (II-5) lives in Scotland but refused to respond to any enquiry, 
from her sister, by letter from us or through her ow n General Practitioner.
A great deal of information has been provided about the branch of the family 
resident in Australia (1-6, II-6, II-8, II-9 and their children) from subject II-8. 
This family member has had a gradual progression of hearing impairment since 
her mid twenties, but had had no auditory test since 1977 when she was examined 
at the Ear, Nose and Throat Hospital, Glasgow. On that occasion she was told 
that there was auditory nerve involvement. Although there is no evidence of 
hearing problems in the four children of II-8 (III-13, III-14, III-15 and III-16), 
III-15 has visual impairment. Dr G Wards of Penrith, NSW has reported that she 
has optic-disc pallor in her left eye, micro left divergent squint with added 
exophoria for near and distance and her left visual acuity (LVA), with glasses, is 
6/9 - the normal value is 6/6. The sister of II-8, II-6 has no hearing problem but 
one of her daughters (III-12) has had hearing impairment since infancy: this child 
wears hearing aids in both ears. Another of the three daughters (III-10) has a 
problem with her vision very similar to that of III-15, with optic disc pallor in 
both eyes, left squint and LVA with glasses, of 6/18 but no hearing loss 
(information provided by Dr G Wards).
Both brothers of II-8 suffer from moderate hearing loss: II-9 has been deaf since 
infancy when he contracted measles at 5 months old. None of his four children 
have hearing problems; it is worthy of comment that the maternal grandparents of 
these four children are both profoundly deaf. This illustrates the potential for 
difficulties in studies of inherited deafness where there is intermarriage of two 
families with entirely different aetiologies of deafness.
The second brother of II-8, subject II-7, resides in Leicester, England. He has not 
recently had his hearing tested, but has informed us that he has worn a hearing aid 
since age 8 and since 1986 has had one for both ears. His mother, 1-6, recalls that 
he suffered from measles as a child, but cannot clearly remember the details.
The remainder of the family live in or around Glasgow and have all been 
examined by Mr G Vemham at the Victoria Infirmary. Subject 11-10 suffers from 
moderate bilateral hearing loss but had not admitted to having a hearing problem 
until recently; consequently age of onset is unknown. Her son and daughter (III - 
22 and 111-21) both have mild bilateral deafness which was diagnosed during their 
primary education. Two of the three sisters of 11-10 (11-11 and 11-12) show no
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evidence of deafness, but have offspring who are moderately deaf. Of the 
children of 11-11, 111-24 has moderate bilateral loss which was diagnosed at the 
age of 6 and is progressive. Her sister, 111-23 has a mild bilateral hearing loss 
which is also thought to be progressive.
One of the daughters of 11-12 has a moderate loss of hearing which was detected 
at age 10; she wears a hearing aid and attends the Victoria Infirmary for 
monitoring of the progression of her deafness. Individuals 111-29 and II-13 are the 
child and her mother whose replies to the questionnaire brought our attention to 
the family.
No member of the pedigree has been reported to suffer from epilepsy, muscle 
weakness or diabetes. A small number report migraine episodes but no more 
than in the general population.
The deafness in this family appears to be maternally inherited (Figure 4:1) leading 
to speculation that a mitochondrial defect could be involved in the development 
of the disease phenotype. In order to investigate this possibility a more detailed 
audiometric study of the family was initiated prior to investigation of their 
mitochondrial DNA.
4:3 PURE TONE AUDIOMETRY OF MEMBERS OF THE PEDIGREE
Pure tone audiometry was carried out in Glasgow at the Victoria Infirmary by the 
staff of the Ear, Nose and Throat Department under the direction of Mr Guy 
Venham; in Australia at Wollongong Hearing Centre under the direction of Dr 
Patrick Rundle. The results on the twenty three members of the pedigree tested 
are summarised in Table 4:1. On advice from Mr Vemham mild hearing loss 
was defined as a bilateral average of 20-35 dB, moderate loss as 35-85 dB and 
severe loss as greater than 85 dB. Only one individual (II-9) had severe bilateral 
hearing loss; 8 of the 23 showed moderate loss. Including the 5 who had mild 
bilateral deafness, 14 of the 23 maternally related members of the pedigree tested 
had some degree of hearing impairment.
In addition to the 23 results given in Table 4:1 audiometric testing of III-17, HI- 
18, III-19 and 111-20 was carried out. These children are maternally unrelated to 
the rest of the family; the results showed no evidence of sensorineural hearing 
loss. A typical audiometric trace from one of the moderately deaf individuals is 
given in Figure 4:2, showing a marked high frequency impairment.
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Pure Tone Averagea
Age at
Patient examination Right Left Hearing b
1-6 73 21 33 Mild loss
II-3 56 16 14 Normal
II-7 28 59 55 Moderate loss
II-8 47 46 39 Moderate loss
II-9 44 103 103 Severe loss
11-10 45 34 37 Moderate loss
11-11 43 8 13 Normal
11-12 41 17 14 Normal
11-13 34 18 27 Mild loss
III-6 32 48 50 Moderate loss
III-12 5 33 40 Moderate loss
III-13 25 11 12 Normal
111-14 22 13 14 Normal
111-15 7 16 12 Normal
III-16 12 6 8 Normal
III-21 21 28 21 Mild loss
111-22 17 19 21 Mild loss
111-23 22 21 25 Mild loss
III-24 19 42 28 Moderate loss
III-25 13 12 13 Normal
III-26 21 62 64 Moderate loss
111-27 18 13 13 Normal
III-28 11 4 3 Normal
III-29 11 39 58 Moderate loss
a Averages at 0.25, 0.5, 1, 2, 4 & 8 for all subjects plus data at 1.5, 3 & 6 KHz 
for aminonity.
b Mild hearing loss defined arbitrarily as a bilateral average of 20-35 dB, 
moderate loss as 35-85 dB, severe loss as > 85 dB.
T able  4:1 A udiom etric data for the index case, 111-29, and her 
maternally related relatives, from measurements taken by staff 
of the Audiometry Department, Victoria Infirmary, Glasgow.
dB HL
0
20
40
60
80
100
120
4 820.25 0.5 1
kHz
F ig u re  4 :2  A 1 ch ic  trace. Pure lone audiom etry  ol a typical, 
moderately deal m em ber of the pedigree (patient III- 26). 
Hearing loss in decibels (dB) is shown lor both light ear (o) 
and left car (\).
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The age of onset of hearing impairment in the family varied between 5 months 
and 18 years, with many patients having progressive loss. Figure 4:3 illustrates, 
however, that there is no obvious correlation between the severity of hearing loss 
and age at examination: there is also no obvious difference in the degree of 
hearing loss between the sexes.
4:4 COMPLETE NUCLEOTIDE SEQUENCE OF THE 
MITOCHONDRIAL DNA OF THE INDEX CASE
The apparent maternal inheritance of deafness within this family would be 
consistent with a mutation in the mitochondrial DNA having a role in the 
development of symptoms. Sequencing of the entire mitochondrial genome of 
one member of the pedigree was undertaken to identify any novel sequence 
polymorphism(s) which could be implicated in the disease. DNA was extracted 
from a blood sample obtained from the index case and, by means of PCR and 
direct sequencing of amplified products the entire mitochondrial DNA sequence 
established (see Chapter 2).
All deviations from the Cambridge sequence (Anderson et al 1981) were 
confirmed by sequencing on both strands: the polymorphisms found are listed in 
Table 4:2, all were homoplasmic, or nearly so, at least within the limits of 
detection of the method (estimated at less than 5%). Of the thirteen differences 
found, nine have previously been reported as probable mistakes in the Cambridge 
sequence. The remaining four deviations have not, to date, been reported 
elsewhere.
Two of these four lie with the D-loop:T->C at np 72 and T->C at np 195; neither 
position has been assigned a function. In Figure 4:4 the position of these 2 
polymorphisms in relation to the major features of the D-loop is illustrated. 
Figure 4:5A shows 10 np upstream and 10 np downstream of the polymorphism 
at np 72, whilst Figure 4:5B shows the region 10 np upstream and 10 np 
downstream of the polymorphism at np 195; the proximity of this polymorphism 
to the origin of H-strand replication is obvious.
The A->G change at np 7445 is at a site which is assigned a function on both 
strands of human mitochondrial DNA. Figure 4:6 shows that on the major coding 
(H) strand this nucleotide is in the stop codon of the gene for cytochrome oxidase 
subunit I (COI), giving the silent AGA->AGG change. On the other strand (L) 
the np 7445 change alters the extreme 3' encoded nucleotide of tRNAser(UNC). 
This position is also part of an Xbal restriction enzyme site: Xbal cuts at 7440 the 
site being TCTAGA; this provides a simple method of screening for the
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Figure 4:3 Plot of Audiometry versus Age at Examination.
Graph of pure tone average results against age at examination. 
Showing no correlation.
Gene
Coordinate
(np)
Change 
on H-strand
Amino acid 
substitution
Previously
Reported?
D-loop 72 T->C - No
195 T->C - No
12S rRNA 750 A->G Yes 
Prezamt et al 
(1993)
1438 A->G Yes 
Marzuki et al 
(1992)
NDl 3423 G->T Silent Yes 
Howell et al 
(1992)
ND2 4985 G->A Silent Yes 
Howell et al 
(1992)
COI/tRNA-ser
(UCN)
7445 A->G Silent
(COI)
No
ND4 11335 T->C Silent Yes 
Howell et al 
(1992)
ND6 14199 G->T Pro->Thr Yes 
Howell et al 
(1992)
14365 G->C Silent Yes 
Howell etal 
(1992)
14368 G->C Phe->Leu Yes 
Howell et al 
(1992)
cytochrome b 14766 T->C Ile->Thr Yes 
Lertrit et al 
(1992)
15110 G->A Ala->Thr No
Table 4:2 Deviations from the Cambridge sequence of mitochondrial
DNA from the index case (111-29).
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Illustration of the D-loop of human mitochondrial DNA 
showing the position of the deviations from the Cambridge 
sequence at np72 and npl95 in relation to the major features of 
the D-loop: origin of light and heavy strand transcription (P^
and Ppj) conserved sequencing boxes (CSB) termination
associated sequence (TAS) and origin of H-strand replication
(Oh )-
A
np -£j2 7|2 £j2
WILD TY PE D-LO OP GTCTGGGGGGTATGCACGCGA
PATIENT III - 29 GTCTGGGGGG CATGCACGCGA
B
np-185 195 205
WILD TY PE D -LO OP : GCG AAC AT ACTT ACT AAAGT Gi
1 origin of H-strand replication
PATIENT III - 29 GCGAACATAC CTACTAAAGTG
Figure 4:5 Illustrations of regions of mitochondrial genome around 
polymorphisms at np72 and npl95.
A - showing lOnp upstream and downstream of the 
polymorphism at np72 
B - showing lOnp upstream and downstream of the
polymorphism at npl95 indicating proximity to origin of 
H strand replication
WILD TYPE
np-7431 7445
H-STRAND T AC AT AAA AT CT AG AC AAAA AA
AMINO ACID 
SEQUENCE Y M K S stof;
L-STRAND :
COI
I
iTGTTTTTT
tRNAser(U C N)
PATIENT III - 29
np-7431
I
7445
H-STRAND TACATAAAATCTAG GCAAAAAA
AMINO ACID 
SEQUENCE Y M K S STOP,
L-STRAND :
COI
“  — ---- 1
.CGTTTTTT
tRNAser(UCN)
Figure 4:6 Upstream and downstream regions around the np 7445 mutation.
The 7445 site has a function on both the H strand where it is the 
3' nucleotide of the COI gene and the L strand where it is the 
extreme 3' nucleotide of the tRNAser(UCN) gene.
mutation. The polymorphism in the gene for cytochrome b at np 15110 causes an 
amino acid change: Alanine->Threonine. The effect of this nucleotide change on 
the amino acid sequence of the region immediately surrounding it is shown in 
Figure 4:7.
4:5 GENOTYPE OF MEMBERS OF THE PEDIGREE AT np 7445
Having found these polymorphisms in the index case other members of the 
pedigree were screened for the nucleotide change at np 7445. This was done in 
two ways: initially by restriction digestion using Xbal and, where doubt remained 
regarding the disruption of the site, direct sequencing was carried out.
4:5:1 Restriction fragment length polymorphism (RFLP) analysis
Blood samples were taken from a) 40 normal controls, by Dr Colin Reid, b) 24 
non-syndromic deaf patients, including 1 with a maternal history of deafness, by 
Mr Guy Vemham; c) members of the pedigree living in Scotland, by Mr Guy 
Vemham; d) members of the pedigree resident in Australia, by Dr Patrick Rundle 
and colleagues. After preparation of DNA (see Chapter 2) PCR was carried out 
using as forward primer FR31/7178B and as reverse primer FR32/7840L (see 
Table 2:1:2) giving an amplified product of 662 np. Digestion of this amplified 
product with Xbal gives fragments of 400 np and 262 np when the site is intact.
In all normal controls and deaf subjects outside of the pedigree, as well as in 
individuals 111-17,18,19 and 20, the fragment sizes predicted from the Cambridge 
sequence were found. In most maternally related members of the pedigree tested 
the amplified product was uncut. However, in a few family members there 
appeared low levels of the 400 np and 262 np fragments, whilst most of the DNA 
remained uncut. Figure 4:8 shows both situations - the samples where the 
amplified product is all intact (samples 111-26 and 111-28) and sample II-3 where 
low levels of restriction digest products are present.
This result could have two causes: heteroplasmy is a situation commonly found in 
mitochondrial diseases, the partial digestion could be the result of the presence of 
two mitochondrial DNA species in one individual one mutant, one normal. 
Alternatively the restriction digestion result could be due to contamination of a 
mutant DNA sample with minute quantities of amplified products from a normal 
individual. Fresh DNA samples were prepared from blood from the six pedigree 
members in which this phenomenon was observed and identical restriction 
digestion results obtained, consistent with heteroplasmy.
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WILD TY PE
np-15101 15110 15119
I I I
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Amino S eq u en ce  L L L A T M
PATIENT III - 29
C T C C T G C T T A C A A C T A T A  
L L L T T M
Figure 4:7 Nucleotide and amino acid sequences in region surrounding
15110 polymorphism. The G —> A change at np 15110 found in 
the index case can be seen to change the codon from that for 
Alanine to that for Theonine.
S U B J E C T  | | - 3  M l-2 6  111-28 C 1  C 2  C 3
Xba\  +  - + -  +  -  +  -  +  -  +
662np
400np
SIZE  
M A R K E R S
F ig u re  4:8  Restriction fragment length polymorphism analysis o f 3
members o f the pedigree and 3 controls. The 662np fragment is 
completely digested in the three control samples (C l, C2, C3) 
giving products o f 400np and 262np. The sample from the two 
family members, 111-26 and 111-28, is undigested, indicating 
loss o f the Xbal site. Sample II- 3 shows partial digestion.
4:5:2 Sequence analysis at np 7445
As cautioned by Johns et al (1993), loss of a restriction site can be accounted for 
by a mutation at any of the nucleotide pairs within the site. In order to confirm 
that the base change causing loss of the Xbal site in all family members was the 
same as in the index case each available family DNA sample was sequenced. The 
662 np fragment was amplified in multiple reactions, purified and sequenced 
using primer FR50/7567L for the L strand and FR49/7324H for the H strand.
Figure 4:9 show s the anti-sense strand sequence of a control and a member of the 
pedigree in which there had been complete lack of digestion of amplified product 
by Xbal. The homoplasmic T->C change at np 7445 can clearly be seen.
The Xbal site loss at np 7440 was reported by Brown et al in 1992 in two patients 
suffering from LHON. Sequencing of the region around this site showed the 
m utation to be a homoplasmic G->A at np 7444 in both LHON patients. 
Examination of 89 normals and a review of the literature by Brown et al showed 
that 6/595 controls had lost this Xbal site. (Horai et al, 1984; Harihara et al, 
1988; Vilkki et al, 1989; Dionne et al, 1991; Ballinger et al, 1992). Brown et al 
sequenced only one of those six and found the same 7444 change. They made 
the assumption that the remaining five had the same change at this position.
M itochondrial DNA from two of the remaining 5 control individuals were 
sequenced in the laboratory of Savontaus (personal communication) and were 
also found to have the np 7444 G->A change. DNA samples from two of the 
remaining three were donated to our laboratory by Drs Dionne and Skinner and 
sequenced: the 7444 change was confirmed in these two samples. DNA from the 
sixth control sample was not available from Japan. Combination of this data with 
that from the normal control samples screened in our study indicates the A->G 
change at np 7445 is not present in more than 600 controls.
Direct sequencing of amplified products from those family members in which 
traces of products of the Xbal restriction had been seen gave the result shown in 
Figure 4:10. At the np 7445 position in each of the six individuals there were two 
nucleotides, i.e. T and C. When the other strand was sequenced A and G were 
seen at position np 7445.
Since heteroplasmy of a mutation site is said by many to be the hallmark of its 
involvement in disease it was important to confirm whether these findings were a 
PCR artefact.
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SUBJECT Cl 111-29
Figure 4:9 Direct sequencing across the COI/tRNAser(UCN) junction 
from patient 111-29 and a normal control. Sequence shown is 
o f the anti sense strand and the nucleotide change indicated by a 
circle.
SUBJECT Cl 11-6
wmm-
Figure 4:10 Sequencing o f mt DNA across the COI/tRNAser(UCN) 
junction from normal control and patient II-6. The presence of 
both C and T at the np 7445 is clear in patient II-6
4:6 FURTHER INVESTIGATION OF HETEROPLASMY AT np 7445
It was possible to take two approaches to resolve the existence of heteroplasmy at 
np 7445 in some members of the pedigree: PCR carried out using a reverse primer 
downstream of FR32/7840L and Southern blotting following Xbal digestion of 
non- amplified mitochondrial DNA. The heteroplasmy question was resolved in 
this instance using the former approach.
Amplification was carried out using the same forward primer as before, 
FR31/7178B, and a reverse primer, (FR34/8562L), further downstream than that 
used previously (FR32/7840L). Direct sequencing of the biotinylated strand was 
carried out using FR50/7567H as an internal primer. If the heteroplasmy is real it 
should be seen at the same level as in the experiments described in Section 4:5. 
If, on the other hand, the apparent heteroplasmy is due to minute contamination 
of a DNA sample mutant at np 7445 with the 662 np PCR product from a normal 
control then this sequencing will show only a single nucleotide at this position. 
The apparently heteroplasmic samples were sequenced in this manner and only 
the A->G change found at np 7445, with no evidence of another nucleotide, at 
least within the limits of detection by DNA sequencing.
4:7 ANALYSIS OF MITOCHONDRIAL GENOTYPE AT np 15110 BY 
SSCP
The polymorphism found at np 15110 in the index case has not been reported in 
the literature. A change at this site is not detectable using an easily obtained 
restriction enzyme. An alternative, rapid method of screening a large number of 
samples was sought. The technique of SSCP is one in which PCR amplification 
products are electrophoresed through a non-denaturing polyacrylamide gel. 
Mobility shifts are observed depending on the structure of the single-stranded 
DNA (Orita et al, 1989). Amplification products should ideally be 200-300 np in 
length but even if the size is within this range not all point mutations can be 
detected using this technique. In order to screen for the 15110 polymorphism 
PCR was performed on control DNA from subjects who had already had the 
region surrounding np 15110 sequenced and been shown to be wild type at this 
site, in addition to using DNA from subject 111-29 as template. The forward 
primer used was FR78/14973H and the reverse primer FR70/15218L giving an 
amplification product of 244 np.
A mobility shift on a silver-stained polyacrylamide gel was only found in the 
PCR product obtained using template DNA from the patient. The control samples 
all had a band at the same position which is different from that of the patient.
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Having confirmed that the np 15110 polymorphism present in patient 111-29 did 
give an observable mobility shift, the SSCP technique was used to screen 22 
normal controls, 24 sporadic deaf patients and 10 members of the pedigree. In all 
experiments one member of the pedigree known to have the homoplasmic G->A 
at np 15110 was included. Figure 4:11 shows a typical silver-stained gel in which 
the PCR product from patient 111-29 (number 31) migrates to a different position 
to that prepared using template DNA from normal controls (11,12,14 & 70) or 
sporadic deaf patients (4,5,10 & 48).
This particular mobiliy shift was only found when DNA from members of the 
pedigree was used as template, indicating that none of the other individuals tested 
had the A->G mutation at np 15110.
4:8 DISCUSSION
4:8:1 Inheritance of sensorineural hearing loss within the pedigree
Sensorineural deafness has previously been reported as the principal symptom in 
a number of pedigrees in which inheritance is apparently via the maternal line 
(Elverland & Torbergsen, 1991; Jaber et al, 1992; Prezant et al, 1993; Mutoni et 
al, 1992). Interactions of mitochondrial DNA with nuclear genes (Bu et al, 1993) 
or environmental agents (Hu et al, 1991) make the role of mitochondrial DNA 
mutations in the development of deafness difficult to define. Extensive sequence 
analysis of the mitochondrial DNA of the index case in the pedigree shown in 
Figure 4:1 was undertaken in order to detect any mutation which could be 
responsible for the phenotype.
Within this pedigree there is no evidence of paternal transmission of the defect; 
the inheritance pattern is compatible with maternal transmission. Although there 
are more females than males in the family in no case where a male could have 
transmitted the trait has he done so. Nevertheless it should be borne in mind that 
individual IV -1 is less than 2 years old and may yet develop symptoms. Maternal 
transmission often resembles the inheritance pattern of autosomal dominant 
except that the affected parent is always female. A test of purely maternal 
inheritance is therefore identification of any evidence of paternal transmission of 
a trait. In an attem pt to create mathematical models for the study of 
mitochondrial inheritance Schork & Guo (1993) took a number of aspects of 
mitochondrial genetics into account including heteroplasmy, tissue specificity and 
interaction of nuclear gene products with mitochondrial gene products. Using a 
hypotheical pedigree they derived complicated models and tested strategies which 
they hope will help in the determination of mitochondrial inheritance. They do,
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Figure 4:11
S u b je c t 70 48 14 12 31 11 10 5 4
Single stranded conformational polymorphism (SSCP) analysis 
o f 4 controls, numbers 11, 12, 14 and 70; 4 cases o f sporadic 
sensorineural hearing loss, 4, 5,10 and 48 and the index case,
31. A product of 244 np was amplified using forward primer 
FR78/14973H and reverse primer FR70/15217L
however, acknowledge the potential problem of the range of phenotypic 
expression of mitochondrial DNA mutations.
Other modes of transmission cannot be completely excluded in this pedigree (e.g. 
autosomal dominant with incomplete penetrance). Many members of generation 
III are still children and since age of onset of deafness in the family ranges to 18 
years it is possible that a number of them may develop deafness and thereby 
clarify the mode of inheritance. Given the present medical history and 
audiometric data, however, maternal inheritance of sensorineural hearing loss is 
most probable. The appearance in the pedigree of two maternally related 
females with unusual ophthalmological symptoms may also be attributable to a 
mitochondrial defect. The optic disc pallor observed in III-10 and III-15 is 
extremely rare but is a symptom also observed in the late acute stage of LHON 
(Nikoskelainen, 1985).
4:8:2 The pathological significance of the np 7445 mutation
The complete sequence of the mitochondrial DNA of patient 111-29 revealed that 
the sequence deviated from the Cambridge sequence (Anderson et al 1981) at 13 
nucleotide positions (Table 4:2). Nine of these deviations have been reported in 
normal controls by a number of different laboratories and they are thought to be 
either mistakes in the original sequence or relatively common polymorphisms. 
Four changes have not previously been reported: at np 72, np 195, np 7445 and np 
15110. Of these the most interesting is the homoplasmic A->G at np 7445. This 
alteration disrupts an Xbal site at np 7440 which is at the junction of the COI and 
tRNAser(UCN) genes.
All maternally related members of the pedigree had the A->G change at np 7445. 
Initially six of these appeared to be heteroplasmic at this site. However, further 
investigations suggested that this was due to experimental contamination of DNA 
with minute amount of PCR products. This serves as a caution for such 
investigations: working practices should be such as to minimise the possibility of 
such contamination and any apparent heteroplasmy must be very thoroughly 
confirmed, using the methodology outlined in Section 4:6.
Precautions to minimise PCR product contamination of reactions should include 
setting up reactions in a laminar-flow cabinet. It should always be the case that 
PCR amplification product is not manipulated in the same room in which 
reactions are prepared. In addition micropipette tips containing filters should be 
used along with positive displacement micropipettes. At each new manipulation 
fresh gloves should be worn; discarded gloves, tubes and tips should all be
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disposed of in a sealed bag which is put immediately into a waste bag for daily 
removal.
The pathological significance of the np 7445 mutation is supported by the fact 
that A-7445 is conserved in man’s closest relatives, i.e. common chimpanzee, 
pigmy chimpanzee and gorilla (Horai et al, 1992). A T at this site is, however, 
not conserved down through the vertebrates: rat and mouse also have T but it is 
an A at this position in cows and G in Xenopus (Roe et al, 1985).
The np 7445 is assigned a function on both strands of mitochondrial DNA (see 
Figure 4:6) changing the stop codon of the COI gene on the H strand from AGA 
to AGG and altering the extreme 3' nucleotide of the tRNAser(UCN) on the L 
strand. The role of the mutation in contributing to the pathological phenotype of 
sensorineural deafness in this family, could involve either strand or both.
Regarding the effect of the mutation on COI, the alteration of the stop codon from 
AGA->AGG is thought to be silent as both are recognised as stop codons in 
human mitochondrial DNA. The mammalian mitochondrial genetic code has 4 
termination codons: UAA, UAG, AGA and AGG (Cantatore & Saccone). Some 
genes have their termination codon created post-transcriptionally by poly- 
adenylation. In the universal genetic code AGA and AGG code for Arginine; 
these codons are not found within any mammalian mitochondrial gene, only at the 
3' end of some genes. AGA has been identified as the termination codon for the 
human COI gene, while AGG has been identified in ND6 at the extreme 3' 
position (Anderson et al, 1981).
In LHON the G->A mutation at np 7444 changes the AGA stop codon to AAA 
which codes for lysine. Brown et al (1992) show an autoradiograph of an SDS- 
PAGE gel which they claim shows the COI polypeptide from a LHON patient, 
with the np 7444 mutation, migrating as a 37 kDa protein in contrast to that from 
normal controls migrating as 38 kDa. They attribute this faster migration to 
extension of the COI polypeptide by the 3 amino-acids Lysine, Glutamine, 
Lysine. In addition they report a 36% decrease in COX activity in one of the np 
7444 positive LHON patients.
Their data would have been more convincing if both experiments had been 
carried out on both LHON patients they identified with the np 7444 mutation. In 
addition similar experiments performed using cells from the normal control 
identified as having the np 7444 mutation would help to clarify whether the 
results can really be attributed to the np 7444 mutation. One of the LHON 
patients was also reported to have the np 3460 mutation previously found to be
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associated with LHON. Brown et al (1992) do not state which patient donated 
samples for each experiment. Obviously this is an important detail which has 
been omitted.
The decrease in COX activity of lymphocytes is surprising given the very specific 
phenotype of optic nerve damage in LHON. Similar studies in the deaf pedigree 
may give some insight into the effect of the np 7445 mutation on the activity of 
Cytochrome oxidase and its role, if any, in their deafness. This will be discussed 
further in Chapter 6.
4:8:3 The effect of the np 7445 mutation on tRNAser(ucN)
The change brought about by the 7445 mutation on the antisense strand is perhaps 
of more significance. All tRNAs are thought to have a similar three dimensional 
structure, the typical "cloverleaf" as illustrated in Figure 4:12. The precise 
structure of human mitochondrial tRNAser(UCN) has not been determined 
directly. In human mitochondria the 3' terminal CCA of tRNAs is not encoded in 
the DNA but added post transcriptionally (Attardi 1985). The change at np 7445 
will therefore be at the 4th nucleotide from the 3' end of the mature 
tRNAser(UCN). In E. coli, yeast and rat the base at this position has been 
reported as invariant in tRNAs specific for a given amino acid (Crothers et al, 
1972). This position was given the term "discriminator” residue and is proposed 
to function as a positive identity element, which the ami no-acyl synthetase 
specific for each amino acid recognises directly. The discriminator residue is 
believed to play an important role in tRNAser in E. Coli (Normanly & Abelson, 
1988). In vitro studies indicated, however, that it is not important in bovine 
mitochondrial tRNAser(AGY) where base replacements at the discriminator site 
did not affect the addition of the serine residue to the tRNA.
A relatively small number of nucleotides are important in the specificity of 
amino- acylation; eight identity elements have been identified in E coli. Unlike 
most tRNAs in E.Coli (with the exception of tRNAaia) tRNAser does not use the 
anti-codon as the major recognition site for amino acylation.
Mis-acylations of tRNAs are relatively easy to induce using special reaction 
conditions (Schimmel, 1987): this implies that subtle changes in tRNA structure 
and/or amino acyl synthetase are sufficient to induce mis recognition and lead to 
mis- charging of the tRNA. Sensorineural hearing loss is a very specific 
phenotype in the family under study. Consequently if there is mis charging of 
tRNAser(UCN) it must be extremely tissue-specific; the tRNAser must be able to 
function normally in other tissues. Tissue-specific mis-charging could arise if
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Figure 4:12 Secondary and Tertiary structure of a stereotypical tRNA.
Typical "cloverleaf" secondary structure and L model tertiary 
structure of tRNA. Dots indicate base pairing. From 
Normanly & Abelson (1989).
4:8:3 cont.
The work of Yokogawa et al. (1991) suggested a novel cloverleaf structure for 
bovine mitochondrial tRNAser(UCN). They conclude from their results that this 
tRNA does not have two U-U mismatches at the top of the acceptor stem as has 
previously been thought. In addition they propose that in mouse mitochondrial 
tRNAser(UCN) the exclusion of one nucleotide at the 3 1 end would allow a 
cloverleaf structure similar to that found in bovine tRNAser(UCN).
If such a structure is proposed for human tRNAser(UCN) then the nucleotide at 
position 7445 in the gene would not be represented in the tRNA . Until the 
precise three dimensional structure of human mitochondrial tRNAser(UCN) is 
determined the involvement of the 7445 nucleotide in the tRNA will be the 
subject of debate.
another less efficient isoform of the specific amino acylsynthetase is present in 
the nerve cells of the vestibular cochlea (8th cranial nerve) in those developing 
deafness.
The mitochondrial amino acyl tRNA synthetases are encoded on the nuclear 
DNA, translated in the cytoplasm and imported into the mitochondria (Ueda et al,
1992). If there are tissue-specific isoforms of amino-acyl-synthetases then there 
are a number of mechanisms which could possibly account for tissue specific mis­
translation of mitochondrial proteins. The charging efficiency may be different 
between isoforms and it is possible to envisage a situation where an equilibrium 
between isoforms of different efficiencies could alter in different tissues. Some 
isoforms could also be less specific in their charging specificity, allowing a tRNA 
to be charged with an amino acid with which it is not usually associated. A defect 
in a nuclear gene resulting either in a less efficient isoform aminoacyl synthetase 
or in a less efficient import into mitochondria could work in concert with the 
mitochondrial mutation to give rise to the pathological phenotype.
There are obvious parallels which can be drawn between the molecular 
mechanisms proposed in the development of AAID associated with the np 1555 
mutation, described in Chapter 3, and those described here. It seems unlikely to 
be only a coincidence that the mitochondrial mutations identified in both 
situations map to regions of the mitochondrial genome which are involved in 
translation. The relationship between the two will be further discussed in Chapter 
7.
4:8:4 Possible RNA processing effects of the np 7445 mutation
An alternative hypothesis is that interference with RNA processing caused by the 
change at np 7445 could interfere with maturation of either COI mRNA, 
tRNAser(UCN) or both. The polycistronic transcripts of mitochondrial DNA are 
processed by mechanisms which involve the recognition of junctions between the 
tRNAs and the mRNAs or rRNAs (M aram & van Tuyle, 1987). These 
mechanisms are thought to be dependent on the stereotypic tertiary structures of 
tRNA segments in the primary transcript and are assumed to involve the 
recognition of boundaries which can be recognised by endonucleases. 
Processing at the 5' terminus of tRNAs has been shown to be carried out by 
RNAseP or RNase P-like enzymes in prokaryotes (Kole & Altman, 1982), yeast 
mitochondria (Hollingsworth & Martin, 1986) and HeLa cell mitochondria 
(Doerson et al, 1985). In addition Maram & van Tuyle (1987) demonstrated that, 
in rat liver mitochondrial extracts, 5' processing of the E. coli tRNAtyr was 
obligatory before 3' processing could take place.
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There have been a number of mutations in mitochondrial tRNAs associated with 
disease phenotypes which are thought to be due to defects in mitochondrial RNA 
processing. An A->G change at np 3243 has been found in MELAS patients, this 
is located in the tRNAleu(UUR) gene. King et al (1992) identified an abnormally 
large amount of an RNA intermediate in cells containing high percentages of 
mitochondrial DNA mutant at the 3243 site. This intermediate was named 
RNA 19 by extension of the nomenclature for the human mitochondrial RNA 
species. It was shown, by Northern analysis, to consist of a polycistronic 
transcript of 16SRNA, tRNALeu and ND1. The 3243 mutation is thought to 
result in an RNA processing defect and this could be involved in the severe 
respiratory chain deficiencies observed in MELAS. What that involvement is has 
not been determined, King et al (1992) suggested that the np 3243 mutation 
causes a number of distinct effects which cumulatively result in the MELAS 
phenotype.
Bindoff et al (1993) found a similar processing deficiency in a patient suffering 
from a mitochondrial myopathy who had a different mutation in tRNALeu; at np 
3302. In this case the mutation is at the 3' end of the tRNA, in the aminoacyl 
stem. Northern analysis revealed that, in addition to RNA 19, there were other 
RNA intermediates present in skeletal muscle and alternative ones in skin 
fibroblasts. Results were consistent with processing occurring at the 3! end of the 
tRNALeu in fibroblasts, and the 5' end in skeletal muscle. Fibroblasts from this 
patient had no biochemical defect while skeletal muscle showed severe loss of 
Complex I activity, in keeping with the phenotype of myopathy.
The nucleotide change at np 7445 could possibly result in an RNA processing 
defect. The extremely tissue specific phenotype may be due to tissue specific 
processing differences. Alteration to the COI transcript resulting from abnormal 
processing could give an altered amount or structure of the COI subunit of the 
Cytochrome c oxidase complex.
Human Cytochrome c oxidase has three mitochondrially encoded subunits and 
ten nuclear encoded subunits (Capaldi, 1990). The three mitochondrially encoded 
subunits which are homologous to the three subunits of the prokaryotic 
cytochrome oxidase, are essential for electron transport and proton pumping. The 
ten nuclear encoded subunits are thought to be regulatory or may have a 
"scaffolding" role within the mitochondrial inner membrane. Several of the 
nuclear encoded subunits are present in two or more tissue-specific isoforms 
(Capaldi et al, 1988). The 7445 mutation in this family may therefore result in an 
altered COI polypeptide which can interact normally with isoforms of nuclear 
encoded subunits present in most tissues. In contrast a different isoform present
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in the auditory neurons may interact with the altered COI in such a way to cause 
decreased activity of the cytochrome oxidase complex. Neuronal tissue is 
extremely sensitive to changes in oxidative phosphorylation (Shoffner & Wallace, 
1990), such a decrease in the 8th cranial nerve could give rise to sensorineural 
hearing loss.
When more than one isoform of an enzyme exist there are sometimes different 
ratios of isoforms in different tissue. For example, the adenine nucleotide 
translocator (ANT) has three isoforms which are present in varying ratios in 
different tissues (Stepien et al, 1992). A tissue specific alteration in the ratio of 
COX subunit isoforms would be consistent with the slow but steady progression 
of sensorineural hearing loss in this family.
4:8:5 Pathological roles of the other deviations from the Cambridge 
Sequence
Pathological roles for the remaining three polymorphisms, found in the index 
case, cannot be excluded but seem less likely. Positions np 72 and np 195 are in 
the hyper- variable segment of the D-loop. Neither site is within a binding site for 
the mitochondrial transcription factor mtTFI (Parisi & Clayton, 1991); a 
conserved sequence box or within the termination associated sequence, TAS 
(Foran et al, 1988). These two positions within the D-loop have not been 
assigned a function although np 195 lies close to the origin of replication of the H 
strand (see Figure 4:5). Both are conserved in chimp, pigmy chimp, gorilla and 
orangutang. Their potential role in the pathology of deafness in this family is 
unknown, and could only be clarified by finding these mutations associated with 
other cases of sensorineural hearing loss.
The change at np 15110 in Cytochrome b changes an Alanine residue to a 
Threonine; this is normally regarded as a conservative amino acid change. 
However, as Figure 4:13 shows, the amino acid encoded at this position is not 
highly conserved. Although it is Alanine in rat and mouse, it is Valine in Sea 
urchin (Jacobs et al, 1988); Leucine in Xenopus (Roe et al, 1985) and Drosophila 
(Clary & Wolstenholme, 1985) and Threonine in cow (Anderson et al, 1982). 
Screening of more than 40 individuals for this polymorphism using SSCP has 
indicated that it is not a common polymorphism in the Scottish population. The 
same mobility shift was seen in all maternally related members of the pedigree 
tested, those whose mitochondrial DNA was sequenced at this position had the 
same homoplasmic G->A change at np 15110. The possibility that this mutation 
is involved in the development of deafness cannot be excluded, as with the 
mutations in the D-loop, but seems unlikely.
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Figure 4:13 Amino acid sequence of region of Cytochrome b from the 
amino acid 116 to 130. Human sequence of HeLa cells is 
aligned with the counter part in Patient 111-29 and rat, mouse, 
sea urchin, Xenopus, cow and Drosophila. The dots represent 
identity with the Human Hela cells amino acid sequence at 
that position. The boxed area shows the lack of conservation 
of the amino acid at position 122 which is that affected by the 
nucleotide change at np 15110 in Patient 111-29.
4:8:6 Conclusions
The homoplasmic change at np 7445 remains, therefore, the most likely candidate 
mutation to have a causative role in the sensorineural loss observed. However, a 
cumulative effect of the four mutations found cannot be excluded. In LHON a 
large number of mutations of mitochondrial DNA have now been reported and in 
some patients two or more occur together. It has been suggested (Brown et al, 
1992; Johns et al, 1991; MacKey & Howell, 1992) that the clinical manifestations 
of LHON can be the result of a number of mitochondrial DNA mutations acting 
synergistically resulting in an overall decrease in mitochondrial oxidative 
phosphorylation in specific tissues. In a similar manner a disease haplotype may 
explain the relationship of the mitochondrial genotype with the phenotype of 
sensorineural hearing loss in this family.
The recent report of an additional family suffering from sensorineural hearing loss 
having the 7445 A->G change (N. Fischel-Ghodsian, personal communication) 
provides additional evidence that this mutation is involved in the aetiology of 
maternally inherited deafness. This family is based in New Zealand and is 
unrelated, as far as we know, to the pedigree described in Section 4:1. The 
hearing loss is more severe and the penetrance of the defect higher than our 
pedigree. Sequencing of the mitochondrial genome has revealed none of the 
polymorphisms unique to our pedigree. This evidence suggests that the np 7445 
mutation has arisen independently in the two families and is strongly indicative of 
its involvement in the development in sensorineural hearing loss in these 
pedigrees.
However, some other factor must be implicated in the development of deafness as 
all maternally related members of the pedigree in Figure 4:1 have the 7445 
mutation, but not all are deaf. Differences in nuclear background; differential 
tissue expression of a nuclear gene product; viral infection; environmental factors 
are all candidates for involvement in the development of deafness.
The possible role of viral infection in the development of deafness in the pedigree 
was briefly investigated in the process of interviewing patients. Individual III-6 
had rubella just before he developed a hearing problem and II-7 had measles as a 
very young child. Other members of the family also had measles, chicken pox 
and mumps but in all cases they (or their Mother) could not remember the exact 
sequence of events. Most seemed to remember that the deafness had developed 
prior to the viral infection. This is obviously an area worthy of more detailed 
investigation, particularly in any other families identified.
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The only environmental factor considered in this study w as cigarette smoking. No 
relationship was found between those who smoke, had smoked or had a parent 
who smoked and the development of deafness.
Further investigation of the effect of the mitochondrial genotype found in the 
index case of this pedigree on cellular biochemical and molecular mechanism was 
undertaken. The results of this study are presented and discussed in Chapter 6.
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CHAPTER 5 INVESTIGATION OF THE MITOCHONDRIAL  
DNA SEQUENCE IN A PATIENT SUFFERING  
F R O M  L H O N  AND S E N S O R I N E U R A L  
HEARING LOSS
5:1 MEDICAL HISTORY OF PATIENT SH
The patient, known as SH throughout the study, presented originally with bilateral 
optic neuritis in 1978 when he was aged 26. He was diagnosed as having Leber's 
Hereditary Optic Neuropathy (LHON) by Dr Bronte-Stuart at the Department of 
Ophthalmology, Western Infirmary, Glasgow. SH has been registered blind since 
1983 and now has a guide dog. Apart from an unexplained episode of apparent 
paralysis at the age of 15 SH had no other neurological symptoms until he 
developed hearing loss in 1988. Mr Andreas Nicolaides investigated this at the 
Victoria Infirmary, Glasgow where the staff of the ENT Department carried out 
audiometry and identified a mild sensorineural hearing loss. Figure 5:1 shows an 
audiometric trace for SH obtained in 1992, showing bilateral loss with a pure-tone 
average of 33 dB. The pattern of the trace indicates that there is no significantly 
greater loss at high frequencies, a pattern unlike that observed in the pedigree 
described in Chapter 4.
This study was initiated in 1991 on the basis of information, provided by Mr 
Nicolaides, on the family history. This was that SH had two maternal relatives 
who also suffered from sensorineural hearing loss: a maternal uncle and aunt. 
When contacted and interviewed, by me, in 1993 SH was found to have a 
different family history. His father (now deceased) suffered from glaucoma and 
had become deaf, but this was probably the result of an industrial accident. A 
maternal uncle has LHON and a maternal aunt has very poor eyesight which has 
never been fully investigated; neither is deaf.
The pedigree of SH as it is now known is given in Figure 5:2. Individuals 1-4,1-5 
and 1-6 are all believed to suffer from deafness of undefined type and severity; I- 
2 suffers from LHON, and 1-1 has very poor eyesight. The brother of SH, number 
II-7 died of a heart attack in his 40s, having been identified as having very high 
cholesterol. As far as SH is aware no member of the family suffers from diabetes, 
epilepsy or muscle weakness.
5:2 FAMILY HISTORY OF PATIENT SH
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Figure 5:2 Pedigree of SH. Patient SH is num ber 118 indicated by an arrow.
5:3 RFLP ANALYSIS
Based on the information provided in 1991 it was possible that the deafness 
developed by SH was caused by mitochondrial DNA mutation. The combination 
of LHON with sensorineural hearing loss was unusual and a sequencing project 
was undertaken, the aim of which was to establish the sequence of the entire 
mitochondrial genome of SH after initially screening for previously identified 
RFLPs associated with LHON.
5:3:1 Creation of a permanent cell-line from the blood of SH
A lymphoblastoid cell-line was created by Epstein-Barr transformation of 
lymphocytes from the blood of SH. This was carried out at Yorkhill Hospital, 
Glasgow by Dr Mair Crouch under the direction of Dr Elizabeth Boyd in 1990. 
DNA was extracted according to the method given in Chapter 2:4, by Josephine 
Anderson, and stored at -20°C until required.
5:3:2 RFLP analysis of the "classical" LHON site
DNA was prepared from a blood sample donated by SH, using the method 
described in Chapter 2:4 . This, and the DNA extracted from tissue culture cells, 
was used as template in PCR reations with forward and reverse primers which 
create a product containing the SfaNI site encompasing np 11778. Primers 
Ll/11688B and L2/11914L create a 226 np fragment; the products of the SfaNI 
restriction are 136 np and 90 np if the site is intact as shown in Figure 5:3. The 
amplified product using both DNA from blood and DNA from the cell-line could 
not be cut with SfaNI; the site had been lost in the patient SH, and the loss was 
homoplasmic.
5:3:3 RFLP analysis at sites previously associated with LHON and MELAS
PCR amplification products, using DNA from SH as template, were screened for 
RFLP sites at 3243,3460, 4160, 7440 and 13708 as described in Chapter 3: . No 
change from the Cambridge sequence was found at any of these sites.
5:4 IDENTIFICATION OF SEQUENCE CHANGE RESULTING IN 
THE LOSS OF THE SfaNI SITE
Since a deviation from the Cambridge sequence at any of the 5 nucleotides 
involved in the SfaNI site at 11777 can result in its loss, the precise nucleotide 
that had been altered had to be determined by direct sequencing of PCR products.
6 6
Restriction digestion o f PCR product by SfaNI. Primers 
Ll/11688B and L 2/11914L w ere used to amplify a 226np 
fragment. Lanes 1, 3 and 5 are undigested products. Lanes 2, 4 
and 6 are digested products from a normal control (1&2) DNA 
extracted from the SH cell-line (3&4) and DNA prepared from 
the blood of SH (5&6).
Using SH cell-line DNA as template, PCR was performed using primers 
Ll/11688B and FR44/12553L. After purification and separation of strands (see 
Chapter 2:7&2:9) the + Bio strand was sequenced using primer L2/11914L. 
Figure 5:4 shows the antisense strand of SH alongside that of a normal control. 
The homoplasmic T->C (which is G->A on the sense strand) can be seen at 
np l 1778 in patient SH. Thus SH does have the "classical" LHON mutation in his 
mitochondrial DNA.
5:5 T H E  CO M PLETE N U CLEO TID E SEQ U EN CE O F TH E 
MITOCHONDRIAL DNA OF SH
The entire mitochondrial sequence of patient SH was determined using direct 
sequencing of purified PCR products as described in Chapter 2:10. Where a 
difference from the "Cambridge" sequence was found it was confirmed by 
sequencing the other standard using, as template, DNA extracted from blood.
Table 5:1 summaries the differences found; 11/17 of these have been previously 
identified and are thought to be mistakes in the "Cambridge" sequence or 
polymorphisms. In addition to the LHON mutation at np 11778, 5 previously 
unreported deviations from the Cambridge sequence were found. Two in the D- 
loop at np 152 and np 16509 and three nucleotide changes causing no alteration in 
the amino acid, at np 4793 in ND2, np 8706 in ATPase 6 and np 15530 in Cyt b.
5:6 DISCUSSION
5:6:1 Mitochondrial DNA mutations associated with LHON
Leber's Hereditary Optic Neuropathy (LHON) is one of the m ost well 
docum ented mitochondrial diseases, as outlined in Chapter 1. Since the 
identification of the so-called "classical" mutation at np 11778 by Wallace et al in 
1988, a large number of mitochondrial DNA mutations have been identified 
which are associated to a greater or lesser degree with the development of LHON. 
The mutations are now divided into two classes, primary and secondary.
Huoponen et al (1993) define a primary LHON mutation as one which fulfils the 
following criteria:
i. it has never been found in a normal control
ii. it alters an otherwise highly conserved amio acid
iii. it is associated with a measurable drop in oxidative phosphorylation
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CONTROL SH
Figure 5:4 Sequence at np 11778 is SH and a normal control. PCR product 
amplified using Ll/11688B and FR44/12553L. The antisense 
strand is shown and the C-+T at np 11778 in SH indicated in 
bold.
Gene
Coordinate
(np)
Change on 
sense strand
Amino acid 
substitution
Previously
reported?
D-loop 152 T->C - No
12S rRNA 750 A->G -
Yes 
Prczant et al 
(1993)
1438 A->G -
Yes 
Marzuki cl al 
(1992)
ND1 3423 G->T Silent
Yes 
Howell et al 
(1992)
ND2 4796 A->G Silent
Yes 
Howell et al 
(1992)
4793 A->G Silent No
4985 G->A Silent
Yes 
Howell et al 
(1992)
ATPasc 6 8706 A->G Silent No
ND4 11335 T->C Silent
Yes 
Howell et al 
(1992)
11778 Ci->A Arg->IIis
Yes 
Wallace et al 
(1988)
ND6 14199 G->T Pro->Thr
Yes 
Howell et al 
(1992)
14365 G->C Silent
Yes 
Howell el al 
(1992)
14368 G->C Phc->Lcu
Yes 
Howell et al 
(1992)
cytochrome b 14766 T->C lle->Thr
Yes 
Lertrit el al 
(1992)
15326 A->G Thr->Ala
Yes 
Marzuki et al 
(1992)
15530 T->C Silent No
D-loop 16509 T->C - No
Table 5:1 Deviations from Cambridge Sequence of mlDNA from patient
SH
Two mutations are universally assigned as primary: the A->G at np 11778 in ND4 
and the G->A at np 3460 in ND1. Two others are the subject of debate: T->C at 
np 4160 in ND1 and T->C at np 14484 in ND6. The mutation at np 4160 has 
only ever been identified in one Australian family (Howell et al, 1991), while that 
at np 14484 has almost always been found in combination with some other 
secondary mutation (Johns et al, 1992) and is associated with partial recovery of 
vision.
Secondary mutations are those whose association with LHON is uncertain as they 
also occur in normal controls although at a lower frequency. In addition to the 
secondary LHON mutations given in Table 1:2 others have now been reported: 
a G->A at np 14459 in ND6 identified in one five generation Hispanic family 
with LHON and early onset dystonia (Jun et al, 1994). At the meeting of the 
European Society of Human Genetics, 1994, de Vries et al reported two further 
mutations in a large Dutch family at npl 1696 in ND4 and npl 4596 in ND6. The 
A->G at np 11696 was heteroplasmic, while the T->A at npl4596 was 
homoplasmic. The phenotype was variable, some members of the family having 
spastic dystonia and LHON and others having only one symptom.
In all LHON pedigrees studied not all individuals who have the mutations 
necessarily show symptoms of disease (Gerbitz et al, 1994). It follows that, in a 
similar manner to the deaf pedigree described in Chapter 4, other factors must be 
involved in the development of the disease phenotype.
5:6:2 Deviations from the Cambridge sequence found in SH
The patient investigated in this study was diagnosed as having LHON in 1978 at 
the age of 26. He received treatment of Cystine and Neo-cytamen from 1979 with 
no improvement by 1983 when the treatment was greatly reduced. At diagnosis 
in 1978 SH was advised to stop smoking cigarettes and changed to pipe smoking. 
Clinicians at the Western Infirmary, Glasgow recognised classical symptoms of 
LHON; optic disc pallor and centrocecal scotoma. After his development of 
deafness in 1988 and in view of what we believed to be a maternal inheritance of 
deafness in addition to LHON this large scale sequencing project was undertaken.
The presence in SH of the most common mitochondrial DNA mutation associated 
with LHON was found at np 11778 by means of restriction enzyme digestion 
using SfaNI (Figure 5:3) and direct sequencing (Figure 5:4).
The entire mitochondrial DNA sequence was subsequently established by means 
of PCR and direct sequencing. There are, in total, 17 nucleotide substitution
6 8
present (Table 5:1). There is a suggestions that LHON patients have more 
polymorphisms than normals (Savontaus - personal communciation), the 
implication being that there is an inherently higher mitochondrial DNA mutation 
rate in LHON patients. This is difficult to substantiate as the mitochondrial DNA 
of only a few LHON patients have sequenced in their entirity. Huoponen et al 
(1993) found 27 nucleotide differences in 23 Finnish LHON families but did not 
report individual sequences and the number of polymorphisms in each patient.
Two of the 5 deviations, from the "Cambridge" sequence found in SH, which 
have not been previously identified, lie within the hypervariable D-loop: T->C at 
npl52 and T->C at np 16509. Neither site has been assigned a function; as can be 
seen from Figure 5:5. Neither lies within a conserved sequence box, a termination 
associated sequence, the origin of H-strand replication or either the light or heavy- 
strand promoters. The significance of mutations at these sites is unknown, but 
unlikely to be of importance.
The remaining 3 differences at np 4793, np 8706 and np 15530 result in silent 
amino acid alterations in ND2, ATPase 6 and Cyt b polypeptides respectively.
There are therefore no deviations from the established human mitochondrial 
sequence, apart from that at np 11778 in patient SH, which are obviously 
involved in the development of deafness. It is possible that the sensorineural 
deafness in SH arises via some unknown mechanism as a result of the specific 
pattern of mitochondrial DNA polymorphisms present. Screening of normal 
controls for each of the 4 previously undocumented differences would reveal 
whether or not they are simply rare polymorphisms. This could be done rapidly 
by SSCP (see Chapter 4) or the ARMS technique (Feme et al, 1992). The recent 
development of a PCR amplification technique which uses only 30 pi of blood or 
a single tissue culture cell (Erickson & Castora, 1993) will be an aid in these 
studies.
The combination of symptoms of optic atrophy and deafness in addition to 
diabetes insipidus, diabetes mellitus and sometimes additional symptoms such as 
epilepsy have now been recognised as Wolfram's Syndrome also known by the 
acronym DIDMOAD, (Pilz et al 1994). This has been considered to be autosomal 
recessive (Fraser et al, 1977) but Bunday et al (1992) suggested that DIDMOAD 
was a mitochondially inherited disorder. The G->A at np 11778 associated with 
LHON has now been idenfied in a patient with DIDMOAD (Pilz et al, 1994). 
This raises the possibility that SH has a form of DIDMOAD. However, he has no 
history of diabetes and the only other neurological symptom was an unexplained 
episode of paralysis when he was 15.
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The deafness in SH may be the result of an interaction of the mutation at np 
11778 with a nuclear genetic factor, or some environm ental factor. If 
sensorineural deafness is a neurological symptom which can be associated with 
the 11778 mutation some individuals with the mutation may develop deafness but 
not optic atrophy. Screening of 33 unrelated patients with sensorineural deafness 
of no known aetiology for the 11778 mutation indicated that all were wild type at 
this site (described in detail in Chapter 3).
In view of the paternal relatives of SH with sensorineural hearing loss it cannot be 
excluded that his deafness has arisen as a result either of genetic factors other than 
mitochondrial or from some external non-genetic factor.
5:6:3 Interactions of external factors with mitochondrial DNA which may 
result in the clinical pathology of LHON
Although LHON has been extensively studied over the six years since Wallace 
identified the np 11778 mutation, the molecular mechanisms which result in 
disease are not defined. There are wide variations of clinical phenotype even 
within members of the same family who have the same mutation (Newman,
1993). In addition to optic atrophy as a result of optic nerve damage there are 
many other manifestations of disease associated with some of the recognised 
mutations. The 11778 mutation has been found in patients with cardiac 
conduction abnormalities (Nikoskelainen et al, 1985) and women with a multiple 
sclerosis-type disease (Harding et al, 1992).
In comparison, how the same clinical phenotype of LHON can result from the 
variety  of m utations reported in different com plexes of the oxidative 
phosphorylation system is unclear. It is likely that the phenotype is not the result 
of a specific enzyme defect but of a general reduction in mitochondrial energy 
production which must be very tissue specific. The CNS is the most reliant of all 
tissues on mitochondrial ATP production but this does not explain the specific 
effect on the optic nerve.
Attempts have been made to look for alterations in Complex I activity in LHON 
patients (Howell et al, 1990; Howell et al 1991) and decreased activity found. 
The relevance of such decreases, found in platelets or tissue culture cells, to their 
involvement in development of disease in neural tissue is questionable.
Some "external" factor must be implicated in the development of LHON; many 
theories have been suggested but none proved. As explained in Chapter 1, 
cigarette smoking was at one time thought to be involved in the development of
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LHON symptoms (W ilson, 1965). This idea has never been thoroughly 
investigated.
The preponderance of males developing LHON led to the suggestion of X-linkage 
and for a period it was thought that there was linkage to a specific region of the 
X-chromosome (Vilkki et al, 1991). Re-evaluation of data by Juvonen et al in 
1993 and a report by Carvalho et al (1992) resulted in the overall conclusion that 
there is no X-linkage locus and that the sex bias reflects biological differences 
between the sexes.
The existence of tissue-specific isoforms in nuclear gene products whose 
interactions with a mitochondrial gene product give rise to clinical symptoms is a 
popular theory. Sudoya et al (1992) produced the diagram shown in Figure 5:6 to 
explain how a changed mitochondrially encoded subunit could be unable to 
interact with a tissue-specific isoform of a nuclear encoded subunit. What this 
nuclear gene product could be in LHON remains to be elucidated.
It has been speculated that visual failure in LHON is due to an abnormal immune 
response against the optic nerve (Harding et al, 1992). It is not clear how 
mitochondrially encoded polypeptides play a role in the immune response but the 
mutation at np 11778 causes an Arginine to be replaced by a Histidine both of 
which are basic, hydrophilic amino acids, and as such could be part of an 
antigenic determinant. Howell et al (1991) suggested that the change in ND1 
brought about by np 3460 mutation could act in a similar manner. It is worth 
noting that Pallini et al (1988) reported that many LHON patients have increased 
levels of immunoglobulins in their CSF.
5:6:4 Final comments on future work
It is evident that there is a great deal still to be investigated in the disease known 
as LHON. The increasing use of automated DNA sequencing will perhaps lead to 
more LHON patients having their entire mitochondrial genome sequenced so that 
the relevance of the changes found in this study, in SH, to the development of 
disease may be established. Additional investigations of deaf patients with 
respect to the mutations associated with LHON will also clarify whether the two 
clinical phenotypes are related in SH.
71
N U C L E U S
m u t a t i o n a l
a l t e r a t i o n
D e f e c t i v e
^  r  r*
N o r m a l
M I T O C H O N D R I A
T i s s u e  sp e c i f  ic e x p r e s s i o n  o f  m t D N A  m u t a t i o n s :  n u c l e a r - c o d e d  p r o t e i n  
s u b u n i t s  o f  th e  r e s p i r a t o r y  e n z y m e  c o m p l e x  a s  a  p h e n o t y p i c  m o d i f i e r .
B l a c k  s u b u n i t s  - m i t o c h o n d r i a l l y  e n c o d e d
S h a d e d  s u b u n i t s  - n u c l e a r  e n c o d e d
C H A P T E R  6 B IO C H E M IC A L  INVESTIG ATIO N O F A
PERMANENT CELL-LINE CREATED FROM A 
M E M B E R  OF THE S E N S O R I N E U R A L  
DEAFNESS PEDIGREE
6 :1 CREATION OF PATIENT-DERIVED CELL-LINES
A permanent cell-line was created by EBV-transformation of lymphocytes from 
patient 111-29 (Figure 4:1) in the pedigree described in Chapter 4. Blood was 
taken from the patient by Guy Vemham and sent to the European Collection of 
Animal Cell Cultures (ECACC), Porton Down, where the cell-line was created. 
Cells were supplied to us as growing suspension cultures; aliquots were retained, 
frozen in liquid N 2 , by ECACC. This cell-line was designated as CT001 by 
ECACC. A control cell-line was provided by Dr Mair Crouch of Yorkhill 
H ospital, Glasgow: this had been prepared by EBV -transform ation of 
lymphocytes from a female of undefined age suffering from no systemic disease. 
This cell-line was designated 01MC by our laboratory.
Both cell-lines were maintained as suspension cultures in RPMI with supplements 
as described in Chapter 2:13. Both grew as typical lymphoblastoid cell-lines: the 
cells grew in aggregates which were large enough to be seen with the naked eye.
When both cell-lines were established DNA was prepared from each (see Chapter 
2:4) and investigated for the np 7445 mutation by means of Xbal restriction 
digestion of PCR products, as described in Chapter 4. As Figure 6 :1 shows the 
patient cell-line, CT001, was found to have lost the site at np 7440, whereas the 
normal control cell-line, 01MC, was wild-type. It may be infered that CT001 had 
retained the A->G mutation at np 7445. This procedure was undertaken in order 
to be sure Firstly that the patient cell-line had maintained the mutation in culture, 
and secondly that the normal control did not by chance have the np 7445 
mutation.
6:2 MITOCHONDRIAL METABOLISM IN PATIENT AND CONTROL 
CELL-LINES
A number of ways of measuring mitochondrial metabolism in cultured cells are 
available. Those investigated here were determination of the ratios of lactate to 
pyruvate produced by cells in culture; complex II/III activities, complex IV 
activity and growth in selective media.
72
Figure 6:1
Cell line CT001 01MC marker 
Xba\ +  - +
— 662np 
—-400np
Digestion with X bal of PCR products amplified using template 
DNA prepared from the cell-lines CT001 and 01MC and 
forward primer FR31/7178B, reverse primer FR32/7840L.
6:2:1 Measurement of lactate/pyruvate ratios in patient and control cell-lines
The measurement of lactate/pyruvate ratios is a general method of estimating 
levels of oxidative phosphorylation in cell-lines or tissue samples (Robinson et 
al, 1987). Lactate is the product of anaerobic respiration; when oxidative 
phosphorylation is not functioning properly and cells or tissues produce ATP via 
glycolysis, lactate levels rise. Lactate accumulation in body fluids (e.g. blood, 
CSF) is considered a useful marker of mitochondrial disease (Tulinius et al, 
1991). Lactate/pyruvate ratios were measured to estimate levels of oxidative 
phosphorylation in cells with the np 7445 mutation, CT001, and normal control 
cells without this mutation, 01MC. This was done by incubating cells as 
described in Chapter 2:19 and subsequently measuring the lactate and pyruvate 
produced. The enzymatic assay measures the levels of NADH by the optical 
density (OD) at 340 nm. The reaction is: 
lactate + NAD   pyruvate + NADH
and the enzyme which acts is lactic dehydrogenase. Standard curves for both 
lactate and pyruvate are produced by carrying out the assay on a range of 
concentrations of the two substrates (see Chapter 2:19). From these, OD340 
readings obtained from cell-lines after 48 hours incubation could be converted to 
concentrations and expressed per mg of protein.
Results are given in Table 6 :1. The levels of lactate produced were extremely low 
in all experiments. Lactate/pyruvate ratios were calculated from the results of 
three such experiments in which cells were incubated for 48 hours prior to the 
assay; the ratio for 01MC was 18.2 + 5.5, that for CT00I was 15.9 + 4.8. These 
results are within the limits of experimental variation and indicate no significant 
difference in oxidative phosphorylation between the two-cell-lines.
6:2:2 Complex II + III activity in the two cell-lines
Complex II + III activity was measured in disrupted cells for both 01MC and 
CT001 cell-lines using the succinate/cytochrome c reductase (SCCR) assay (see 
Chapter 2:18). The results of one experiment are shown in Figure 6:2 ; the assay 
was carried out in duplicate on one batch of cells, OD550 readings (absorbance of 
cytochrome c) were taken and a mean calculated. The mean change in OD550 
values was 0.005/m in for both cell-lines. When the respective protein 
concentrations were taken into account this gives figures of 0.73 nmol 
substrate/min/mg protein for cell-line CT001 and 0.93 nmol substrate/m in/mg 
protein for cell-line 01MC. These figures are extremely low when compared to 
those quoted by Shoffner et al (1992) but this reflects the fact that experiments
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CELL-LINE LACTATE PYRUVATE LACTATE/
PYRUVATE
01MC
CTOOl
Table 6:1
1.2 mM 57.4 pM 20.9
521 pM 44.3 pM 11.8
1.4 mM 64.4 pM 21.6
Mean + SE
18.1 ± 5 .5
986 pM 6 5  pM 15.2
774 pM 67 |liM 11.4
1.4 mM 6 8  pM 20.9
Mean + SE
15.8 + 4.8
Lactate and pyruvate production ratios, after 48 hours, in three 
separate experiments, calculated from OD340 values obtained 
in the enzym e assays described  in C hapter 2:19. 
Concentrations of lactate and pyruvate are per mg of protein.
Pyruvate standards were 1 pM - 200 pM; lactate standards 
were 10 pM - 20 mM
s e e n  ASSAY
O D
5 5 0
0 .0 1 6
0 .0 1 4  - -
0.012  - -
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0 .0 0 8  - -
0 .0 0 6
0 .0 0 4  - -
0.002
- 4 — 01M C  
■ — CT001
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S E C O N D S
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Figure 6:2 S u c c i n a t e / c y t o e h r o m c-c  r e d u c t a s e  ( S C C R )  a s s a y  m e a s u r i n g
c o m p l e x  II + III a c t i v i t y  in  t h e  p a t i e n t - d e r i v e d  c e l l - l i n e ,  
C T 0 0 1 ,  a n d  th e  c o n t r o l  c e l l - l i n e  0 1 M C .  T h i s  e x p e r i m e n t  w a s  
c a r r i e d  o u t  in d u p l i c a t e  o n  1 .2 5  x  105 c e l l s  w h i c h  h a d  b e e n  
d i s r u p t e d  b y  f r e e z i n g  a n d  t h a w i n g
were done using whole cells, while those of others used purified mitochondria 
and their figures are per mg of mitochondrial protein.
6:2:3 Complex IV activity (Cytochrome-c  Oxidase assay)
The cytochrome-c-oxidase (COX) assay measures the oxidation of cytochrome- c 
by complex IV of the oxidative phosphorylation system in mitochondria. This 
activity was measured as absorbance at OD550 in both 01MC and CT001 cell- 
lines: results shown in Figure 6:3 are the mean of duplicate readings. Calculated 
from these results the mean change in OD550 for 01MC was 0.038/min and for 
CT001 was 0.034/min. These results convert to 4.3 nmol/min/mg protein for 
CT001 and 4.8 nmol/min/mg protein for 01MC.
The results of the SCCR and COX assays can be expressed as a ratio to give a 
way of measuring complex IV activity relative to the flux through complexes II + 
III (I. J. Holt, personal communication). In most cases of mitochondrial disease 
complex IV is the most severely impaired of the respiratory chain activities. 
Expressed in this way the COX/SCCR ratio for 01MC was 5.1 and for CT001 5.8.
6:3 M E A S U R E M E N T  O F G R O W T H  O F T H E  T W O
LYMPHOBLASTOID CELL-LINES BY MTT ASSAYS
The number of viable cells in a culture can be measured by Mosmann's MTT 
assay (Mosmann, 1983). The ability of the two cell-lines to survive under various 
culture conditions was investigated and compared using a modification of this 
assay as described in Chapter 2:20
6:3:1 Growth of cell-lines on galactose
The ability of the two cell-lines to grow using Galactose as carbon source was 
measured, by the MTT assay, in cells maintained in RPMI containing galactose 
substituted for glucose. In Figure 6:4 the growth curves of both cell-lines are 
shown under both conditions: in RPMI containing glucose (Figure 6:4:A) and in 
RPMI containing galactose (Figure 6:4:B). The graphs show that the patient 
derived cell-line, CT001, grew better than the control, 01MC, under both 
conditions. Mean doubling time was calculated by plotting log 10 of the OD570  
readings against time (not shown). The length of time taken for the OD readings 
to double can be estimated from the shape of this graph. In glucose the doubling 
time for the CT001 cell-lines was 32 hours, and 55 hours for the 01MC cell-line; 
in galactose the figures were 56 hours and 80 hours respectively. Calculated from 
these figures there was an increase in the mean doubling time in Galactose of 1.4
7 4
COX ASSAY
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Figure 6:3 Cytochromc-c oxidase assay measuring complex IV activity in
the cell-lines CT001 and 01MC. The assay was carried out in 
duplicate on one batch of cells; 1.25 x 10s’ cells were disrupted 
by freezing and thawing and treatment with 10% digitonin.
OD
57
0 
O
D
57
0
A - Glucose
0 . 5  _
0 . 4  _
0 . 3 -
0.1 1
72 960 24 48
Hours
B - Galactose
0 . 4 -
0 . 3 -
0 .2 -
72 960 24 48
Hours
•  CT001 
■ 01MC
Figure 6:4 Measurement of cell growth in various media by MTT assays.
A: growth in RPMI containing glucose 
B: growth in RPMI containing galactose
The data plotted are the means of two experiments in which 
measurements were taken in triplicate. Standard errors (not 
shown) were all less than 0.05 OD units.
times for 01MC and 1.7 times for CT001. These ratios are probably not 
significantly different, given the experimental errors inherent in the technique.
6:3:2 Growth of patient and control cell-lines in the presence and absence of 
streptomycin
Standard growth conditions for lymphoblastoid cell-lines include 100 pg/ml of 
streptomycin and 100 units/ml of penicillin in the RPMI growth medium, in order 
to combat bacterial contamination of cell cultures. In an attempt to gauge 
whether inclusion of higher doses of streptomycin in the culture medium had any 
effect, either inhibitory or enhancing, on the growth of the two cell-lines. MTT 
assays were carried out on cells grown under conditions of no streptomycin, 2 0 0  
pg/ml streptomycin and 400 pg/ml streptomycin, all with 100 U/ml penicillin. 
Figure 6:5 shows the growth curves in each situation: Figure 6:5:B indicates that 
both cell-lines can grow as well without streptomycin as they can with 1 0 0  pg/ml. 
Figure 6:5:C and D show the results of two experiments in which growth was 
measured in 200 pg/ml and 400 pg/ml streptomycin. The two sets of results are 
shown separately due to the differences in the results. Comparison of growth 
curves shown in Figure 6:5:A (control 100 pg/ml streptomycin) and C indicates 
that in the first experiment (19.8.94) conditions of 200 pg/ml streptomycin 
resulted in a marked decrease in growth of both cell-lines. Comparison of Figure 
6:5:A and D indicates that 400 pg/ml streptomycin caused stasis of the control 
cell-line, 01MC, whilst growth of CT001 was decreased but not stopped. 
Contrary to these results, in the second experiment (16.9.94) at a concentration of 
200 pg/ml there was no decrease in the growth of CT001 and only a small 
decrease in that of 01MC. But at 400 pg/ml there was a decrease in the growth of 
both cell-lines, although a smaller effect was seen in the patient derived cell-line. 
These results require clarification by repetition of the experiment.
6:3:3 Growth of cell-lines in the presence of chloramphenicol
Chloramphenicol inhibits mammalian mitochondrial protein synthesis (Lamb et 
al, 1968). If there is an impairment of mitochondrial protein synthesis in the cell- 
line CT001 with the np 7445 mutation, which is not sufficient to cause a decrease 
in respiration under normal culture conditions, stressing the cells by growing 
them in the presence of chloramphenicol may reveal a growth defect in the CT001 
cells.
Some mutations in the 16S rRNA gene of mitochondrial DNA are known to 
confer resistance to chloramphenicol (Howell & Lee, 1989). None of the
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Figure 6:5 Growth curves (by MTT assay) of cell-lines 01MC and CT001 
in the presence of: 100|ig/ml streptomycin (A), no streptomycin 
(B), 200p.g/ml streptomycin (C), and 400|ig/ml streptomycin 
(D). Penicillin (100 U/ml) was present in the RPMI culture 
medium in all experiments. Each growth curve is the mean of 
triplicate samples. Standard errors (not shown) were all less than 
0.05 OD units.
mutations of mitochondrial DNA found in patient 111-29, from whom the CT001 
cell-line was created, are known to be chloramphenicol resistance mutations and 
it was decided to test both cell lines for their ability to grow in RPMI containing 
chloramphenicol. A concentration of 1 mM was found to kill (an OD570 reading 
of approximately zero in MTT assays) both cell-lines within 48 hours. The 
growth curves in 0.1 mM chloramphenicol are shown in Figure 6 :6 , although 
growth under control conditions (Figure 6 :6 :A) was poor in this experiment, it 
can be seen that growth in the presence of 0.1 mM chloramphenicol was similarly 
reduced in the two cell-lines. Constraints of time did not permit the experiment to 
be repeated in order to confirm this result.
6:4 PR E L IM IN A R Y  A N A L Y S IS  OF M IT O C H O N D R IA L
TRANSCRIPTS IN THE PATIENT-DERIVED AND CONTROL 
CELL-LINES
The position of the np 7445 mutation at the boundary of the COI gene on one 
strand and the tRNAser(ucN) gene on the other could result in a difference in 
RNA processing (as outlined in Chapter 4:8:4). Preliminary experiments were 
undertaken to investigate whether there was a difference in the length or level of 
the COI transcript, between the patient-derived and control cell-lines.
RNA was prepared from whole tissue-culture cells as described in Chapter 2:14 . 
A fter electrophoresis through a formaldehyde agarose gel and transfer to 
postively charged nylon membrane, the RNA was hybridised with DIG-random 
labelled PCR product. This product had been amplified from template DNA 
prepared from a blood sample donated by a normal control, forward primer 
FR29/6456B and reverse primer FR30/7252L. These primers amplify a 790 np 
product which contains only sequence within the COI gene. Thus when used to 
hybridise to a Northern blot which is subsequently washed a high stringency, only 
the COI transcript should hybridise.
Figure 6:7 shows an autoradiograph of a Northern blot hybridised in this way. 
The apparent difference in signal between the two RNA samples was due to a 
loading difference as estimated from examination of the methylene blue stained 
filter prior to hybridisation.
In order to confirm and extend these results Dr Howy Jacobs carried out a 
Northern analysis of the same RNA samples using a high specific activity probe 
made by 32P-labelling of the same PCR product as used in the experiment 
described above. Several exposures of the autoradiograph produced are shown in 
Figure 6 :8 ; showing the same major transcript as was seen with the DIG-labelled
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Figure 6 : 6  Growth curves (by MTT assay) of cell-lines 01MC and CT001 
on RMPI without chloramphenicol (A) and with 0.1 mM 
chloramphenicol (B). Results are the mean of triplicate samples 
from one experiment, standard errors were all less than 0.05 OD 
units (not shown).
2 1
Figure 6:7
1) 01MC
2) CT001
1 .8kb
Northern blot o f 10pg o f total RNA extracted from CT001 
cells andO lM C  cells, hybridised with DIG-random labelled 
PCR product created using primers FR29/6456B and 
FR30/7252L. Bands o f the same size corresponding to the COI 
transcript (approximately 1800 nucleotides) are seen in both 
RNA samples.
Figure 6:8 Northern blot of lOpg of total RNA, extracted from CT001 
cells and 01MC cells, hybridised with ^2P-dCTP random 
labelled PCR product created using primers FR29/6456B and 
FR30/7252L and normal human control DNA as template. 
Hybridisation was carried out in 50% formamide, 5XSSC at 
43°C; the final wash was in 0.1 XSSC/0.1% SDS at 55°C. 
This Northern analysis was carried out by Dr Howy Jacobs on 
RNA samples prepared by the author.
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probe; in addition a slightly larger transcript was seen in both RNA samples. This 
is probably the longer precurser of COI which also contains sequence for the 5 
antisense tRNAs upstream of the COI gene. Neither the DIG-labelled probe nor 
the 3 2P-labelled probe detected any difference in the length of the COI transcript 
between the RNA from patient-derived cells and control cells, nor any difference 
in the structure of precursor-like transcripts containing COI sequences. When 
adjusted for relative loading (Figure 6 : 8  plus additional data obtained by Dr 
Jacobs, not shown) the level of COI mRNA in the two cell-lines is very similar.
6:5 M E A SU R EM EN T OF M IT O C H O N D R IA L L Y -E N C O D ED  
PROTEIN SYNTHESIS IN CELL-LINES
The synthesis of mitochondrial-encoded proteins was investigated by 35S- 
methionine incorporation in the presence of emetine, which is an inhibitor of 
cytosolic protein synthesis. 35S-labelled proteins were prepared as described in 
Chapter 2:16 and electrophoresed through a 12% polyacrylamide-SDS gel. The 
proteins were visualised by coomassie blue staining of the gel before fixing and 
treatm ent w ith "Amplify". The radio-labelled proteins were detected by 
fluorography. Figure 6:9 is one such experiment in which cells were 
preincubated in methionine-free medium in the presence of emetine. As shown 
the bands corresponding with COI, ND5, ND4, Cyt b, COIN, ATPase 6 , ND6  and 
ND3 have been tentatively assigned in the 1(H M emetine tracks. In this 
experiment chloramphenicol was not included; another experiment in which 
chloramphenicol was present in addition to 10*4  M emetine, in one set of samples, 
showed that the prominent assigned bands shown in Figure 6:9 were not present 
when chloramphenicol was included (data not shown). This indicates that the 
proteins seen in the lO*4  M track are translated in the mitochondria. The most 
important thing to note is that there are no additional bands, no loss of bands and 
no difference in the intensity of the bands in the CT001 samples.
6 : 6  DISCUSSION
In order to investigate the biochemical and molecular effects of the mutation at np 
7445, a permanent cell-line was created from lymphocytes of the index case. As 
a control a similar lymphoblastoid cell-line was studied, derived from normal 
control lymphocytes.
6 :6 :1 Biochemical investigations of patient-derived and normal cell-lines
Many of the studies of mitochondrial diseases have measured, directly or 
indirectly, the oxidative phosphorylation activity of cells from patients in
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F ig u re  6:9  Fluorograph of ^S-M ethioninelabelled  proteins
electrophoresed through SDS-polyacrylamide. 1 x 10^ cells
were labelled with 25 pCi o f 33S-Methionine at each
concentration o f emetine ie 10"3, 10"^ and 10 '3. Proteins were 
assigned according to sizes given by Bourgernon et al (1992).
comparison with those from normal controls. In this study lactate and pyruvate 
production were measured and a lactate/pyruvate ratio calculated. The ratios of
18.1 for the normal cell-line, 01MC, and 15.8 for the patient-derived cell-line, 
CT001 are not significantly different although slightly lower than the ratios 
reported by Robinson et al (1987) for control fibroblast cell-lines (ratios 21.5 to 
26.9). Of most importance in attempting to identify a biochemical phenotype 
attributable to the mitochondrial genotype of the patient-derived cell-line is that 
there is no difference in the lactate/pyruvate ratios. This suggests no difference in 
oxidative phosphorylation.
The activity of individual complexes was measured by the SCCR and COX 
assays; results are shown in Figure 6:2 and Figure 6:3. It is clear that there is no 
difference in Complex II + III activity, measured by SCCR, or Complex IV 
activity, measured by COX, between the two cell-lines. If the results of these two 
assays are expressed as a ratio the figures are COX:SCCR of 5.1 for 01MC and
5.8 for CT001. A review of literature indicates that ratios in normal human 
controls range from 2.2 (Wallace et al, 1988) to 7.5 (Haginoya et al, 1993). In a 
number of mitochondrial myopathies muscle biopsies were investigated by these 
assays and gave equally variable results: 2.4 in mitochondrial encephalomyopathy 
(Servidei et al, 1987), 2.4 and 3.7 in KSS (Shoffner et al, 1989), 3.9-6.9 in Leigh's 
disease (Shoffner et al, 1992).
The similarity of the ratios obtained from the two cell-lines is in agreement with 
the lactate/pyruvate results. Both indicated that the mutation at np 7445 in the 
patient-derived cell-line is not resulting in a decrease in oxidative 
phosphorylation, at least in lym phocytes. A decrease in oxidative 
phosphorylation in lymphocytes would presumably result in much more 
generalised systemic disease than is found in the pedigree under study. There are 
no clinical symptoms apart from sensorineural deafness in the majority of the 
family (the exceptions being III-10 and III-15 who have ophthalmological 
symptoms). Lymphoblastoid cells are not the ideal choice of cells to use in an 
investigation of deafness in this family. Neuronal tissue or tissue derived from 
the cochlea would give much more meaningful results. Samples of these tissues 
are, however, difficult to obtain and maintain. It would also be hard to justify 
such studies ethically.
6:6:2 Growth of patient and control cell-lines under various conditions
The ability of cells to grow in various culture conditions was investigated using a 
modified MTT assay. MTT is a tetrazolium salt, 3-(4, 5-dimethyl-thiazol-2-yl)- 
2.5-di-phenyltetrazolium bromide which is bright yellow in colour and produces a
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dark blue formazan product when incubated with live cells (Mosmann, 1983). A 
homogeneous solution which can be measured for optical density is produced by 
addition of 10% SDS (Tada et al, 1986). The tetrazolium ring of MTT is cleaved 
in active mitochondria by dehydrogenases.
This method was used to measure growth of the two cell-lines in RPMI (with 
additives as shown in Chapter 2) with galactose as carbon source, in the presence 
of chloramphenicol and in various concentrations of streptomycin. In general the 
patient-derived CT001 cells grew better than the control 01MC cells under all 
conditions tested.
Neither cell-line grew as well on galactose as on glucose (see Figure 6:4), but the 
increase in doubling time was similar for both cell-lines indicating no difference 
in their ability to utilise galactose as a carbon source. Galactose is converted to 
galactose-1-phosphate, a reaction which requires ATP, and this is converted to 
UDP-galactose. The UDP-glucose formed is then catabolised in the same way as 
that formed from glucose. However, the rate of galactose utilisation via this 
pathway is held to limit the rate of supply of precursors for glycolysis such that 
the cell is unable to obtain sufficient ATP from glycolysis alone for growth and/or 
survival. (Sun et al, 1975; Lehninger, 1982). This assay is therefore a further test 
for respiratory impairment.
At a concentration of 1 mM, chloramphenicol was found to kill both cell-lines, 
but at the lower concentration of 0.1 mM growth rates for both cell-lines were 
reduced by approximately the same factor (see Figure 6 :6 ). The results of this 
preliminary experiment indicate that the cell-lines did not respond differently to 
growth under conditions of stress (i.e. chloramphenicol). The mutation at np 
7445 does not appear to be resulting in a decrease in growth in this situation.
Sensitivity to higher than normal levels of streptomycin in growth medium was 
measured by MTT assays. Figure 6:5 shows that the two experiments in which 
growth was measured in 200 pg/ml and 400 pg/ml streptomycin gave different 
results. Unfortunately time did not permit me to repeat these assays, but six 
control lymphoblastoid cell-lines have been obtained from ECACC to establish 
the range of sensitivity to streptomycin in control lymphoblastoid cell-lines. Only 
when these assays have been completed, in triplicate (in addition to re-assay of 
01MC and CT001) will any conclusion be possible regarding the effect of the np 
7445 mutation on the streptomycin sensitivity of cell-line CT001.
If it is found to be significantly less sensitive to streptomycin than normal then I 
suggest that fesh blood samples be obtained from patient 111-29 and a number of
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lymphoblastoid lines created from this patient which could be similarly tested. 
This would reveal whether any difference in sensitivity observed between the two 
cell-lines was a real phenotypic effect of the mitochondrial genotype.
As described in Chapter 4 the position of the np 7445 mutation is at the extreme 3' 
end of the tRNAser(UCN)- This potentially implicates the m utation in 
mitochondrial protein translation although in the experiments described in Section 
6 :4 , above, no mis-translation of mitochondrial proteins was detected in the cell- 
line with the mutation, CT001.
Streptomycin has been shown to bind the 16S rRNA in E. coli and is proposed to 
cause mis-translation in mitochondria in a similar manner to its binding to the 16S 
rRNA of prokaryotes (Prezant et al, 1993). The experiments to investigate the 
growth of cell-lines CT001 and 01MC in the presence of streptomycin were 
undertaken to test whether the combination of the np 7445 mutation with the 
affect o f streptomycin would result in a growth difference. If, when the 
experiments are repeated, a difference is found between the growth CT001 and 
01MC then all the experiments described in this Chapter, lactate/pyruvate, SCCR 
assay, COX assay, mitochondrial protein synthesis should be repeated on cells 
grown in increased concentrations of streptomycin.
The results of similar MTT assays as performed on 01MC and CT001 on a range 
of lymphoblastoid cell-lines under various growth conditions would clarify 
whether the shorter doubling time observed for CT001 under normal growth 
conditions is within the normal range or is really a result of phenotypic expression 
of the genotype, nuclear or mitochondrial, of this cell-line.
6:6:3 Investigation of the effect of the np 7445 mutation on mitochondrial 
RNA
The Northern analysis shown in Figure 6:7 and Figure 6 :8  indicated that there is 
no difference in the size of the COI transcript between the two cell-lines. In 
Figure 6 : 8  where the larger precurser transcript is present in addition to the 
mature COI transcript of approximately 1800 nucleotides, there is no differently 
sized or additional band present in the patient cell-line. This result suggests that 
the A->G change at np 7445, which is at the overlapping boundary between the 
COI gene on the major coding strand and the tRNAser(ucN) 8 ene °n  the other 
strand, makes no difference to the length of the COI mRNA. The AGG created is 
presumed to act as a stop codon in the same way as the wild-type AGA, unlike 
the G ->A change at np 7444, reported by Brown et al (1992) in Leber's patients,
80
which they claimed, causes an increase of 3 amino acids in the length of the COI 
polypeptide.
6:6:4 Investigation of the effect of the np 7445 mutation on mitochondrially 
encoded protein synthesis
The possible effects of the np 7445 mutation on mitochondrially encoded protein 
synthesis was investigated by 35S-Methionine incorporation in the presence of 
emetine. Figure 6:9 shows a Fluorogram of one such experiment. Assignment of 
bands is difficult as not all mitochondrially-encoded proteins can be identified. 
However, this is true for both cell-lines, and must be due to experimental 
procedure. Both cell-lines show the same pattern of bands and each at similar 
intensities, indicating no difference in the sizes of any of the mitochondrially- 
encoded proteins or in the levels of their synthesis.
In contrast similar experiments on cybrid cell-lines containing mitochondrial 
DNA with the MELAS np 3243 mutation showed variable decreases in some of 
the mitochondrially-encoded polypeptides (King et al, 1992). In particular there 
was a decrease in the larger polypeptides such as ND2. A correlation between the 
number of leucine (UUR) codons in the polypeptide genes and the decreases 
observed was investigated by King et al but not found. It would be imagined that 
if the np 7445 mutation did decrease the charging efficiency of the tRNAser(ucN) 
some effect would be seen, particularly on mitochondrially-encoded polypeptides 
with large numbers of serine residues specified by UCN codons.
Mis-charging of the tRNAser with another amino-acid would result in proteins 
which are altered in their primary and consequently, secondary and tertiary 
structure. This would ultimately result in a loss of function of mitochondrially 
encoded proteins. There is no evidence for gross alterations in the structure ofthe 
mitochondrial encoded proteins of the lymphoblastoid cell-line, CT001 and it 
must be concluded that mis-charging is not occurring at a substantial level in this 
cell-type.
6:6:5 Concluding remarks
All the preliminary data presented in this Chapter indicate that the mutation at np 
7445 in the pedigree with sensorineural deafness does not result in a decrease in 
oxidative phosphorylation, at least in lymphocytes. Nor does the mutation result 
in alteration of the size or amount of COI mRNA, or in the level or size of 
mitochondrial encoded proteins. However, the clinical phenotype in the pedigree 
is extremely tissue-specific, limited to the sensorineural auditory system and it is
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perhaps not surprising to find no identifiable phenotype in lymphoblastoid-cell 
cultures.
In Chapter 4 of this thesis the involvement of a nuclear genetic factor was 
suggested in the development of the sensorineural deafness phenotype exhibited 
in some members of the pedigree. The nuclear background in which the 
m itochondrial genotype is expressed may be extremely important in the 
expression of a measurable biochemical phenotype. Experiments similar to those 
described by Bodnar et al (1993), may help to resolve the role of the nuclear 
background. In these experiments enucleated patient fibroblasts were fused with 
rho° fibroblasts created from normal controls and the resulting cybrids used to 
investigate the influence of the nuclear genome on the function of the 
mitochondrial genome. However, until a culture system can be devised in which 
there is a readily detectable phenotypic difference between cells with the np 7445 
mutation and wild-type, it is difficult to envisage exactly how these experiments 
could be done. As is further discussed in Chapter 7, it is also difficult to suggest 
other means of investigating the molecular mechanisms of disease in this family 
which are not extremely invasive and, as such, probably unethical.
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CHAPTER 7 PERSPECTIVES AND PROPOSALS
The results of the research described in this thesis have implications for further 
study. In particular a number of problems, associated with the investigation of 
mutations of the mitochondrial genome, have been identified. These will be 
described and solutions discussed.
A large-scale sequencing project such as this is greatly impeded by the lack of a 
database of known mitochondrial mutations. As described in Chapter 1 all human 
mitochondrial sequence is traditionally compared to the so-called "Cambridge" 
sequence published by Anderson et al (1981). However, a number of differences 
have been reported in normal control individuals by numerous laboratories. This 
was commented upon by Howell et al (1992) and Marzuki et al (1991) and a need 
identified for international collaboration to establish which "mutations" are 
relatively common polymorphisms. Rare polymorphisms are disease-associated 
if two criteria are fulfilled. Firstly, the nucleotide change (for point mutations) 
must never have been identified in a normal control. It is my opinion that 
mutations, claimed to be associated with disease but also identified in disease-free 
controls, e.g. some of the LHON mutations, should not be quoted as disease- 
associated mutations. Very often careful consideration of the data contained in 
such studies reveals that the statistics are extremely questionable. A case in point 
is the claim by Shoffner et al (1993) that a mitochondrial DNA mutation is 
associated with Alzheimer disease and Parkinson disease. In order to substantiate 
this claim and two disease groups were combined. In addition, the control group 
was too small to identify the nucleotide change if it was simply a rare 
polymorphism. The credibility of all research of mitochondrial diseases is greatly 
damaged by claims of association of mitochondrial mutations with specific 
diseases based on questionable statistics.
Secondly, a mutation has to be identified in a second, unrelated family, with 
similar symptoms, for it to be considered proven that it has a part to play in the 
aetiology of the disease. W ithout an international database of human 
mitochondrial DNA sequence these two criteria can only be fulfilled by searches 
of the literature and personal communication.
In this study ,the A->G transition at np 750, when found in both patient SH and 
patient 31 had not previously been reported. When Prezant et al (1993) published 
their work identifying the np 1555 mutation in association with maternally 
inherited AAID their table of other differences found included the A->G 
transition at np 750. This change in mitochondrial DNA sequence is therefore 
probably a relatively common polymorphism.
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If a database of mitochondrial DNA sequence existed all the mutations identified 
in this study could have been put into it. This would make the existence of these 
changes known to others and may have revealed to me that they had previously 
been reported. The importance of the mutation at np 7445 reported by us (Reid et 
al, 1994) was always questionable until it had been reported in another deaf 
pedigree (N. Fischel-Ghodsian, personal communication). A database would 
facilitate all research into the association of mitochondrial mutations with specific 
diseases.
One of the greatest puzzles of mitochondrial diseases is the tissue specificity of 
phenotypic expression observed in many of the mitochondrial mutations already 
identified. The mutation at np 7445 identified in this study is a good example of 
this.
W here heteroplasmy is the case e.g. in MELAS, the difference in tissue 
expression can be related to the balance between normal and m utant 
mitochondrial DNA. Threshold effects have been suggested to explain tissue 
specificity. Letellier et al (1994) carried out experiments in which they 
progressively inhibited the activity of cytochrome c oxidase, of rat muscle 
mitochondria, with increasing concentrations of KCN. This effectively mimics 
the effects of varying the degrees of a defect on the activity of the enzyme. Their 
results show that respiration remains nearly maximal until a low level of 
cytochrome c oxidase activity is reached. Then there is an abrupt decrease in 
respiration.
Where a homoplasmic mutation is present tissue specific expression could be 
explained by a similar mechanism involving a nuclear encoded gene product. 
Much o f the work on mitochondrial diseases requires the hypothetical 
involvement of a nuclear gene to fully explain the mechanisms by which disease 
arises. It is likely that much of the research carried out over the next few years in 
the area of mitochondrial diseases will be to determine the identity of some of 
these nuclear genes and their products.
There is a problem in the choice of tissue used in many studies undertaken to 
evaluate the role of specific mitochondrial mutations with specific diseases. 
Those mitochondrial diseases in which there are pathological signs of muscle 
disease and comparable clinical symptoms pose no problem. Muscle biopsies are 
relatively simple to obtain (although painful) and biochemical studies of such 
tissue have direct relevance to the clinical symptoms.
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In the mitochondrial diseases in which the major symptoms result from defects in 
neural tissue e.g. LHON and sensorineural deafness, it is much more difficult to 
study relevant tissue. In the pedigree described in Chapter 4 biochemical studies 
were carried out on lymphoblastoid cells (Chapter 6 ), although no clinical 
symptoms of a defect in this tissue were present. Muscle biopsies of these 
patients could perhaps be justified but, in my opinion, given the lack of muscle 
symptoms this would provide little information of value in determining the role of 
the mutation in development of disease.
Both the mutation at np 7445 and that at np 1555 are at positions in the 
mitochondrial genome involved in mitochondrial protein synthesis. Both 
mutations seem to result in similar clinical symptoms. The defect in both seems 
to be within the ear, either in the nerve (8 th cranial) or in the hair cells within the 
cochlea. The obvious tissue of choice for thorough biochemical investigation 
would come from the inner ear. Cochlear implants are now undertaken and 
cochlear tissue is available, but these manipulations are not done on patients such 
as those described here. The deafness has to be much more profound and of 
specific aetiology before cochlear surgery would be considered. It would be 
unethical to embark upon such studies in patients with mild to moderate hearing 
loss. The problem remains: how can meaningful experiments be undertaken?
The answer must initially be in in vitro studies of the m echanism s of 
tRNASer(UCN) charging (for the np 7445 mutation) and the interaction of 
antibiotics with the mitochondrial 12S rRNA (for the np 1555 mutation).
As described in Chapter 4 the np 7445 mutation changes the nucleotide at the -4 
position of the tRNAser(ucn). This position has been identified as being the 
"discriminator" nucleotide in amino acid charging of tRNAs. In vitro work in 
which the wild-type tRNAser(ucn) and the mutant tRNAser(ucn) are compared 
for charging efficiency and specificity should help to evaluate the role of the 
mutation in these mechanisms. Preliminary results (H.T.Jacobs, personal 
communication ) indicate that tRNAser(ucn) levels are depleted in the patient- 
derived lymphoblastoid cell-line, compared with control cells.
Other mitochondrial diseases in which specific mutations have been identified are 
under investigation in Dr. Jacobs' laboratory. Three projects have been 
undertaken, in recent years, to code correct mitochondrial genes by site-directed 
mutagenesis. The genes in question were ATPase 6  and 8  to study NARP, ND4 
to study LHON and COI to study Keams-Sayre Syndrome. This was done with a 
long-term aim of studying each disease in a transgenic-mouse model. Each of the 
mitochondrial genes studied in this way encode polypeptides which are part of the
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respiratory chain. A similar strategy would not be possible with the two 
mutations now identified in association with sensorineural hearing loss. Both arc 
in genes encoding RNAs, 12S rRNA in the case of np 1555 and tRNAser(ucn) in 
the case of np 7445. Mouse models would only be possible if maternally 
inherited deafness could be identified in mouse lineages. Identification of 
mitochondrial mutations at positions of significance in mitochondrial translation 
would allow relevant studies to be undretaken. Unlike the situation in humans , 
ther e would be no objections to studying a wide range of tissues from mice.
Perhaps one of the most informative studies would be a thorough neurological 
investigation of members of the pedigree described in Chapter 4. So far only 
thier audiological and visual status has been established. A more detailed 
investigation may reveal other neurological symptoms which have so far not been 
identified. Our understanding of the mitochondrial disease in this family could 
only be enhanced by such a study.
This is obviously work for the future. As with all scientific research interchange 
of ideas at local, national and international level increases the pace of work in 
specific areas of study. It is to be hoped that elucidation of the mechanisms by 
which the mitochondrial mutations identified in association with sensorineural 
hearing loss will progress quickly and bring benefit to the patients.
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